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ABSTRACT 
IMMUNE MODULATION BY MAREK’S DISEASE VIRUS 
Nitish Boodhoo      Advisors: 
University of Reading      Professor Ian M. Jones 
The Pirbright Institute      Dr. Shahriar Behboudi 
 
The emergence of highly pathogenic Marek’s Disease Virus (MDV) strains, defined by 
acute onset of Marek’s Disease (MD), has led to renewed emphasis for understanding 
host-pathogen interaction. Little is known about the mechanism of MDV replication due 
to its highly cell associated nature. An association between lipid metabolite remodelling 
and MDV infection in MD-susceptible lines of chickens based on atherosclerotic plaque 
formation has been previously established. Immunosuppressive lipid can impair immune 
system cell function; limit activation, infiltration into active sites of virus replication and 
modulate recognition of infected cells. Therefore the correlates of immune protection are 
unknown as antigen specific T cell responses against MDV have yet to be reported. Our 
primary objective was to use a pathway interference approach to study lipid biosynthesis. 
We demonstrate that infection with MDV leads to induction of fatty acid synthesis that 
can contribute towards eicosanoid synthesis in a COX-2 dependent manner. Specifically 
we identified induction of prostaglandin E2 (PGE2) biosynthesis in MDV infected CEFs 
and demonstrate a dependence for replication. Eicosanoids are well characterised for their 
ability to modulate immune system cell function including T cells. The second objective 
was to evaluate in vivo T cell responses or cell mediated immunity against MDV in both 
the MD-resistant (B21) and MD-susceptible (B19) lines of chicken. We demonstrate 
detection of a T cell response against MDV with the eliciting response directed against 
viral MEQ and pp38 in chickens that were either challenged (RB1B), vaccine 
(CVI988/RISPENS)-challenged (RB1B) or vaccine-boosted but not mock infected. 
CD4+TCRvβ1+ cells were the main responding T cell subset recognising the identified 
immunodominant pp38 epitopes (pp385-20, pp38161-176 and pp38171-186) in all the MD-
resistant (B21) and MD-susceptible (B19) lines of chicken. Induction of transcripts for 
cytokines (IL-2, IL-4 and IL-10) and CD4+ T cell proliferation was observed in a peptide 
specific manner. However, challenge impaired the ability of T cell to degranulate based 
on cell surface translocation of CD107a; although peptide specific induction for transcript 
of perforin and granzyme B can be detected. Taken together we demonstrate that T cell 
responses against MDV are limited and may be linked to lipid induced biosynthesis. 
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1.1 Introduction: Epidemiology 
Since the initial recognition of a previously unrecognized disease in 1907, Marek’s 
Disease (MD) has evolved into a highly pathogenic infection. Marek’s Disease Virus 
(MDV) or Gallid herpesvirus 2 (GaHV-2), an oncogenic alphaherpesvirinae, targets 
avian species (Gallus domesticus) and is defined as the etiologic agent for MD. Chickens 
act as the primary zoonotic pool for spread of MDV (1). The virus is widely prevalent in 
commercial stocks and affects young birds. MD has been shown to occur worldwide 
according to data from the world Organization for animal Health (OIE) but is not a 
notifiable disease (Figure 1). It is classified as a disease with socio-economic and public 
health importance, estimated at more than $1 billion annually, in countries which have 
established international trades for animals and animal by-products. 
 
 
 
Figure 1: Worldwide map depicting distribution of MDV whereby evidence for 
presence has been submitted to the OIE. 
Distribution data was obtained from the World Organization for Animal Health (OIE) 
distributed through the World Animal Health Information Database (WAHIS) interface 
(http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail) and 
summarized above based on absence (blue) and presence of disease with reported cases 
(red) before and after 2009. (A) World map depicting countries positive for MDV was 
constructed using the imapbuilder software (http://www.imapbuilder.net/). Both China 
and Egypt (black) are endemic areas for MDV with outbreaks reported on a yearly basis 
(B) Pie chart demonstrates the number of countries that have reported MDV cases to the 
OIE based on their geographical location (continent). Data is summarized based on 
absence (blue), and presence of disease with reported cases (red). 
 
 
Global vaccination efforts have been efficacious in preventing disease and reduced 
losses associated with culling of birds. Live virus vaccines, used since the 1970, remain 
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the basis of disease control programmes (2). These are usually administered to day-old 
chicks at hatching to provide protection against viral challenge from poultry operations. 
It is the first oncogenic disease against which a vaccine has been developed. However, 
day old, specific pathogen free (spf), birds become infected when introduced into 
poultry production facilities delineating an insufficiency in implanting biosecurity 
measures. Virus shed from feather follicle epithelium can linger in the environment for 
months as dust and dander (3). This has resulted in infected broilers which are active 
shedders for the duration of their production cycle. 
 
The emergence of highly virulent pathotypes , increasing reports of vaccine escape and 
visibly notable areas of the world that are becoming endemic with reported cases of 
viral outbreaks has led to renewed effort to study the dynamics that promote viral 
virulence at the interface of host-pathogen interaction (4) and eliciting immune 
responses against infection (immune responsiveness) which can be used to estimate 
vaccine efficacy. 
 
 
1.2 Marek’s Disease Virus  
Characterized after its human orthologue (Herpes simplex virus, HSV-1), MDV is an 
alphaherpesvirus, predominantly infects avian species. MDV was first isolated in 1967 
from different parts of the world and subsequently classified into three distinct 
serotypes. MDV is an avian double-stranded DNA herpesvirus that belongs to the 
Mardivirus genus in which three closely related but distinct serotypes have been 
grouped. Four pathotype of GaHV-2 are currently recognized; mild (m), virulent (v), 
very virulent (vv) and very virulent + (vv+). The Gallid Herpes Virus type 3 (GaHV-3) 
serotype consists of naturally a non-pathogenic strain used in combination with 
Mellagrid Herpes Virus 1 (MeHV-1; serotype 3) as either bivalent or trivalent vaccine 
formulation. Its genome (Figure 2) is approximately 175 kb long consisting of 70 open 
reading frames (ORF). The MDV genome consists of specific segments namely two 
unique sequences, unique long (UL) and unique short (US), encoding the core genes 
enclosed by the inverted repeat sequences repeat short (RS) and repeat long (RL) (5). All 
herpes viruses have evolved immune evasive strategies associated with 
immunosuppression or triggering alternative arms of the immune system. Herpes virus 
infection is life-long thus an intricate balance occurs between host and invading 
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microbe. The exact mechanism by which MDV replicates in the nucleus is not well 
known but it is thought to be similar to other alphaherpesviruses (6). The Infectious 
particle is an icosahedral capsid that is comprised of more than 30 different proteins 
assembled according to a complex architecture of central capsid containing the viral 
genome, a tegument protein layer and a lipid bilayer anchored with glycoproteins.  
 
 
Figure 2: Organization of the MDV genome and illustration of key viral proteins 
identified 
The MDV genome, based on the deposited and annotated sequence (5), when packaged 
into a fully infectious virion is a linear double stranded DNA. The MDV genome is 
defined by 4 main segments; UL (unique long), Us (unique short), IR (Internal Repeat 
long; IRL and Internal Repeat short; IRs) and TR (Terminal Repeat Long; TRL and 
Terminal Repeat Short; TRS). Infection and replication results in circularisation  
 
1.2.1 GaHV-2: Serotype 1 
A large diversity exist within serotype 1 with strains ranging from mild to highly 
oncogenic (listed below). The emergence of these pathotypes is thought to be result of 
continuous evolution imposed by vaccine stresses. The vaccine CV1988/RISPENS is 
currently used as the industry gold standard and is highly efficacious in preventing 
death as well as T cell neoplastic transformation. Its mechanism of action is currently 
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unknown. Virulent MDV strains tested in vivo replicate earlier, faster and induce a 
higher viraemia titre (7). Furthermore, the classification is based on the ability of each 
pathotype to induce disease severity scored by: survival rate, immunosuppression, 
viraemia and rate of viral shedding, neuropathy, induction of CD4+ T cells 
transformation and lymphoma dissemination and changes in immune organs weight in 
relationship to body weight. 
 
   Mild (m)     HPRS-B14, Cu2 and Conn-A,  
Virulent (v)    HPRS-16, JM and GA,  
Very virulent (vv)   RB1B, ALA-B and MD5,  
Very virulent plus (vv+)  610A and 648A,  
Avirulent strains    58Ap80C, CV1988/RISPENS and  
Md11 
 
1.2.2 GaHV-3: Serotype 2  
GaHV-3 strains ((listed below) have been utilized in vaccine formulations against 
virulent strains of MDV because they are non-pathogenic in chickens. Vaccination 
results in a lifelong infection and virus replication which is thought to stimulate immune 
cell. It is still utilized worldwide due to its high efficacy and relative ease of production 
which makes it a cheap vaccine to produce.  
 
Avirulent strains    SB-1, HPRS-24 and 301 B/1 
 
1.2.3 MeHV-1: Serotype 3 
The Mellagrid Herpesvirus 1 (MeHV-1) was first isolated from turkeys where it is 
pathogenic. However it’s use in chickens due to its sequence similarity with GaHV-2 
meant that it has been used worldwide as a vaccine strain. The Herpes Virus of Turkey 
(HVT) strain is commercially available worldwide. Implementation of bacterial 
artificial chromosome (BAC) technology has meant that recombinant technique have 
been applied to modify HVT into a multivalent vaccine strain against other chicken 
pathogens. Chicken do become carriers but don’t show any symptoms. 
 
Avirulent strains   HVT-FC126 and HPRS-26 
 
  
24 | P a g e  
 
 
1.3 Pathogenesis of Marek’s Disease  
1.3.1 Marek’s Disease 
MDV, the causative agent of MD in chicken, results in transformation of CD4+ T cells.  
The natural route of infection is defined by inhalation of airborne cell-free virus 
particles within the contaminated dust and dander (Figure 3), shed from infected host 
produced in terminally differentiated feather follicle epithelium (8), into a naïve 
respiratory track (9). MD pathogenesis has four phases in the susceptible birds; an early 
cytolytic phase within 2 to 7 days post infection (dpi) which delineates as semi 
productive lytic viral replication in lymphocytes. This is followed by a latency phase 
that occurs between 7 and 10 dpi in CD4+ T cell subset that result in systemic viral 
dissemination. Cutaneous viral infection can occur as early as 4 dpi and eventually 
results in fully productive viral replication and shedding (10). MDV reactivation in 
CD4+ T cells initiates a late cytolytic and immunosuppressive phase starting around 18 
dpi. Finally a proliferative phase around 28 dpi (11, 12) is characterized by formation of 
visceral tumours that originate from CD4+ T cells lymphoma. There is no transmission 
from chicken to eggs (vertical transmission) but the birds are usually infected in early 
stage after hatching (horizontal transmission). The presence of maternal antibody 
against MD can protect the neonatal chicks, and with the development of functional 
immune system a degree of resistant to MD is developed (13). However, husbandry-
related stress or concurrent infection with other immunosuppressive pathogens such as 
chicken infectious anaemia virus (CIAV), Reovirus and Infectious bursal disease virus 
(IBDV), significantly enhances susceptibility to MDV (14). Another important factor in 
the susceptibility to MD is the genetic background of chicken lines which is to some 
extent associated with the major histocompatibility complex (MHC). MDV-associated 
lymphoma can only develope in genetically susceptible chickens; however the virus can 
replicate and shedding still occurs in both susceptible and resistant chicken lines. 
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Figure 3: Model of Marek’s Disease Virus (MDV) infectious life cycle in resistant 
birds.  
MDV infection of naive host occurs via inhalation of dust or skin dander encapsulated 
viral particles into the respiratory tract 1. Primary infection occurs when virus particle 
breaks mucosal tolerance in the lungs, site of entry into the epithelial cells. Local viral 
replication establishes infection and initiates viral immediate-early gene, viral 
Interleukin-8 (vIL-8), transcription and translation. Inflammatory responses in the 
underlying tissue recruit innate immune system cells which result in uptake of 
infectious virus particle by macrophages. Infiltration of lymphocytes via action of vIL-8 
follows resulting in MDV infection of B cells. 2. Viral replication in B cells initiates 
Semi Production Lytic Viral Infection and disease progression. MDV infected B cells 
secret vIL-8 that acts as a chemotactic factor for and gains access to T cells. This 
specific lymphotropism (B cells and T cells) enables systemic disseminated viraemia. 
Viral replication causes apoptosis of B and T lymphocytes in a hallmark of 
immunosuppression. MDV integrates specifically into the genome of CD4+ T cells 
enabling escape from immune detection and initiates Latent Viral Infection. Early 
latently infected and activated CD4+ T cells have not been phenotypically characterised 
by cell surface markers a. Early latently infected and activated CD4+ T cells migrate to 
cutaneous sites of replication namely feather follicle. 3. Infection of feather follicle 
epithelium enables fully productive viral replication. Viral replication results in syncytia 
formation. Infection of feather epithelium leads to secretion of mature virion in skin 
danders and dust that act as the major source of infectious materials. Horizontal 
transmission is the only recognized form for environmental persistence and infection in 
field conditions. Systemic infection and neoplastic transformation of CD4+ T cells in 
susceptible birds is further discussed (Figure 4). 
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1.3.2 Establishment of primary infection 
It is speculated that lungs epithelial cells are one of the primary target cells for MDV 
infection. MDV antigens, with well-defined expression during cytolytic and latent phase 
of replication, have been detected at significant levels at various time points in lung 
epithelial cells in ovo (15), and in vivo (16) suggesting an establishment of successful 
infection. The later was performed via an aerosol method which simulates natural 
infection as a respiratory disease (9). Viral replication in the lungs could be detected as 
early as 1 dpi. Purchase et al. (17) were among the first to demonstrate a novel route for  
high replication kinetics of infectious MDV antigens in lungs epithelial cells of chicks 
inoculated via intra-abdominal route. However when they repeated the experiment, a 
lower immunofluorescence was detected at 5 dpi compared to 7 dpi. The route of 
administration, whether intra-abdominal or intra-tracheal might affect viral replication 
as well as systemic dissemination that results in MD (18). In addition, infection of lung 
resident Antigen Presenting Cells (APCs), such as macrophages, is thought to result in 
subsequent transport to primary and secondary lymphoid organs such as thymus, bursa 
of fabricius, and spleen (19). Although it is unclear whether macrophages and lung 
epithelial cells get infected simultaneously or rather infected lung epithelial cells may 
play a role in transmitting viral particles to macrophages. It is evident that post MDV 
infection, immune responsiveness leads to macrophage infiltration although viral 
replication is unaffected (16). It is also believed that presence of MDV particles in the 
lung, during the earliest infection, stimulates secretion of cytokines and chemotactic 
factors that help attract B cells to site of infection (20, 21). One of the defined 
chemokine is a viral interleukin-8 (vIL-8) which is similar to CXCL13 and is involved 
in recruiting immune systems cells to site of viral replication (22) and is defined as a 
homologue to the host interleukin-8 (IL-8) gene. IL-8 has a well-defined role as a 
chemotactic molecule for T cell (21, 23) and B cells (21). Immune cells recruited to the 
lung such as B cells can be detected as early as 2 dpi (24). 
 
1.3.3 Semi productive lytic viral replication 
MDV has a specific tropism for immune system cells and preferentially infects 
lymphocytes; B cells and T cells (αβ and γδ). Infection of B cells may occur in the lung 
and viral replication in B cells is defined as semi-productive lytic viral replication. Lytic 
activity due to viral replication has been linked to phosphoprotein 38 (pp38) activities 
(25, 26). PP38 role as an early immediate gene is defined only in lymphocytes, 
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specifically B cells and T cells (27, 28). It has been shown that an MDV 
rMd5Deltapp38 deletion mutant for pp38 lacked the ability to induce cytolytic activity 
characterized by B cell apoptosis (29). This is in accordance with the notion that 
recruitment of lymphocytes such as B cells to site of viral replication is a key step for 
transmission of virus and dissemination. Deletion mutants of vIL-8 (RB1BvIL-
8ΔsmGFP) when tested in vivo showed a reduced capacity to successfully infect 
lymphocytes and induce lytic infection (22). A lack of IL-8 therefore result in impaired 
ability to recruit B cells and as well as an observable reduction in cytolytic activity due 
to reduced viral titer and dissemination by lymphocytes. Infection with wild-type MDV 
restored lytic activity and viral dissemination to primary lymphoid organs (27). Viral 
lytic activity in B cells results in a drastic downfall in the overall antibody production 
and ability to fight against an infection. Consequently, the infected chicken suffers from 
immunosuppression, making it more susceptible to MD and other infections (30). 
During the early cytolytic phase, transcriptional modification and epigenetic changes 
(DNA methylation, histone post-translational modifications and non-coding RNAs), 
along with post-transcriptional and post-translational modifications, regulate viral 
replication cycle and subsequent expression of cellular and viral genes. Either way, it’s 
been postulated that disseminated viremia to various organs in a cell associated manner 
results in systemic infection. Infected B cells may also be able to produce vIL-8 mRNA 
which would have chemotactic activity for T cells. Infected B cells therefore are able to 
recruit T cells which would allow for transmission of MDV virus particle from infected 
B cells to activated T cells. Viral replication in T cells also leads to cytolysis associated 
with pp38 activity. The RB1BvIL-8ΔsmGFP deletion mutant lacked the ability to attract 
B cells and subsequently impaired its ability to infect T cells albeit at a lower frequency 
(22). Furthermore, MDV preferentially targets CD4+ T cell subsets and infection results 
in viral latency and immune evasion (21).   
 
1.3.4 Immune evasion and latency 
Hereafter, MDV enters the latency phase (Figure 3) such that it can no longer be 
detected by the host immune system while it continues to replicate inside the 
lymphocytes (12). One of the important immune evasion strategies include down 
regulation of MHC class I molecules on infected lymphocytes. A specific gene, 
encoding for viral RNA telomerase (vTR) subunit, has been reported to be present only 
in the oncogenic MDV pathotypes, but not in their non-oncogenic counterparts. In 
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addition, further study has confirmed about 88% identity of the vTR gene with the 
chicken terminal repeat (cTR) gene of the host. This would mean that vTR gene is also 
complement to host Telomerase reverse transcriptase (TERT) for cTR. Consequently, 
MDV and other herpes virus integrate at the ends of host’s chromosomes, preferably at 
TR sequences. It is, therefore, thought that vTR subunit might, in fact, have a significant 
role in maintaining the viral oncogenicity through telomeric elongations at the host’s 
chromosomal ends thereby inhibiting programmed cell death trough telomere 
shortening (31). However, it has recently been shown that both oncogenic and vaccinal 
strains of MDV have the ability to integrate into DNA, suggesting that integration alone 
is not sufficient for MDV-induced transformation (32). Chromosomal insertions of 
alphaherpesvirus DNA segments, including those from HSV and equine herpes virus 
types 1 (EHV-1) and EHV-3, have been associated with their oncogenesis, because 
many of the cells carrying integrated viral DNA displayed a transformed phenotype 
(31). Consistent with this, Delecluse et al. (33) has demonstrated evidences of MDV 
genome integration into host’s chromosomes for all lymphoma established, MDV cell 
lines. Additionally, expression of MDV-MEQ gene is essential for MDV-induced 
neoplastic transformation of latently infected cells (Figure 4). MEQ expressed 
specifically by oncogenic GaHV-2 has transcriptional activities that lends to modulation 
of host genomic activity. In relation to this, Lupiani et al. (34) conducted a study using a 
recombinant Md5 pathotype, attenuated by deletion of MEQ-gene. As expected, MDV 
did infect and replicate in the lymphoid organs and feather follicles; but there was no 
tumour induction, implicating that the integrating viral genome must requires a MEQ 
gene for induction and maintenance of oncogenic properties. Reactivation of MDV 
from latency and tumorigenic transformation of latently infected lymphocytes, mainly 
occurs in CD4+ T cells (35) 
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Figure 4: Model of MDV Neoplastic transformed CD4+ T cells and subsequent 
disseminated Systemic Infection in susceptible (B19) birds.  
4. Fully latent MDV-Transformed CD4+ T cells proliferate in all sites where immune 
systems cells are involved in primary and secondary line of defence. Early latently 
activated CD4+ T cells undergo neoplastic transformation due to transcriptional and 
transrepressional activity of viral oncogenic proteins such as MEQ. Pathogenesis arise 
in cases where vaccination failure is suspected (suboptimal dosage/titre, damage to 
vaccine or confirmed immunological vaccine failure), vaccination is not performed 
(backyard birds). B. Fully latent neoplastic MDV-Transformed CD4+ T cells infiltrate 
and establish a reservoir of MDV genome in peripheral nerve fibres interspace. These 
cells have a CD4+CD25+ Treg phenotype although additional cell surface markers have 
yet to be determined. Expression of viral neurovirulence factor, phosphoprotein 14 
(pp14), promotes neuropathy and cell survival. Neuropathy (Polyneuritis) is presented 
as transient or acute paralysis of legs, wings, neck, with vision impairment and weight 
loss depending on MDV-1 virulence factor. Birds infected with serotype-1 eventually 
succumb to death from paralysis. C. Reactivation from latency enables a second phase 
of replication whereby viral oncogenic protein MEQ acts on T cell signaling pathways 
causing uncontrolled cellular proliferation leading to disseminated lymphoma formation 
in visceral organs, peripheral and central nervous system, musculoskeletal systems, skin 
and eyes. Severe lymphoma eventually causes death in birds. Highly pathogenic viruses 
(serotype-1, vv+ MDV) kill birds before they reach the lymphoproliferative phase of the 
disease. 
 
 
Another important factor in the susceptibility to MD is the genetic background of 
established chicken lines which is, to some extent, associated with the MHC. MDV-
associated CD4+ T cell lymphoma can only be developed in genetically susceptible 
(B19) lines of chicken; however, the virus can replicate and be shed from both 
susceptible (B19) and resistant (B21) lines of chicken. It is believed that only a few 
subsets of CD4+ T lymphocytes undergo transformation, and thus are the origin of 
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lymphoma (36). This may explain why in most cases of MD tumour cells obtained from 
different anatomical sites, such as liver, kidneys, gonads, skin and muscles, all have 
similar CDR3 length profile suggesting that tumour cells are monoclonal (37). In most 
lymphoma cells, the virus is in the latent phase and does not produce viral particles and 
only 0.1% of tumour cells are in the lytic phase (38). Omar et al. (25) have revealed an 
association between the genetic background of chickens and their resistance to MDV; in 
relation to slight variations on MDV associated-MHC presentations between resistant 
(B21) and susceptible (B19) lines of chicken. These studies showed evidences of T cell 
mediated immune responses against the MDV antigen, ICP4, only in the resistant (B21) 
lines of chicken; but not in the susceptible (B19) ones. In contrast, both B21 and B19 
lines of chicken have been reported to show T cell immune responses against the other 
three MDV antigens: gB, MEQ and pp38. Nevertheless, these studies suggest that T cell 
mediated responses in combination with MHC play an important role in genetic 
resistance against MD. 
 
1.3.5 Cutaneous infection, replication and shedding 
Viral genomes are detectable by quantitative PCR in blood cells and feather tips of birds 
infected with oncogenic or vaccinal strains (10). Similar to other herpes viruses, MDV 
has a tendency to be transported towards cutaneous sites such as skin, and feather 
follicles. MDV is shed into the environment via scales and feather debris, which is a 
major source of contamination (39, 40). It is possible that T cells transport the virus to 
feather follicles, but the role of other immune cells in transporting the virus has not yet 
been ruled out. Infiltration of CD4+ and CD8+ T cells and expression of pro-
inflammatory cytokines into the skin of birds infected with a highly virulent virus (like 
RB1B) or by a vaccine strain of the virus (like CVI988/RISPENS or HVT) suggest that 
the immunity against the virus is ineffective at blocking virus replication and shedding 
(41, 42). Cell-free MDV is only produced in feather follicle epithelial cells, and it is 
believed that MDV relies exclusively on cell-to-cell transmission (43, 44). However, in 
a recent report, this notion has been challenged by demonstrating that in a cell-blebbing 
phenomenon and cell apoptotic corps clearance mechanism, MDV can be transmitted in 
a cell-free condition (45). MEQ expressing tumour tissues can also be found in the skin 
of infected birds and neoplastic cutaneous lesions in the scaleless chickens indicate that 
feather follicles are not necessary for skin tumour development. Finally, the data 
indicate that inoculation with supernatant fluid from homogenized and sonicated skin 
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samples of MDV-infected scaleless chickens induces MD in susceptible birds, 
suggesting that skin epithelial cells not associated with feather follicles also harbour 
infectious viral particles (46). The process of apoptotic corps clearance may well be 
related to its specific tropism for adaptive immune cells which leads to 
immunosuppression. It is still unclear whether either phenomenon also occurs in vivo 
during the early hours of infection or vaccination as well as the respective cells 
involved. Furthermore, vaccinated and challenge birds don’t show clinical signs of 
immunosuppression therefore an inherent resistance to cellular apoptosis is observed. 
This may have important implications in our understanding of MDV pathogenesis and 
development of next generation MDV vaccines. MDV can be detected in the feather 
follicles at around 11-14 dpi, using standard biochemical methods, and 6-7 dpi, using 
sensitive methods such as qPCR. In cutaneous sites, fully productive infection and 
replication is re-activated in feather-follicle epithelium and enveloped infectious viral 
particles in a cell free form are released. MDV can be found in the epithelium of feather 
follicles infected chickens more frequently than other tissues, both, in terms of 
incidence and levels of viral antigen expression (47). The virus replicates as enveloped, 
cell free MDVs in the feather follicles epithelium of infected chickens. These cell-free 
MDVs are highly infectious and are easily released into the poultry dust or litter. They 
have a very protective envelope, allowing them to survive for months in poultry thus 
facilitating horizontal transmission and infection of naïve animals in following 
production cycles (48).  
 
MDV infection and its global presence could also be a product of natural reservoirs 
located in backyard and migratory birds (Figure 5) such as Common teal, White-fronted 
goose, Pintail, European wigeon, and Mallard (49) and more recently in Roulroul 
partridges (50). The presence of MDV in wild and migratory birds has been well 
documented since the early 1980. So it is of no great surprise that new reports emerge as 
these viruses cause disease in newly identified host. Further monitoring is required to 
understand the importance of wild birds as reservoirs along migratory routes for 
pathogenic serotypes. 
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Figure 5: Model for Horizontal and Vertical transmission of MDV between avian 
species 
MDV serotypes can infect several different avian species globally. It has been 
confirmed that MDV cannot be transmitted horizontally from layer hens to eggs but day 
old chicks become infected in broiler production housing systems from shedders. 
Several avian species have been grouped based on literature: Free ranging and farm 
animals and Migratory birds. Chicken red mites have also been identified as carriers of 
avian pathogens. Free ranging and farm animals consist of turkeys, common pheasant, 
common grey partridge and European quail. Migratory birds that have been confirmed 
positive are ducks and white footed geese. Although these birds become infected and 
are carriers, what has not been identified is their role in viral virulence factors as well as 
ability to infect broiler production system. Furthermore, the presence of chicken red 
mites has yet to be confirmed in broiler production system which could contribute to 
viral persistence. 
 
1.3.6 Infection of immune cells 
Based on the current model of MDV pathogenesis, phagocytic cells such as 
macrophages and dendritic cells in the respiratory tract become infected either directly 
or after an initial round of viral replication. The virus can also replicate in macrophages 
and induce cytolysis in the infected phagocytic cells as demonstrated by high levels of 
cell death in splenic macrophages expressing three herpesvirus kinetic classes: ICP4 
(immediate early), pp38 (early) and gB (late). The level of infection in macrophages 
isolated from MDV-infected birds depends on the virulence of MDV. The in vivo 
results demonstrate that, at 4-6 days post infection, more virulent viruses (C12/130) 
induce 3-10 times higher percentages of pp38+ macrophages compared to that infected 
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with less virulent MDV. The results also show that pp38+ macrophages are prone to cell 
death. Interestingly, MDV antigens could only be detected in MDV infected 
macrophages, but not in uninfected macrophages that have phagocytosed MDV infected 
cells (51). Consistent with this view, Abdul-Careem et al (16) have shown an up-
regulation in nitric oxide synthase (NOS) gene in lung macrophages of MDV infected 
chickens. This results in production of nitric oxide (NO) reported to have anti-microbial 
activity against many viruses including MDV for both in vivo and in vitro conditions 
(19). Likewise, a similar distribution profiles of MDV antigen have been observed in 
MDV infected B lymphocytes during the early cytolytic phase. Replication of MDV in 
the lung induces host innate immune response as demonstrated by up-regulation of Toll-
like receptors (e.g. TLR 3 and TLR 7), pro-inflammatory cytokines (e.g. IL-1β and IL-
8) and iNOS genes as well as infiltration of macrophages (16). Host immune response 
to MDV in the lungs is ineffective in controlling virus replication in the lungs 
epithelium (16, 19, 24).  
 
Generally, the infection of mammalian immune cells such as macrophages and B cells 
with herpes viruses down-regulates the expression of both MHC class I and II 
molecules consequently, evading hosts’ cell mediated immunity (52). It has been shown 
that MDV infection down-regulates surface expression of MHC (B complex) class I 
(BF) glycoproteins during active but not latent infection of chicken cells (53). Further 
studies demonstrated that MDV012 and MDV pUL.49.5 genes (Table 1) are involved in 
down-regulation of MHC class I molecules by interfering with Transporter Associated 
with Antigen Processing (TAP) function. However, the effects of MHC class I down-
regulation in the pathogenesis of the disease is unknown and recombinant viruses 
lacking the cytoplasmic tail of pUL49.5 exhibit almost similar pathogenicity as wild 
type virus in both the resistant (B21) and susceptible (B19) lines of chicken (54, 55). 
NK cells and more importantly cytotoxic T lymphocytes (CTL) which monitor cell 
surface MHC class I molecules and viral peptide complex respectively may play a 
major role in host defence against infection. Contrary to MHC class I,  MDV infection 
up-regulates MHC class II molecules on chicken APC’s such as macrophages (56, 57), 
and this may contribute to virus spread within the infected host by increasing the 
interaction between infected macrophages and activated CD4+ T cells. Since MDV 
requires cell-to-cell contact for virus spread and productive infection of T cells and 
other immune cells, this up-regulation of MHC class II molecules might, in fact, be 
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essential in the pathogenesis of Marek’s Disease within the infected host by increasing 
the interaction between infected macrophages and activated CD4+ T cells (53, 56). HIV 
infection can also induce activation of innate response and up-regulation of MHC class 
II molecules which can lead to immuno-pathology (58, 59).  It is still unclear whether 
MHC class II up-regulation observed after MDV infection can induce 
immunopathology which is clearly manifested in MDV pathogenesis. In the infected 
cells, MDV virus expresses a viral antigen with high amino acid sequence homology to 
CXCL13, termed viral IL-8 (vIL-8) (60). CXCL13 exerts its chemotactic effects by 
interacting with chemokine receptor CXCR5 and is a major regulator of trafficking for 
B cells and subsets of T cells. This viral chemokine has the ability to recruit immune 
cells to the site of infection (22). The deletion of vIL-8 from open reading frames 
severely affects MDV pathogenesis and tumour incidence (22, 61, 62). vIL-8 induces 
chemotaxis of B cells and regulatory T cells (CD4+CD25+ T cells), and these cells are 
targets for both lytic and latently infected cells, thus demonstrating a virus specific 
tropism (62). Within 24 hours after infection, the virus can be detected in the bursa of 
Fabricius, spleen, and thymus (11, 12). It is believed that macrophages and dendritic 
cells can disseminate the virus from the lungs to B cells and CD4+ T cells in these 
lymphoid organs. Splenic B cells play an important role in the replication of MDV, and 
the high titre of circulating virus is due to the replication of the virus within B cells, but 
in the absence of B cells, the virus replicates in other immune cells and MD can still be 
developed. In the cytolytic phase of the disease, large number of splenic B cells 
undergoes apoptosis and cell death. Depletion of B cells and CD4+ T lymphocytes in 
lymphoid tissues, such as cecal tonsils (CTs), of susceptible chicken lines within 5 day 
post infection  may contribute to immunosuppression observed in late cytolytic phase of 
the disease. The depletion of B and T cells in the CTs of the resistant line of chicken 
was minimal at 5 dpi, which also recovered by 21 dpi (63). Virus replication in B and T 
cells reaches its peak between 3 and 7 dpi. B lymphocytes constitute the majority 
(around 90%) of cytolytically infected (MDV-antigen positive) cells, while CD4+ and 
CD8+ T lymphocytes represent only 3 and 8%, respectively (64, 65). MDV can be 
transmitted directly to T cells from the infected macrophages or dendritic cells; 
however, the transfer of virus from B cells to T cells is also conceivable.  
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Table 1: MDV genes and their respective products involved in immune modulation and 
pathogenesis 
MDV Gene 
(Protein) 
Function 
Antigenic 
potential 
Infectio
n Stage 
Reference 
MDV003/078 
(vIL-8) 
Viral chemotactic (CXCL-) protein involved in recruiting 
immune systems cells to site of viral replication 
-- 
L
Y
T
IC
 R
E
P
L
IC
A
T
IO
N
 
(22, 61) 
MDV010 
(vLIP) 
Shares homology to host lipase enzyme and forms covalent 
bonds with lipids 
-- (66) 
MDV011/012 
Immune evasion protein that down regulates cell surface 
MHC I expression 
-- (54) 
MDV 
ORF012 
Phosphoprotein required for viral growth both in-vivo and 
in-vitro 
-- (67) 
MDV040 
(gB) 
Hypothetical function: Virion membrane protein that  
heterodimerizes with other glycoproteins facilitating viral 
fusion with host membrane 
Yes (25, 26) 
MDV052/053 
UL39/40 
(RR) 
Viral Ribonucleotide Reductase (RR) is essential for 
replication both in-vivo and in-vitro 
-- (68) 
MDV064 
(UL49.5) 
Partially reduces MHC I expression by interacting with 
TAP protein 
-- (55) 
MDV073 
(pp38) 
Early protein expressed during cytolytic infection and 
phosphorylated by  Us3p 
Yes (25-28) 
MDV092 
(Us3p) 
Serine/threonine protein kinase that phosphorylates pp38 -- (69) 
MDV084/100 
(ICP4) 
Viral gene transactivation function Yes (25, 26) 
MDV001a 
(vTR) 
Required for integration of viral genome into host DNA for 
immune evasion, neoplastic transformation and viraemia 
-- 
L
A
T
E
N
C
Y
 
(70) 
MDV0 
(pp14) 
Neurovirulence factor required for PNS neuropathy (acute 
or transient paralysis) 
-- (71) 
MDV062 
(VP22) 
Tegument protein essential for viral replication and 
modulates host cell cycle 
-- (72) 
MDV057 
(gC/UL44) 
Type 1 transmembrane protein required for horizontal 
transmission/shedding from feather follicle epithelium 
-- 
F
E
A
T
H
E
R
 
F
O
L
L
IC
L
E
 
S
H
E
D
D
IN
G
 
(73) 
MDV005/076 
(MEQ) 
Viral oncogenic protein involved in T cell neoplastic 
transformation which forms homodimers and heterodimers 
with specific intracellular signalling proteins that modulates 
host cell cycle 
Yes 
N
E
A
O
P
L
A
S
T
IC
 
T
R
A
N
S
F
O
R
M
A
T
I
O
N
 
(25, 26, 
34) 
MDV029 
(pUL17) 
Co-localizes with VP5 and VP13/14 tegument protein and 
essential for in-vivo viral growth, capsid maturation and 
DNA packaging. 
-- (74) 
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Cytolytic infection of B and T cells is semi-productive, which is defined by their 
inability to express certain viral structural components. No cell-free virus is produced 
by the infected T and B lymphocytes and only non-enveloped intra-nuclear particles are 
detected (14). The precise mechanism as to how in vivo MDV spreads from cell to cell 
has not been elucidated. However, it is assumed that MDV glycoproteins (g) B, gC and 
gD, similarly observed in most herpes virus, are likely to interact with host’s cell 
surface receptors; thereby, forming an intracellular bridge between infected and 
uninfected cells which might, in turn, contribute to cell associated viral spread in MD. 
Similarly, co-existence of MDV gH and gL have been reported to be vital for GaHV-2 
cell to cell viral spread. The primary peptide of gL has a high affinity for specific region 
of gH, and therefore binds to it giving rise to a complex, hetero-oligomer structure that 
anchors itself onto the cell surface of infected host cell, promoting MDV proteins (gp) 
cell surface expression (75). In support, Schumacher et al. (76) demonstrated that 
deletions of  gE (20DeltagE) or gI (20DeltagI) were essential in restricting viral spread 
and plaque formation, although viral replication was not abolished. Transfecting gE or 
gI did not support viral spread indicating that gE and gI could work in synergistic 
manner to aid viral spread. Furthermore, It is possible that MDV mainly replicates 
within B and T cells by mitosis of infected cells rather than production of virions. Thus, 
expression of all viral genes are not necessary for replication in vivo. By not producing 
all the MDV viral antigens that may be highly immunogenic, the virus can escape 
immune control. This notion is supported by the fact that the resting T cells, with low 
proliferative abilities, are less susceptible to MDV infections than the activated 
lymphocytes. T cell activation may increase the expression of surface molecules that is 
engaged in virus entry, thus enhancing the occurrence of MDV infection in these cells. 
 
Similar to MDV, the infection of human CD4+ T cells by Human T-cell leukaemia virus 
type 1 (HTLV-1) is increased in activated CD4+ T cells. This is reflected on up-
regulation of heparan sulfate proteoglycans (HSPGs), a receptor for HTLV-1, on 
activated CD4+ T cells (77). No specific receptor for MDV entry into chicken CD4+ T 
cells has yet been identified. It is conceivable that MDV infection induces cytolysis/ 
inflammatory responses and T cell activation, which leads to T cell infection and viral 
replication via mitosis by passing the virus to daughter lymphocytes.  
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The underlying genetic variation within different chicken lines may play a key role in 
the pathogenesis and prognosis of the MDV infection. The percentages of T cells that 
become cytolytically infected in the lymphoid organs are less than 2% in MD-
susceptible chickens and 0.2% in the resistant chickens (14, 64). In support, Omar et al. 
(25) have demonstrated evidences of T cell mediated immune responses against the 
MDV antigen, ICP4, only in resistant (B21) lines of chicken; but not in susceptible 
(B19) ones. In contrast, both B21 and B19 lines of chicken have been reported to show 
T cell immune responses against MDV antigens: gB, MEQ and pp38. Nevertheless, 
these studies suggest that the role of T cell mediated immunity, and differences in T cell 
receptor repertoire generation in conjuncture with other inherent genetic resistance 
mechanism against MD cannot be ruled out. In latent phase of infection, MDV antigens 
cannot be detected in the lymphoid tissues and there is no production of infectious 
viruses. It is difficult to distinguish latent infection from transformation phase, as both 
represent non-productive infections. Following in vitro reactivation of MDV from virus 
antigen-negative lymphocytes, the majority of latently infected lymphocytes were 
identified as T cells with only 3% being B cells (14). MEQ antigen from MDV plays a 
crucial role in maintaining latency by blocking apoptosis of latently infected CD4+ T 
cells. One of the pronounced differences in gene expression profile between MDV-
resistant and susceptible lines of chicken after MDV infection are genes that are 
associated with apoptosis (78). In addition to MEQ, it has been shown that microRNA 
miR-M3, an MDV-encoded miRNA, abrogates apoptosis by directly targeting Smad2, a 
critical component in the transforming growth factor (TGF)-β (79) providing an 
environment beneficial for latency and oncogenesis. miR-M4, an orthologue of the 
oncogenic miR-155, was shown to have a direct effect on inducing MDV-induced T cell 
lymphoma, as viruses deleted in miR-M4 or having mutations in the seed region failed 
to induce lymphoma (80). Viral miR-M4 exerts its effects by reducing the levels of 
latent TGF-β binding protein-1, which is involved in the maturation of TGF-β. This 
leads to a reduction in the levels of active Smad2/3 and release of the inhibition of the c-
Myc promoter, resulting in a rise in c-Myc transcription. The production of viral protein 
MEQ allows the formation of complexes with c-Myc (81), which is associated with 
transformation. In the susceptible chickens, a second wave of semi-productive infection 
and cytolysis are observed between 14 and 21 dpi (11). This late cytolytic phase is 
associated with immunosuppression, atrophy of lymphoid tissues such as thymus, bursa 
of fabricius, cecal tonsils and infiltration of mononuclear cells and heterophils (11, 82). 
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Virus is probably transferred to the skin by latently infected CD4+ T cells and infects 
skin and feather follicles in a yet unknown mechanism. Syncytia formation in skin 
epithelium may be a product of viral protein which facilitates and pools greater 
resources for viral replication. The involvement of other immune system cells such as 
macrophages and dendritic cells to transport the virus to the skin cannot be excluded. 
Replication of MDV starts at 7 dpi, well before tumour development. Therefore, it is 
possible that early infected CD4+ T cells, but not necessarily latent or transformed CD4+ 
T cells, transport the virus into the skin at this time.  
 
 
1.4 The immune response to MDV 
1.4.1 Innate immunity:  
While effective immunity against human alphaherpesviruses relies on both innate and 
adaptive mechanisms, the innate immune response has been shown to be of paramount 
importance (83). Less is known about the role of innate immunity in the control of 
MDV in chickens. 
 
1.4.1.1 Interferons:  
Type I IFNs belong to a family of cytokines that attracted much attention owing to their 
protective role against viral infection. IFNs are widely expressed cytokines that possess 
strong antiviral and immunomodulatory properties. The IFN family can be classified 
into three main types of cytokines: type I, type II and type III IFNs. IFN-α and IFN-β 
belongs to type I IFN family, while the type II IFN family includes only one cytokine: 
IFN-γ, which also exhibits antiviral activities (84). The third type of IFNs is the IFN-λ 
family. In mammals, plasmacytoid dendritic cells (pDCs), monocytes, epithelial cells 
and fibroblasts are the main producers of type I IFNs (85), while type II IFNs are 
predominantly produced by NK cells and activated T cells. In spite of the fact that 
chicken type I IFNs are shown to inhibit viral infection both in vivo and in vitro, 
chicken pDCs have not been identified.   
 
Chickens become infected with MDV via the respiratory system by inhaling infected 
dust. MDV is taken up by phagocytic cells such as macrophages or dendritic cells 
within the respiratory system. Chicken lung has a different anatomical structure than the 
mammalian counterpart consisting of air sacs; and due to narrower pulmonary 
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capillaries than in mammals there are fewer airway resident macrophages (86). 
Therefore, it is likely that MDV has to cross lung epithelial lining before being 
transported by phagocytic cells to lymphoid tissues. In the respiratory system, the virus 
can be recognized by toll-like receptors (TLRs), such as TLR21 (recognizing 
unmethylated CpG DNA), leading to the initiation of protein signalling cascaded which 
stimulates the expression of type I interferons (α and β), shown to be involved in 
antiviral defence. In fact, an increase in the expression of TLR receptors in the lungs of 
MDV-infected birds (35), IFN-α expression in the blood of susceptible chickens (87) 
and interferon regulatory factors (IRF)-1 and IRF-3 in MDV-infected chicken 
embryonic fibroblasts cells (CEF) have been reported (88, 89). The role of IFNs in the 
control of MDV replication has been confirmed in an in vitro model showing that 
chIFNs reduces plaque formation and expression of pp38 and gB in the infected cells 
(90). The protective role of IFNs is also indicated by the results demonstrating the 
differential expression patters of IRF-3 and IFN-β genes in resistant and susceptible 
lines of chicken (91). Similarly, oral administration of IFN-α are shown to reduce MDV 
viral replication in vivo (92).  
 
In addition to their direct effects on viral replication, type I interferons may also activate 
other immune system cells such as Natural killer (NK) cells and increase their cytotoxic 
function (93). However, it has been suggested that chicken NK cell cytotoxicity is not 
increased after oral administration of recombinant chicken IFN-α or inoculation of 
recombinant MDV expressing chicken IFN-α. In chickens inoculated with rMDV (IFN-
α), NK cell cytotoxicity was not enhanced over control chickens at 4 and 7 days dpi. 
Furthermore, at 4 dpi, chickens inoculated with R2/23 actually had decreased NK cell 
cytotoxic activity. Therefore, it is concluded that chIFN-α, given at high doses orally in 
the drinking water or via expression in a recombinant MDV vector, does not increase 
NK cell cytotoxicity as originally hypothesized (92). The suppression of immune 
responses by oral administration of IFN-α is not a novel phenomenon as similar 
observations are reported in murine model where, bone marrow functions were 
suppressed by administration of murine IFN-α orally or subcutaneously (94). In fact, it 
has been shown that type I IFNs modulate the function of both innate and adaptive 
immune cells including DCs and T cells in the gut and suppress the intestinal 
inflammation. Taken together, it is believed that type I IFN response by MDV-infected 
cells promotes the activation of immune cells and inhibits MDV replication and 
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dissemination. Considering the complexity of MDV and co-evolution of the virus with 
the host’s type I IFNs response, it is very likely that there is a complex relationship 
between MDV and host response. The exact role of type I IFNs in the pathogenesis of 
MDV in chickens is poorly understood due to lack of immunological reagents, 
complexity of MDV infection and the cell-type specific effect of type I IFNs. However, 
it is possible that type I IFNs may be involved in promoting latency infection of MDV 
as has been observed in other alphaherpesviruses (95). 
 
The role of type II IFNs, IFN-γ, is discussed in more detail in adaptive immunity 
section. IFN-γ is induced during MDV infection and shown to have inhibitory effects on 
MDV replication by inducing nitric oxide production (90) and the administration of 
IFN-γ with MDV vaccine positively influenced vaccine-induced protective immunity in 
vivo (96). There is no information on the role of type III IFNs on viral infections in 
chickens. 
 
1.4.1.2 Macrophages 
There is very little information on the type and function of immune system cells 
involved in the initiation of immune responses against MDV in the respiratory system 
of chicken. However, it is believed that chicken professional APC’s such as 
macrophages and dendritic cells play an important role in the development of adaptive 
immunity against MDV. In addition to their ability to present MDV antigens in 
association with MHC class I and II molecules to initiate adaptive immunity, 
macrophages can also be directly involved in inhibition of MDV replication and 
development of MD. Macrophages isolated from B21 chickens have higher phagocytic 
activity than B19 chickens to MDV (97). Moreover, macrophages obtained from MDV-
infected chickens inhibited viral replication in vitro more efficiently than macrophages 
isolated from non-infected chickens (98). Further confirmation on the role of 
macrophages in MDV infection is obtained from the results demonstrating that 
depletion of macrophages from splenocytes increases MDV replication (97), while 
stimulating macrophages in vivo reduces the incidence of MD (99). Taken together, the 
evidence presented here from several studies confirms that macrophages play a pivotal 
role in control of MDV replication and MDV-derived tumour incidence. One of the 
mechanisms involved in the inhibitory function of macrophages on Marek’s disease is 
their ability to produce inducible nitric oxide (iNOS). The production of NO has been 
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reported in the spleen, brain and lungs of MDV-infected chickens (10, 100-102) and NO 
is shown to inhibit MDV replication with highest level of NO production detected in 
serum and spleen of resistant chickens compared to susceptible chickens (102, 103). 
Further experiments demonstrated that the inhibition of iNOS in chickens increases 
viral load, suggesting that NO plays an important role in the control of MDV replication 
in vivo (102). Another function of macrophages is their ability to kill tumour cells and it 
is believed that activated chicken macrophages have the ability to lyse MDV-derived 
tumour cells in vitro (104). In contrast to activated and fully functional macrophages, 
tumour associated macrophages (TAMS) represent key regulators of the complex 
interplay between the immune response and cancer. TAMS produce tumour growth 
promoting factors and induce immunosuppression by releasing immuno-modulatory 
factors (105). Macrophages isolated from tumour tissues of MDV-infected chickens 
demonstrate similar functional abilities as TAMS and have been shown to suppress T 
cell proliferation in vitro. The development of immuno-regulatory macrophages in 
MDV-infected chickens correlates with transient immunosuppression observed during 
primary cytolytic phase of infection (106), suggesting that TAMS may be involved in 
MDV-induced immuno-suppression. 
 
1.4.1.3 Natural Killer cells:  
NK cells represent important effectors of the innate immunity and can respond to 
stimuli and produce anti-viral cytokines such as IFN-γ. In addition, these cells have 
ability to recognize virus- infected cells/ tumour cells via ligation of cell death receptors 
and the release of granules. NK cells from MDV-resistant chickens have higher 
cytotoxic capability than the MDV-susceptible chickens, suggesting that these cells may 
be involved in determining resistance to MDV. This hypothesis is also supported by the 
results demonstrating that MDV-infected chickens have higher NK cell activity than the 
cells isolated from the non-infected birds and; this activity lasted longer in the resistant 
chickens than the susceptible chickens (107). The exact role of NK cells in providing 
vaccine-induced protection against MDV is still unknown, however, there are some 
evidences demonstrating that vaccination against MDV increases the functional abilities 
of NK cells. This may explain how MDV vaccine can provide protection in vaccinated 
chicks as early as 3 days post vaccination (107). NK cells also play a fundamental role 
as antitumor senses through downregulation of cell surface markers such as MHC I. A 
notable characteristic of herpes viral infection and specifically MDV is down regulation 
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of MHC I cell surface translocation. Further to that, anti-tumor activity has not yet been 
demonstrated in an MDV resistant model independent of genetic factors that predispose 
resistance to neoplastic transformation of CD4+ T cells. Taken together, it has been 
suggested that NK cells may play an important role in controlling MDV infection (107-
109). Using recently identified markers such as CD56 and CHIR-AB1 (110) for 
identification of chicken NK cells, researchers will be able to elucidate the role of these 
important cells in providing protection against MDV.  
 
1.4.2 Adaptive immunity 
The key components of adaptive immunity are B and T lymphocytes which specifically 
recognize antigens and generate memory response. B cells are involved in humoral 
immune response, whereas T cells are involved in cell-mediated immune response. 
 
1.4.2.1 Humoral immunity 
As MDV is a cell-associated herpes virus and is strictly intracellular, antibodies should 
not have a major role in the protective immunity against MDV infection. However, 
antibodies against several MDV glycoproteins including gB, gE and gI have been 
detected in MDV-infected chicken (111, 112). The role of these antibodies in providing 
protective immunity against MDV has not been clarified. However, there is some 
evidence suggesting that anti-gB neutralizing antibody may have a protective role 
against MDV, perhaps via blocking virus entry into the host cells or antibody dependent 
cell-mediated cytotoxicity (ADCC) of infected cells. The role of antibody response in 
the control of MDV infection is also confirmed by the fact that the presence of maternal 
antibody delays the development of clinical signs and tumour. However, the presence of 
maternal antibody can interfere with live replicating vaccines against MDV by 
neutralizing the vaccinal virus (14). Therefore vertical transmission of immunological 
factors such as maternal antibodies can be a limiting factor for both generations of 
protective immunity as well as delaying immune responsiveness to infection of 
offspring from vaccinated layers. Maternal antibody and interference with vaccination 
has been reported in both human and veterinary medicine regardless of the types of 
vaccine formulations used. It has been shown that while maternal antibody can interfere 
with antibody response, vaccine-induced cell-mediated immune responses are largely 
unaffected. This has been confirmed in humans, murine models and farmed animals 
(113-118). With regard to the inhibitory effect of maternal antibody response, new 
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strategies have been developed to overcome the inhibitory effects of maternal antibody 
on vaccine-induced antibody response (116). Therefore, it should be possible to 
overcome the neutralizing effects of maternal antibody against MDV in novel 
vaccination strategies. 
 
1.4.2.2 Cell-mediated immunity 
Antibody and cell mediated immunity is involved in the control of infection with highly 
cell-associated human alphaherpesviruses such as VZV. Both CD4+ and CD8+ effector 
and memory T cells are shown to be essential for recovery from VZV and maintaining 
the latent stage of infection in the subclinical state. Generally, it is believed that (a) 
broad (response to several epitopes), (b) durable (memory response), and (c) multi-
functional (capable of producing several Th1 type cytokines/ kill virus infected cells) T 
cell response is associated with the control and resolution of viral infections. MDV is 
also a highly cell-associated alphaherpesviruses, and thus it is postulated that cell-
mediated immunity is crucial for the vaccine induced protection (119, 120). Since MDV 
exists in cell associated forms inside the host, except in feather follicles, T cell mediated 
immunity is thought to be more important than the antibody mediated immunity in the 
control of the disease in chickens (121). Studies have shown evidences demonstrating 
the presence of CD8+ T cells against MDV antigens such as: gB, MEQ, pp38 and ICP4. 
However, the role of CTL in conferring long term immunity, generation of memory 
cells, in genetically resistant chickens is unknown (35) and the role of cell-mediated 
immunity in vaccine-induced protection has not been determined. No cytotoxic 
response against ICP22 and a weak cytotoxicity against MEQ were detected in MDV-
infected chickens (14, 25). Other studies confirmed the presence of anti-gB and anti-gI 
TCRαβ1+CD8+ T cells with cytotoxic abilities in MDV-infected birds (122).  
 
The presence of herpes virus specific CD8+ T cell response coincides with protection 
from cytomegalovirus (CMV) infection and adoptive cell transfer of CD8+ T cells 
provide protection in animal models. The importance of CD4+ T cells in providing 
protection against herpes virus infection was also demonstrated by CD4+ T cell 
depletion experiments in animal models. There was an inverse correlation between the 
number of virus-specific CD4+ T cells and prolonged shedding (119, 120). Therefore, it 
is very likely that both CD8+ and CD4+ T cells are also involved in the control of MDV 
replication. This notion is confirmed with the early studies showing that T cells are 
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crucial for the control of tumour growth in HVT-vaccinated chickens. The importance 
of T cells in the control of tumour growth was confirmed by demonstrating that HVT 
vaccinated birds treated with cyclosporine, a drug shown to inhibit T cell function, 
developed MDV-lymphoma (123, 124). However, later studies suggested that  T cells 
are only involved in the control of viral replication but not essential for the control of 
tumour growth (125). Further studies are required to confirm the exact role of CD4+ and 
CD8+ T cells in the control of MDV replication and tumour growth. The availability of 
CD4+ and CD8+ knockout chicken will provide valuable tools to study the role of these 
cells in vaccine-induced protective immunity against viral replication and tumour 
growth. MHC-determined resistance to MDV in MHC: B21/B21 birds indirectly 
confirms the role of T cells in control of tumour development. For MHC class I 
molecules, the relative level of expression varies between different MHC haplotypes 
and reflects the consensus hierarchy of response by different MHC haplotypes with the 
most susceptible chickens (MHC B19/B19) having the highest expression while the 
most resistant chickens (MHC: B21/B21) expressing the lowest level (126). It is 
believed that the differences in cell surface expression level ensure the development of 
optimal peripheral T cell responses against MDV. The detection of MDV-specific CD8+ 
T cells with cytotoxic ability to recognize target cells expressing MDV antigen is 
technically challenging. However, Schat and co-workers developed a heterologous 
system to investigate cytotoxic T cell response to MDV using reticuloendothelial virus-
transformed cells stably transfected with specific MDV genes. The cell lines derived 
from resistant (MHC: B21/B21) and susceptible (MHC: B19/B19) birds were generated 
and antigen-specific cytotoxicity were analysed in vitro. The cytotoxicity was low 
compared to mammalian cytotoxic T lymphocyte (CTL) assays (14). In these studies, a 
relatively more potent cytotoxicity was detected against target cells expressing pp38 and 
gB antigens. No cytotoxic response against ICP22 and a weak cytotoxicity against MEQ 
were detected in MDV-infected chickens (14, 25). Other studies confirmed the presence 
of anti-gB and gI TCRαβ1+CD8+ T cells with cytotoxic abilities in MDV-infected birds 
(122). Vaccination of chickens with a recombinant Fowl Pox Virus (FPV) expressing 
these two glycoproteins have been reported to induce protective immunity when 
challenged with MDV and shown to induce anti-MDV neutralizing antibodies (127, 
128). Recombinant FPV expressing gB was later shown to induce cytotoxic T cell 
response recognizing target cells expressing gB (129). These data support the 
importance of anti-MDV CD8+ T cells responses in the control of the disease, however, 
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the role of MDV-specific CD8+ T cell responses in the control of viral infection or 
tumour growth in birds immunized with HVT or CVI988/RISPENS is still unknown. In 
addition, there is very little information on the magnitude and quality of MDV-specific 
T cells responses in resistant vs. susceptible chickens. The only available information 
suggest that anti-ICP4 CD8+ T cell responses is only detected in the resistant chickens 
(25), while anti-gE CD8+ T cell response is only detected in the susceptible chickens. 
These results suggest that the response to ICP4, an immediate early MDV gene product, 
but not to gE may be an important factor in genetic resistant to MDV. It has been shown 
that CTL responses characterized by release of perforin and granzyme B can be induced 
against MDV antigens such as pp38, MEQ and ICP4 (35). Moreover, there is still no 
information on the presence of MDV-specific CD4+ T cell responses and whether 
transformed CD4+ T cells have antigen specificity to MDV antigens. Further studies are 
required to identify CD4+ and CD8+ T cell epitopes within MDV antigens and 
determine their MHC restriction. Moreover, it is important to examine the quality, 
broadness, durability and magnitude of the CD4+ and CD8+ T responses in MDV 
infected or vaccinated chickens and determine the correlates between T cell responses 
and protection.  
 
In addition to T cell responses against MDV viral antigens, it is possible that T cells 
may also recognize self-antigens expressed by tumour cells. However, the nature of 
these self-antigens and their relevance to immunity and inhibition of tumour growth in 
birds is still unknown. A few decades ago, Marek’s disease tumour-associated surface 
antigens (MATSA) was identified in the MDV-transformed T cells (130). However, it 
was later discovered that activated T cells can also express MATSA antigens, and this 
molecule is not solely expressed on transformed T cells (131). Several of these MATSA 
are found to be activation associated lymphocyte antigens, and one of them is identified 
as CD30 molecule (48). Meanwhile CD30, a co-stimulatory molecule, has been shown 
to have pleiotropic effects on human T cell activation, apoptosis, effector function 
(cytotoxicity) and regulating T cell trafficking/migration (132). It has a fundamental 
role across all T cell lineages such as CD4+, CD8+ and Th17 cells (133) and may 
influence T cell interaction; suppressive action in the tissue microenvironment. 
 
Immunomodulatory processes that influence CTL functional abilities in relation to 
persistent viral infection and tumorigenesis may be mediated via interaction of 
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inhibitory receptors such as CTLA4, programmed death-1 (PD-1) and its respective 
ligand programmed death ligand-1 (PD-L1) (Figure 6). The evidence suggests that 
MDV infection up-regulates the expression of CTLA-4, PD1 and PD-L1 in chicken 
immune system cells. The expression level of PD-1 was increased in chickens at the 
early cytolytic phase of the MDV infection, while the PD-L1 expression level was 
increased at the latent phase. In addition, the expression levels of PD-1 and PD-L1 were 
increased at tumor lesions found in MDV-infected chickens (134, 135). Furthermore, T 
cell responsiveness may be affected by chronic antigen stimulation leading to 
exhaustion thus altering phenotypic characteristics such as PD-1 expression also 
observed during in vitro MDV infection. A combination of reduced MHC class I and 
increased PD-1 cell surface translocation provides a platform for highly efficacious 
immune evasion tactic. CTLA-4, a potent inhibitory receptor, expressed by CD4+ T 
cells has also be reported during the early cytolytic phase in MDV infected birds (134). 
Significant differences in CTLA-4 and PD-1 expression levels, which could result in a 
delayed immune responsiveness (anergy) and cell death respectively, were reported 
between resistant and susceptible lines of chickens challenged with MDV. A similar 
phenotype has been reported in patients infected with human alphaherpesviruses such 
as VZV whereby CD4+ T cell predominantly express CTLA-4 and PD-1 (136). 
Induction of an early immune unresponsiveness (anergy) and cytolysis (4-7 d.p.i.) could 
well be a hallmark, for alphaherpesviruses, to establish early semi-productive viral 
replication and disseminated viraemia. Blocking or down regulating CTLA-4 or PD-L1 
could be therapeutically significant during early infection. Furthermore, PD-L1 
expression results in immune suppression thus can be used as a marker for CD4+ T cell 
lymphoma. PD-L1 expression in MDV challenged chickens, could limit the quality of T 
cells immune responsiveness to MEQ, pp38, ICP4 or gB at the immunological synapse 
(Figure 5). PD-1 and CTLA-4 ligation with its cognate receptor results in cross-pathway 
interference resulting in inhibition of RAS, ERK 1/2, AKT, JNK and PLCγ 
phosphorylation altering cell fate; growth/proliferation, effector function and survival. 
Expression of inhibitory molecules on both antigen presenting cells can lead to the 
generation of chicken regulatory CD4+ T cells (Treg cells). The role of naturally 
occurring and peripheral derived Treg cells in modulation of anti-MDV immunity is still 
unknown. However, it is known that MDV infection up-regulates the expression of 
inhibitory molecules such as CTLA-4 and expression of inhibitory cytokines such as IL-
10.  The expression of regulatory molecules such as CTLA-4 and IL-10 on both CD4+ 
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and CD8+ T cells are at 10 and 21 dpi and this effect was more pronounced in the 
MDV-susceptible lines of chicken (137).   
 
 
 
Figure 6: T cell activation and tolerance by tumour cells/ antigen presenting cells.   
Inhibitory or stimulatory molecules expressed on the surface of antigen presenting cells 
(APC) or tumour cells regulate T cell function. Moreover, stimulatory or inhibitory 
cytokines may drive the generation of different T cell populations (e.g. Th1, Th17, Treg 
etc.) with diverse functional properties. Signal one is provided to the T cell receptor of 
T cells by presentation of antigens via MHC class I or II molecules expressed by APCs 
or tumour cells, while the signal 2 is provided by co-stimulatory molecules such as B7 
family. Co-stimulatory signals induce the generation of effector T cells, which can 
recognize and lyse target cells or produce cytokines such as IFN-γ, involved in the 
control of tumour growth. In contrast, inhibitory molecules deliver negative signals and 
suppressing the effector T cell function, and induce T cell anergy or exhaustion.  
 
1.5 Persistence in the face of vaccination 
Vaccination against MD started in the late 1960s using turkey herpesvirus (HVT) which 
does not induce disease in chickens. Vaccination reduced the incidence of MD by 99% 
and was the first successful vaccine against naturally occurring virus-induced cancer. 
Since then MDV has evolved, perhaps due to vaccine induced immune response, and 
the escape of new mutants from immune pressure. Currently only the attenuated MDV 
strain; CVI988/RIPENS is effective in providing protection against the very virulent 
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MDV. Live vaccines are administered either to day-old chicks or to the 18-day-old 
embryo. MDV vaccine inhibits the development of MDV-induced lymphoma but does 
not prevent infection and replication of pathogenic strains of MDV. Both vaccination 
and maternal antibodies against MDV increases viral shedding and onward transmission 
of hyper-virulent strains of MDV due to the survival of the host without controlling the 
virus shedding (138). The failure of current vaccines to induce sterile immunity can be 
attributed to MDV inducing latency with minimal viral replication and viral protein 
expression. The ideal MDV vaccine is to control both the disease and viral shedding in 
the infected birds. Revaccination (prime-boost) with the current cell-associated MDV 
vaccine (CVI988/RIPENS) improve protection against the disease and increases the 
magnitude of anti-MDV T cell responses as demonstrated by enhancement of anti-MDV 
neutralizing antibody and proliferation of CD4+ and CD8+ T cells (139). However, the 
type and quality of immunity after even revaccination with the current MDV vaccines 
cannot control virus shedding.  
 
To generate more effective vaccines against MDV, we need to (A) have a better 
understanding of the type of immunity required for reducing viral shedding/ inducing 
sterile immunity (B) design a vaccine that can induce protective immunity against the 
virus. It is believed that the quality, broadness, durability and homing of both CD4+ and 
CD8+ T cell responses may explain why vaccines against some alpha-herpes viruses 
(VZV) are more effective than vaccines against other alpha-herpes viruses (HSV) (140). 
As yet there is little information as to whether cell-mediated immunity is induced by the 
MDV vaccine.  
 
The lack of established methodology to assess cell-mediated immunity to MDV vaccine 
is the major obstacle to have a better understanding of how MDV vaccine actually 
works. Several factors including genetic background of chickens (141), presence or 
absence of maternal antibodies, virulence of MDV, vaccine dose (142) and concurrent 
infections with other immunosuppressive pathogens such as CIAV (122) can influence 
the efficacy of MDV vaccines. It is very likely that the induction of both innate and 
adaptive immune responses by vaccine strain is similar to those induced by pathogenic 
MDV (107, 143). There are some evidences demonstrating that a number of MDV 
antigens, including gB when administered as recombinant vaccine in a fowl pox vector, 
are immunogenic and immunity to these antigens confers protection (129). It is 
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postulated that vaccine-induced adaptive immunity plays a major role in providing 
protection against the disease. However, the types and magnitude of vaccine-induced 
protective immune responses to these antigens are still unknown.  
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2.1 Abstract  
1,25-Dihydroxyvitamin D3 (Vitamin D) is a naturally synthesized fat soluble vitamin 
shown to have immunomodulatory, anti-inflammatory and cancer prevention properties 
in human and murine models. Here, we studied the effects of Vitamin D on the 
functional abilities of avian T lymphocytes using chicken Interferon (IFN)-γ ELISPOT 
assay, BrdU proliferation assay, Annexin V apoptosis assay and PhosFlow for detecting 
phosphorylated signalling molecules. The results demonstrate that Vitamin D 
significantly inhibited the abilities of T lymphocytes to produce IFN-γ and proliferate in 
vitro (P ≤ 0.05), but retained their ability to undergo degranulation, which is a maker for 
cytotoxicity of these cells. Similarly, Vitamin D did not inhibit Extracellular signal-
Regulated Kinase (ERK) 1/2 phosphorylation, a key mediator in T cell signalling, in the 
stimulated T lymphocytes population, while reduced ERK1/2 phosphorylation levels in 
the unstimulated cells. Our data provide evidence that Vitamin D has immuno-
modulatory properties on chicken T lymphocytes without inducing unresponsiveness 
and by limiting immuno-pathology can promote protective immunity against infectious 
diseases of poultry.   
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2.2 Introduction 
A vital component for competent physiological function, Vitamin D is a 
naturally synthesized lipid soluble vitamin classically involved in calcium and 
phosphorus homeostasis but recent evidence indicate a broader range of action not 
limited to its immune modulatory effects on mammalian leukocyte (144-146). 
Ultraviolet B (UV-B) irradiation of epidermal cells constitutes the primary step for 
photolytic conversion of 7-dehydrocholesterol to Vitamin D. Modern poultry farming 
practices have led to an increase in density housing with minimal ultraviolet light B 
(UV-B) exposure. Thus, eggs produced from indoors housed chickens have a 
significantly lower (3.8 µg Vitamin D/100g of dry matter) egg yolk Vitamin D3 content 
compared to those housed outdoors (14.3 μg Vitamin D/100g of dry matter). The 25-
hydroxyvitamin D3 (25[OH]D3) content of egg yolk was also influenced by sunlight 
exposure, although less pronounced than the vitamin D content  (147). Alternatively, 
Vitamin D3 can be acquired in the diet or as supplements. Vitamin D3 is subsequently 
hydroxylated by hepatic mitochondrial cytochrome P450 (CYP27A1) into 25(OH)D3. 
Finally, 25(OH)D3 is hydroxylated by renal mitochondrial cytochrome P450 
(CYP27B1) into 1α, 25-dyhydroxyvitamin D3 (1α, 25(OH)2D3). The latter is 
biologically relevant and active form with endocrine actions. Macrophages have been 
shown to express both CYP27A1 and CYP27B1 (144, 148) enzymes required to 
produce 1α, 25(OH)2D3, whereas T cells can only perform the final metabolic step (149, 
150). Therefore, immune system cells may be able to use Vitamin D in an autocrine and 
paracrine manner.   
 
The immune modulatory functions of 1α, 25(OH)2D3 have been linked to 
genomic effects mediated by Vitamin D Receptor (VDR), a member of the nuclear 
hormone superfamily found in most immune cells (146, 151) such as macrophages 
(152), dendritic cells (153), B cells (151, 152, 154) and T cells (151, 152). Mice VDR-/- 
models have been used to demonstrate this interdependent relationship (155-157). 
Genetic polymorphism in the VDR gene has been associated with susceptibility to 
several viral infections in human; Dengue Virus (DENV; rs2228570) (158), Hepatitis B 
Virus (HBV; FokI C>T) (159), Respiratory Syncytial Virus (RSV; rs10735810) (160) 
and even in chickens; Marek’s Disease Virus (MDV; S1P4) (161). In humans, Vitamin 
D has been shown to be effective in the prevention and control of viral diseases such as 
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Human Immunodeficiency Virus (HIV) (162, 163) and RSV (164).  Studies into the 
mechanistic effects have demonstrated that Vitamin D regulates immune system cells 
functional abilities in an attempt to maintain immune homeostasis.  
 
In the context of innate immunity, Vitamin D may influence the type and 
magnitude of antigen presenting cell responses and their retrospective ability to 
modulate T lymphocyte function. It has been recently demonstrated that chicken 
macrophages exposed to 25(OH)D3 have a 5-fold increase in nitric oxide production 
(165). Stimulating nitric oxide production enhances phagocytic activity of macrophages 
and induces cytostatic or cytotoxic action against viruses, bacteria, fungi and tumour 
cells (166).  In addition, low dose Vitamin D treatment may restore human macrophage 
proliferative ability (167), and increase antimicrobial peptide production such as 
cathelicidin and β-defensin in response to stimuli (168). Vitamin D may perturb 
dendritic cells responsiveness to microbial stimuli, thus impeding maturation (169). 
Human dendritic cells and macrophages have been shown to produce less interleukin 
(IL)-12 when treated with high dose Vitamin D (170). This could reduce their 
functional capacity as antigen presenting cells (APC) required for initiation of Th1 type 
T cell responses.  
 
In the context of adaptive immunity, defence against intracellular pathogens is 
mediated in part by CD4+ and CD8+ T lymphocytes. Vitamin D alters naive and effector 
T cell activation, and their cytokine secretion patterns (171). This pleiotropic lipid 
soluble vitamin may be important for potentiating induction of naive T cells via an 
alternative mitogen-activated protein kinase (MAPK) pathway (172). The latter is 
involved in establishing intracellular PLC-γ1 protein which plays a central role in 
classical T cell receptor (TCR) signaling pathway. However, human PBMC’s 
stimulated with a T cell specific mitogen (PHA; phytohemagglutinin) in the presence of 
Vitamin D was observed to inhibit cellular proliferation which has been associated with 
a decrease in IL-2 production (173). Additionally, Vitamin D has been shown to inhibit 
IL-17 production (174) and increase IL-4, IL-5, IL-10 and IL-13 cytokines expression 
(175-177). T cell trafficking and homing to specific tissues may be influenced by 
Vitamin D (146). Vitamin D positively redirected T cell specific translocation to 
epidermal keratinocytes by stimulating expression of chemokine receptor 10 (CCR10), 
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which recognizes the chemokine CCL27 (178). This will influence the retention of T 
cells with specific phenotypes and effector function within the skin (179).  
 
Vitamin D has profound effects on the function of human and murine T cells but 
there is an information deficit regarding its effects on the functional abilities of avian 
immune system cells, especially chicken T cells and their responses to pathogens. Here, 
we demonstrate that Vitamin D inhibits IFN-γ production and T cell proliferation 
without inducing program cell death. In contrast to its inhibitory effects on the 
inflammatory functions of T lymphocytes, Vitamin D did not inhibit CD107a 
expression, a degranulation and cytotoxicity marker, and is shown to be crucial for the 
control of intracellular pathogens.  Moreover, Vitamin D did not inhibit Extracellular 
signal-Regulated Kinase (ERK) 1/2 signalling pathway, which is regulated in T 
lymphocytes by T cell receptor (TCR)-CD3 complex interacting with peptide epitopes 
presented by antigen presenting cells.   
 
 
2.3 Materials and Methods  
2.3.1 Experimental Animals:  
Inbred mixed sex Rhode Island Red chickens, specific pathogen free as not gnotobiotic, 
were reared in filtered-air positive pressure rooms on floor pens with wood shaving at 
The Pirbright Institute. Birds were group housed, and had ad libitum access to water and 
commercial feed. The work was performed according to home office guidelines. Tissue 
samples were taken from animals after humane killing under schedule 1. Three week 
old birds were culled by cervical dislocation, and spleens were removed and collected 
aseptically. 
 
2.3.2 Spleen mononuclear cell preparation 
Whole spleens were kept on ice in PBS as soon as they were removed from chickens. 
After being rinsed in PBS, spleens were placed onto 40-μm BD cell strainers (BD 
Biosciences, UK), and crushed through using the flat end of a syringe plunger. 
Splenocytes cell suspension were prepared by layering (2:1) onto LymphoprepTM 
(Axis-shield PoC AS, Norway) density-gradient centrifugation, and centrifuged at 2100 
rpm for 20 min to allow the separation of mononuclear cells. Mononuclear cells were 
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subsequently aspirated from the interface, and washed at 1500 rpm for 5 min in RPMI 
1640 with penicillin (10 U/ml), and streptomycin (10 μg/ml). Mononuclear cells were 
suspended in complete RPMI cell culture medium; RPMI 1640 medium containing 10% 
foetal bovine serum (Sigma-Aldrich, Dorset, UK), penicillin (10 U/ml), and 
streptomycin (10 µg/ml). Cell number and viability were calculated using a 
haemocytometer, and trypan blue exclusion method. Mononuclear cells were suspended 
in complete RPMI cell culture medium at a density of 5 × 106 cells/ml and kept on ice.  
 
1α, 25-Dihydroxyvitamin D3 (Sigma-Aldrich, Dorset, UK) was suspended in Dimethyl 
Sulfoxide (DMSO) (Sigma-Aldrich, Dorset, UK) at 2.5 x 10-4 M. Mononuclear cells 
were stimulated in the presence of 1α,25-Dihydroxyvitamin D3 (10-7 M and 10-8 M), or 
DMSO (vehicle-control) in Sterilin™ 7 mL polystyrene bijou containers (ThermoFisher 
Scientific, UK) and incubated (4 hrs; 41°C, 5% CO2). Cells were harvested, washed and 
centrifuged at 1500 rpm for 5 min, and suspended in complete RPMI cell culture 
medium for use in subsequent assays. 
 
2.3.3 Bromodeoxyuridine (BrdU) incorporation and proliferation Assay:  
Detection and quantification of mononuclear cell proliferation was measured by BrdU 
integration (Roche, UK) into DNA. In brief, mononuclear cells were seeded in 
triplicates at 4.0 x 104 cells per well into 96-well microtiter plates and stimulated with 
medium alone or in the presence of Concanavalin A (ConA; 10 µg/ml). Cells were 
incubated (41°C, 5% CO2) for 72 hrs with an 18 hour pulse of 10 µM BrdU. BrdU 
integration was detected by labelling with 100 µl anti-BrdU-POD monoclonal antibody 
and incubating at room temperature (RT) for 90 min. A Tetramethyl-Benzidine (TMD) 
substrate solution was used to develop the colour at RT for 15 min in the dark. The 
reaction product was inactivated with 1 M sulphuric acid. Immune complexes were 
detected by reading absorbance at 450 nm (OD450). 
 
2.3.4 Chicken IFN-γ ELISPOT Assay: 
IFN-γ production was detected using an IFN-γ Chicken antibody pair kit (life 
technologies, UK). In brief, MAIPS4510 MultiScreenTM-IP 96 well plates (Millipore, 
UK) were coated overnight at 4°C with 2 µg/ml mouse anti-ChIFN-γ in PBS. Plates 
were washed twice with blocking buffer (RPMI 1640 plus 2% FCS) and incubated (1 
hr; 37°C, 5% CO2) with blocking buffer. Mononuclear cells were seeded in triplicates at 
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5.0 x 105 cells per well, stimulated with medium alone or in the presence of PMA (50 
ng/ml) plus Ionomycin (ION; 1 µg/ml); (Sigma-Aldrich, Dorset, UK) and incubated 
(41°C, 5% CO2) overnight. Plates were washed twice with SQ water followed by three 
time wash with washing buffer (PBS + 0.1% Tween 20). 1 µg/ml of anti-chicken IFN-γ 
biotinylated antibody in assay buffer (PBS + 0.1% Tween 20 + 1.0% BSA) was added 
to the plate and incubated for 1 hour in the dark at RT. Plates were washed with 
washing buffer and incubated for a further 1 hour with Streptavidin-HRP (1/1250) in 
assay buffer. A final wash with washing buffer was performed and a 3-Amino-9-
ethylcarbazole (AEC) substrate solution (BD Biosciences, UK) was used to develop the 
colour at RT in the dark. After 20 min, the reaction was inactivated by washing in 
distilled water, air dried overnight and spots forming units (SFU) were counted using an 
automated ELISPOT reader. 
 
2.3.5 Flow Cytometry/Phosflow:  
Cytotoxicity assay: Unconjugated CD107a (LEP) and isotype control (CC63) antibodies 
were conjugated using the Alexa Fluor 647 labelling kit (Life Technologies, UK) 
according to manufacturer’s recommendation prior to use. The degranulation marker, 
CD107a, of mononuclear cells were assessed: mononuclear cells were seeded in 
triplicates at 5.0 x 105 cells per well and stimulated with medium alone or in the 
presence of PMA (50 ng/ml) plus ION (1 µg/ml) with the following antibodies; LEP 
(CD107a-Alexa Fluor 647) or isotype control (cc63-Alexa Fluor 647) and incubated (4 
hrs; 41°C, 5% CO2). Following a wash in PBS, cells were labelled with CD3-FITC 
(Southern Biotech) for 15 min at 4°C and dead cells were excluded using 7-AAD-PE 
staining. Cells were acquired on a FACS Calibur flow cytometer and data processed by 
FlowJo software. 
Apoptosis assay: To determine the effects of Vitamin D on cell apoptosis, mononuclear 
cells were stained with Annexin V-APC (BDTM Pharmigen, UK) and 7-AAD-PE 
(BDTM Pharmigen, UK). Apoptotic and dead cells were acquired with a FACS Calibur 
flow cytometer and data were analysed using FloJo software.  
Phosflow signalling: Mononuclear cells were seeded in triplicates at 5.0 x 105 cells per 
well and incubated (5 and 15 min; 41°C, 5% CO2) with medium alone or in the presence 
of PMA (50 ng/ml). Cells were fixed for 30 min using the fixation/permeabilization kit 
(eBioscience, Thermofisher, UK). Cells were incubated in Perm buffer for 10 min at 
4°C, followed by staining with ERK 1/2-PE (T202/Y204) (BDTM Pharmigen, UK), 
  
58 | P a g e  
 
antibody for an additional 30 min at 4°C. Cells were washed twice in Perm buffer, and 
resuspended in FACS buffer. Cells were acquired on a FACS Calibur flow cytometer 
and data processed by FlowJo software. 
 
2.3.6 Statistical Analysis 
All data are presented as mean + SD. ELISpot SFU data were adjusted to 1.0 x 106 
cells. Quantification was performed using Graph Pad Prism 6 for windows. All data 
points in each experiment were analysed by non-parametric Wilcoxon tests (Mann-
Whitney). Results were considered statistically significant at P < 0.05 (*).  
 
 
2.4 Results 
2.4.1 Vitamin D inhibits T cell proliferation and IFN-γ production 
Mononuclear chicken splenocytes were cultured in complete RPMI medium containing 
high (100 nM) or low (10 nM) concentration of Vitamin D for 4 hrs and their ability to 
proliferate ex vivo was examined using a BrdU-based proliferation assay. Some cells 
were cultured in vehicle only (DMSO) or medium only and were used as the control 
groups. All data points, experiment 1-3 (Figure 7A), were plotted and the results 
demonstrate that the cells treated with high concentration (100 nM) Vitamin D, but not 
low concentration (10 nM) Vitamin D, had lower proliferative ability in response to 
Con A (10 µg/ml) stimulation compared to the cells treated with vehicle only (DMSO; 
P = 0.0002) or medium only. The mean inhibitory percentage was calculated for both 
low and high levels of Vitamin D (Figure 7B). In three independent experiments 
performed using mononuclear cells from three different birds, Vitamin D (100 nM) 
inhibited proliferation by 46.2 % (experiment 1), 30.4 % (experiment 2) and 29.3 % 
(experiment 3), whereas Vitamin D (10 nM) inhibited proliferation by 1.76 % 
(experiment 1), 1.08 % (experiment 2) and 17.7 % (experiment 3) compared to the cells 
treated with vehicle only (Figure 7B). In experiment 3, low levels of Vitamin D also 
significantly reduced T cell proliferation (P = 0.0009). An additional proliferation assay 
was performed in which vitamin D-treated cells were stimulated with different 
concentrations of Con A (1, 5, 10, 20 µg/ml). Cells stimulated with 1 or 5 µg/ml Con A 
had lower proliferation levels than those stimulated with 10 or 20 µg/ml. However, 
there was no differences in the proliferation levels between cells stimulated with 10 and 
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20 µg/ml in both Vitamin D-treated and vehicle-treated cells, suggesting that Vitamin D 
treatment does not increase threshold of T cell activation (data not shown).   
 
Having demonstrated that Vitamin D (100 nM) significantly inhibits T cell proliferation 
ex vivo, we analysed the influence of this vitamin on chicken T cells ability to produce 
IFN-γ using a chicken IFN-γ ELISpot assay. Vitamin D-treated (100 nM or 10 nM) or 
vehicle-treated chicken splenocytes were stimulated with a cocktail of PMA (50 ng/ml) 
and Ion (1 µg/ml) for 18hrs. Spots Forming Unit (SFU) at 1.0 x 106 cells confirmed that 
Vitamin D (100 nM) significantly inhibited IFN-γ production (P = 0.0002; Figure 7C) 
compared to the cells pre-treated with vehicle only. Low levels of Vitamin D also 
significantly reduced IFN-γ production compared to the vehicle only (P = 0.0073). In 
the five independent experiments performed, an average percentage of inhibition was 
calculated (Figure 7D). Vitamin D (100 nM) inhibited IFN-γ production by 25.3 % 
(experiment 1), 18.9 % (experiment 2), 32.6 % (experiment 3), 48.7% (experiment 4) 
and 43.0% (experiment 5) whereas low level of Vitamin D (10 nM) inhibited IFN-γ 
production by 7.6 % (experiment 1), 16.5 % (experiment 2), 25.1 % (experiment 3), 
31.4% (experiment 4) and 20.4% (experiment 5)  compared to the control group. In all 
five experiments, there was a significant difference in the ability of IFN-γ production 
between the cells treated with low levels of Vitamin D (10 nM) and the control groups 
(P = 0.0119; Figure 7D). No significant difference was observed between vehicle 
treated and untreated control cells, indicating that vehicle does not influence chicken T 
cells to produce IFN-γ.  
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Figure 7: Vitamin D inhibits chicken T cell proliferation and IFN-γ production ex 
vivo. 
Splenocytes were pre-treated for 4hrs with Vitamin D (100 nM and 10 nM) or vehicle 
only (DMSO). (A) BrdU incorporation measured by ELISA assay to quantify T cell 
proliferation after Concanavalin A (Con A; 10 µg/ml) stimulation. The results are 
presented as absorbance at OD450 from three independent experiments with 3-4 
biological replicates in each experiment (ten replicates in total). (B) Represents the 
average percentage of inhibition for T cell proliferation induced by Vitamin D treatment 
in three independent experiments (Exp. 1, Exp. 2 and Exp. 3). (C) The frequency of 
IFN-γ producing mononuclear cells stimulated with a T-cell stimulation cocktail of 
PMA and Ion was detected using a chicken IFN-γ ELISPOT assay. The results are 
presented as spots forming unit (SFU) per 1.0 x 106 cells from five independent 
experiments with 3-5 biological replicates in each experiment (19 replicates in total). 
(D) Represents the average percentage of inhibition for IFN-γ production by 
mononuclear cells after Vitamin D3 pre-treatment. Non-parametric Wilcoxon tests 
(Mann-Whitney) was used to assess normal distribution and test significance (B, C). 
The results are shown as mean ± SD (A, C). (symbol) represents cells treated with 
Vehicle  only (DMSO). * indicates a statistically significant difference compared to 
vehicle (P < 0.05). 
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2.4.2 The inhibitory effects of Vitamin D on T cells is not due to cell death or 
apoptosis 
To examine whether the Vitamin D induced inhibition of T cell proliferation and IFN-γ 
production is due to Vitamin D induced-cell death or apoptosis, mononuclear 
splenocytes were stained with 7AAD and Annexin V post Vitamin D (100 nM) pre-
treatment. The percentages of live cells (7AAD-Annexin V-), apoptotic cells (7AAD-
Annexin V+) and dead cells (7AAD+Annexin V+) were determined 4 hrs after the 
treatment using flow cytometry (Figure 8A). No significant difference was observed in 
the percentages of live, apoptotic or dead cells between Vitamin D (100 nM) and 
Vehicle (DMSO) pre-treatment cells (Figure 8B). The results were confirmed in four 
independent experiments performed on splenocytes from four different birds. To 
examine whether vitamin D induces T cell apoptosis after a longer term Vitamin D 
treatment, the percentages of apoptotic and dead cells were analysed in the treated cells 
24 hrs post Vitamin D (100 nM, 10 nM) or vehicle treatment (Figure 8C). No 
significant differences in the levels of apoptosis or cell death were observed in these 
groups, suggesting that Vitamin D does not induce T cells apoptosis. However, higher 
levels of apoptosis were observed in the cells 24 hrs after treatment compared to those 
treated 4 hrs after treatment (Figure 8C). Taken together, the results demonstrate that 
the inhibitory effects of Vitamin D on T cell proliferation and IFN-γ production are not 
due to cell death or apoptosis.  
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Figure 8: Vitamin D treatment does not induce cell death/apoptosis of chicken 
splenocytes.  
Chicken splenocytes were treated with Vitamin D (100 nM) or vehicle (DMSO) for 4 
hrs. The cells were stained with 7AAD (dead cell marker) and Annexin V (early 
apoptotic marker) and the data were analysed using flow cytometry. (A) Shows dot 
plots of the stained cells and the numbers in each quadrant represents percentage of 
cells. (B) The percentages (as mean ± SD) of live cells (Annexin V-7AAD- cells), 
apoptotic cells (Annexin V+7AAD- cells) and dead cells (Annexin V+7AAD+ cells) are 
shown from four independent experiments with three biological replicates in each 
experiment (12 biological replicates in total). (C) The data represent the percentage of 
live, apoptotic and dead cells 24 hrs post Vitamin D (100 nM) or vehicle (DMSO) 
treatment. (P = NS indicates no statistical significance). 
 
 
2.4.3 Vitamin D does not inhibit CD3- or CD3+ T cell degranulation 
Translocation of lysosome-associated membrane protein 1 (LAMP1/CD107a) is a 
marker of degranulation, an important function of lymphocytes such as T cells and NK 
cells.  We studied the effects of Vitamin D on the ability of CD3- and CD3+ cells 
degranulation in vitro. Chicken mononuclear splenocytes were cultured in medium 
containing Vitamin D (100 nM or 10 nM) or vehicle only (DMSO) for 4 hrs, and were 
stimulated for an additional 4 hrs in medium with PMA (50 ng/ml) and ION (1 µg/ml). 
The expression of CD107a was assessed on CD3- cells and CD3+ T cells using flow 
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cytometry (Figure 9A). The percentages of CD3-CD107a+ cells (Figure 9B) and 
CD3+CD107a+ T cells are shown (Figure 9C). The results demonstrate that Vitamin D 
(100 nM or 10 nM) has no significant effects on the cytotoxicity (degranulation) of 
CD3- cells or CD3+ T cells in vitro. The results were confirmed in four independent 
experiments performed in triplicates.   
 
 
 
Figure 9: Degranulation of chicken T cells is not influenced by Vitamin D.   
(A) Representative flow cytometry dot plots of spleen mononuclear cells that were 
cultured in medium containing Vitamin D (100 nM or 10 nM) or vehicle only (DMSO) 
for 4 hrs and were stimulated with a T cell stimulation cocktail of PMA and Ion for an 
additional 4 hrs. The expression of CD107a in CD3+ and CD3- cells was analysed using 
flow cytometry. Upper right quadrant and lower right quadrant shows the percentages of 
CD107a+ cells within CD3+ and CD3- T cells, respectively. The bar graphs represents 
the percentages of CD3-CD107a+. (B) and CD3+CD107a+ cells (C) in the treated cells. 
The results are shown as mean ± SD of the study population of CD107a expression (P = 
NS indicates no statistical significance).  (symbol) represents the cells treated with the 
Vehicle  only (DMSO). Similar data were obtained in four independent experiments. 
 
 
2.4.4 Vitamin D limits ERK1/2 phosphorylation in unstimulated CD3+ T cells 
ERK1/2 signal pathway is an important regulator of T cell function. Here, we examined 
the effects of Vitamin D on phosphorylation of ERK1/2 (T202/y204) in unstimulated 
and activated CD3+ T cells using Phosflow (Figure 10). Mononuclear splenocytes were 
cultured in medium containing Vitamin D (100 nM) or vehicle only for 4 hrs. PMA has 
been used in many studies for analysing human/ murine T cell signalling. In our hands, 
Con A cannot stimulate ERK1/2 phosphorylation and IFN-γ production by chicken T 
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cells. Therefore, we decided to use PMA for analysing ERK 1/2 signalling. The 
phosphorylation of ERK1/2 (T202/y204) was analysed in the unstimulated cells and in 
the cells stimulated with PMA for 5 min. The results demonstrate that Vitamin D 
treatment reduces ERK1/2 phosphorylation in the unstimulated CD3+ T cells compared 
to the cells treated with vehicle only. However, there were no significant differences 
observed in the levels of ERK1/2 phosphorylation between Vitamin D and vehicle-
treated cells after PMA stimulation (Figure 10). The results were confirmed in three 
independent experiments. 
 
 
Figure 10: Vitamin D limits ERK1/2 phosphorylation in the resting chicken CD3+ 
T cells.  
Following incubation of splenocytes with Vitamin D or vehicle only for 4 hrs, 
phosphorylation of ERK1/2 (T202/Y204) was evaluated in CD3+ T cells in the resting 
cells (unstimulated) or cells stimulated with PMA for 5 min using flow cytometry. The 
data represents flow cytometry analysis of ERK 1/2 phosphorylation in cells treated 
with vehicle (thick line), Vitamin D (thin line) or Isotype control (grey area) in the 
resting cells and PMA-stimulated T cells.  
 
2.5 Discussion 
The immuno-modulatory, anti-inflammatory and cancer prevention properties of 
Vitamin D are attributed to its direct effects on immune system cells, including T 
lymphocytes in human and animal models (164, 180-184). The results presented in this 
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report demonstrate that the active Vitamin D metabolite modulates avian T lymphocytes 
effector functions similar to the results obtained from human and murine studies (157, 
172, 185). The functional heterogeneity of T lymphocytes is crucial for both limiting 
immuno-pathogenesis and promoting protective immune responses against pathogens. 
In this report, we demonstrate that Vitamin D reduces chicken T lymphocyte 
proliferation as well as the frequency of IFN-γ producing cells. The modulatory effects 
of Vitamin D were further confirmed based on down-regulation of ERK1/2 
phosphorylation status that impacts subsequent downstream signal transduction 
pathways. Additionally, the results show that Vitamin D does not trigger programmed 
cell death by apoptosis, and its functional effects can only be attributed to the 
modulation of T lymphocyte effector function. In contrast to the inhibitory effects of 
Vitamin D on T cell proliferation and cytokine production, it did not have any 
significant effects on CD107a cell surface translocation, a marker for cytotoxic 
degranulation, confirming that Vitamin D does not induce general immuno-suppression 
of T cell functions.  This notion was also confirmed with the results demonstrating that 
Vitamin D did not inhibit ERK1/2 phosphorylation in the activated T cells and only 
reduced base line ERK1/2 phosphorylation in the unstimulated cells.   
 
T lymphocytes are the main adaptive immune cells and one of their main effector 
functions is their ability to proliferate in response to the stimuli or a specific antigen. 
Functional studies assessing Vitamin D effect on human immune system cells indicate a 
regulatory role as demonstrated by their ability to reduce the magnitude of T 
lymphocyte responses. Lemire et al (186) and Rigby et al (173) were among the first to 
demonstrate a dose dependent inhibition by Vitamin D on human PBMC proliferation 
after mitogen stimulation. Provvedini et al (151) provided the first evidence for the 
presence of a VDR in human immune system cells. However, little is known about the 
effect of Vitamin D on avian immune cells in health and disease and the consequent 
responses to the treatment. Our group and others have reported that Vitamin D may 
have both modulatory and stimulatory effects on chicken macrophages (168, 180, 187). 
In this report, we present our data demonstrating that Vitamin D modulates T 
lymphocyte ability to proliferate in response to the stimuli. In human, the inhibition of T 
lymphocyte proliferation by Vitamin D has been linked with a reduction in IL-2 
cytokine production (173). Vitamin D interacts directly with its receptor (VDR), which 
has a VDR responsive element on the IL-2 gene, thereby repressing transcriptional 
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activation (188, 189), which may explain in part its mechanism of action. Adding 
recombinant human IL-2 to the Vitamin D-treated T lymphocytes only partially restored 
T cell proliferative ability (173), suggesting that Vitamin D may exert its inhibitory 
effects in both IL-2 dependent and independent manner. A nuclear threshold mechanism 
for Vitamin D to promote VDR signalling is required to repress cytokine gene 
expression (145, 151). On the other hand, supplementing Vitamin D restored human 
PBMC proliferative function in patients diagnosed as hypovitaminosis D (172). Vitamin 
D also exerts immuno-regulatory effects on murine T cells. For example, it has been 
shown that pathogenic T lymphocytes are generated in VDR-/- knockout mice due to 
overproduction of IL-2 resulting in excessive proliferation (190). Moreover, in a 
multiple sclerosis (MS) model, T lymphocyte proliferation was inhibited via the 
addition of exogenous Vitamin D (181). In addition, it has been demonstrated that 
Vitamin D reduces T lymphocyte effector function by generating dendritic cells that 
have lower ability to produce IL-12 (170, 185). In this report, we show for the first time 
that Vitamin D is able to control the rate of avian T cell proliferation similar to what had 
been previously reported on human and murine T cells. It has previously been suggested 
that the effect of Vitamin D upon proliferation of human T cells varies according to the 
strength of the stimulation and particularly affected by a lack of co-stimulation (191). 
Based on the results obtained from Vitamin D-treated cells stimulated with different 
concentration of the stimuli, we have demonstrated that Vitamin D does not increases 
the threshold of avian T cell stimulation, however further studies are required to 
determine the role of co-stimulatory molecules in activation of Vitamin D-treated avian 
T cells.    
 
To our knowledge, this is the first report demonstrating that primary T lymphocytes 
treated with Vitamin D have lower ERK 1/2 (T202/Y204) phosphorylation levels at 
baseline in non-stimulated cells. ERK1/2 phosphorylation level was not affected in the 
stimulated T lymphocytes, suggesting that Vitamin D only reduces the baseline in the 
treated cells but these cells are fully responsive to the stimuli, confirming that Vitamin 
D may modulate avian immune responses but does not induce immuno-suppression or 
immune-unresponsiveness. Studying the effects of Vitamin D on human γδ T 
lymphocytes demonstrated a reduction in ERK 1/2 phosphorylation (192), suggesting 
that Vitamin D exerts anti-inflammatory effects by modulating the overactive immune 
system cells. Our data confirm these findings in avian T lymphocytes by studying ERK 
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1/2 in unstimulated and stimulated cells. ERK1/2 is one of the foremost studied 
Mitogen-activated protein kinase (MAPK) within RAF-MEK-ERK signalling pathway 
in mammalian systems (193). Integrated upstream signalling from TCR stimulation and 
cytokines activates the mechanism for ERK1/2 phosphorylation that transactivates 
transcriptional factors to regulate cellular proliferation at specific cell cycle checkpoint. 
In avian systems, specifically T cells, the complex MEK-ERK signalling pathway is 
scientifically compelling and hasn’t been explored to elucidate potential implication in 
immune responsiveness, pathogenesis and disease control. In concordance, Buza et al 
(194) outlined the importance of understanding ERK pathway transactivation and 
crosstalk signalling specifically in chicken viral diseases that leads to T Lymphocyte 
transformation. Proteomic analysis of chicken cell lines correlates ERK 1/2 function as 
a key regulator of cellular proliferation, apoptosis and transformation. Pathogens that 
hijack cellular signalling are of particular consequence in immune evasion tactics and 
transformed cell lines can be considered as models for pathway interference analysis in 
human lymphomas studies. ERK1/2 has the intrinsic ability to regulate neighbouring 
pathways specifically ERK1/2 phosphorylation has direct effects that leads to an 
increase in functional activity of mTORC inhibitor Rheb resulting in decrease cellular 
proliferation (195). In contrast, ERK1/2 has been associated with downstream signalling 
effects such as phosphorylation of VDR (196). These finding provide a framework to 
elucidate the genomic effects of ERK1/2 and furthermore integrated cross pathway 
inhibition in avian systems to establish T cell functional competence when challenged 
with pathogenic microbes and/or in combination with Vitamin D deficiency 
(Hypovitaminosis D) status.  
 
There is an increasing body of evidence reporting an anti-tumor role for Vitamin D by 
inducing apoptotic proteins in cancer cells from mice (182) or human tumours (183, 
184). These finding indicate that Vitamin D catabolism could differentially modulate 
tumour cell fate. However, there has been no report to date of Vitamin D-induced 
apoptosis in primary mammalian cells, and our data demonstrate that physiological 
levels of Vitamin D does not induces apoptosis of primary avian immune cells, 
including T cells. The physiological serum Vitamin D concentrations (25(OH)D3) in 
both healthy chickens (147, 197) and humans has been estimated to range between 60-
100 nM (198-200), while the levels of serum 1,25(OH)2D3 are significantly lower. It 
has been shown that APCs and T cells are able to convert 25(OH)D3 to 1,25(OH)2D3 at 
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physiologically relevant concentrations and respond to this in an autocrine fashion 
which can justify the supra-physiological concentration of  1,25(OH)2D3 used by 
several groups and including our study to analyse the effects of Vitamin D on T 
lymphocytes (199). Further studies are required to establish whether avian tumour cells, 
similar to what is observed in human and murine cancer cells, are susceptible to 
Vitamin D induced apoptosis. These experiments are being planned in our laboratory 
with several tumour cell lines as well as primary tumour cells. Taken together, these 
results support our findings demonstrating that the reduction in frequency of IFN-γ 
producing cells and proliferation after Vitamin D treatment is not due to apoptosis of T 
cells, confirming that Vitamin D specifically inhibit the production of this cytokine 
from the activated T lymphocytes. IFN-γ is an antiviral cytokine and has an important 
role in the generation of anti-viral innate and adaptive immunity in both mammalian and 
avian systems. Lymphoid cells such as NK cells, γδ T cells, CD4+ T cells and CD8+ T 
cells are able to produce IFN-γ in response to the stimulation. The expression of IFN-γ 
significantly influences the initiation of anti-viral adaptive immunity, including the 
generation of effector Th1 cells (201). In humans, Vitamin D has been used successfully 
in the prevention and control of viral infections (163, 164, 202). Reichel et al (203) 
demonstrated the inhibitory effects of Vitamin D on human T cells ability to produce 
IFN-γ in a dose dependent manner (204). In clinical settings, a reduction in IFN-γ 
production may reduce immunopathology observed in autoimmune and acute or chronic 
inflammatory diseases induced by infectious agents. Vitamin D provides a homeostatic 
framework required for generation of a protective immune response against infections 
without causing immunopathology. Adaptive immune system cells such as T and B 
cells have been shown to express VDR and constitutively transcribe the 1α-hydroxylase 
enzyme required for producing the active Vitamin D molecule (151, 154, 178, 188). 
Therefore Vitamin D can directly modulate T cell effector function. However, Vitamin 
D may also indirectly affect avian T cell function via generation of immuno-modulatory 
antigen presenting cells (187). In vitro exposure to Vitamin D can sustain suppression 
of T lymphocyte transcriptional activation and consequent production of IFN-γ mRNA 
in long-term culture systems (204), which could be of particular importance in over-
activated T lymphocytes. These findings may have significant importance in avian 
systems and needs to be further explored. Restoring T lymphocyte functional abilities 
could be key in defence against pathogens as previously outlines in human PBMC 
proliferation (172).  
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Additionally, we evaluated cell surface co-mobilization of lytic granule membrane 
protein CD107a to study activation of cytotoxic T lymphocytes (CTLs) when treated 
with Vitamin D. CTLs play an import role in defence against viral infections as well as 
cancer. Activation of CTLs leads to degranulation and secretion of lytic granules 
containing perforin and granzymes. Recently, CD107a cell surface mobilization has 
been described as a marker for cytotoxic T cell degranulation and shown to be strongly 
up regulated in activated T cells (205). Human natural killer (NK) cells cytotoxic 
function has been characterized based on a positive association between stimulatory 
cytokines such as IL-2 and IFN-γ and up-regulation of CD107a to the cell surface (206). 
Experimental evidence suggests an increase in cell surface expression of CD107a in 
PBMCs of patients with autoimmune diseases. In avian system, CD107a is also a 
marker for cytotoxic activity of T cells (207) and NK cells (208), and has been 
suggested to be important in the control of viral infections such as Infectious Bronchitis 
Virus (IBV) by reducing viral load. Here, we demonstrate that physiological levels of 
Vitamin D do not alter cytotoxic abilities of lymphocytes, and the levels of 
degranulation in CD3+ T cells (including CD4+ and CD8+ T cells) or CD3- lymphocytes 
(including NK cells) are not affected by Vitamin D treatment. It seems that IFN-γ 
production and degranulation are differentially regulated in avian T cells and non-T 
cells. Taken together, our results demonstrate that Vitamin D preferentially down-
regulate the production of pro-inflammatory cytokines such as IFN-γ but does not 
inhibit their cytotoxic abilities, which is required for control of the infected cells or 
transformed cells. Degranulation and cytokine production can be differentially detected 
in different maturation stages of murine and human lymphocytes. For example, 
CD11blowCD27high murine NK cells preferentially degranulate while CD11bhighCD27low 
NK cells display reduced degranulation but with maintained IFN-γ production (209, 
210). Preferential function of different maturation stages of human NK cells has also 
been reported, in which CD56brightCD16- NK cells (immature NK cells) are abundant 
cytokine producers, while they are less effective in degranulation and cytotoxicity 
(211). It is possible, but not proven, that Vitamin D exerts its preferential effects on 
CD3- lymphocyte function by modulating the maturation stages of these cells. The 
effects of Vitamin D on maturation stages of immune system cells was evident from our 
previous results demonstrating that Vitamin D inhibits up-regulation of maturation 
markers such as CD86, CD80 and MHC class II on avian macrophages, while 
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increasing their abilities to produce nitric oxide (187). The activation stage of antigen 
specific CD8+ T cells can also influence the preferential functional abilities of CTLs. 
Fully differentiated CTLs can undergo degranulation without producing IFN-γ, while 
many effector memory CD8+ T cells produced IFN-γ but are not able to degranulate in 
response to stimuli (156). There is no information on the effects of Vitamin D on the 
activation stages of murine or human T cells. However, the results presented in this 
report indicate that Vitamin D-treated avian T lymphocytes may have functional 
abilities as fully differentiated T cells, with reduced frequency of IFN-γ secretion, but 
retain their ability to undergo degranulation.  
 
Respiratory infections are the major problems in poultry farms, with many possible 
causes including viral, bacterial and fungal. In humans, the peak incidence of 
respiratory tract infection coincides with the time of the year when there is insufficient 
UV-B light to produce Vitamin D resulting in low serum Vitamin D levels in the 
population (212, 213). Based on these aforementioned epidemiological assessments, 
indoor housed chickens may be at greater risk for respiratory infection and this might be 
explained by many mechanisms including variation in the levels of Vitamin D (147). It 
is now believed that the effects of Vitamin D on innate and adaptive immunity may play 
an important role in controlling seasonal respiratory infections (214).   
 
In conclusion, we demonstrated that Vitamin D can modulate the function of avian T 
lymphocytes by reducing T cell proliferation, cytokine production and a reduction in 
phosphorylation of non-stimulated T lymphocytes. However, Vitamin D treatment did 
not alter the ability of T lymphocyte to undergo degranulation and did not suppress 
ERK1/2 phosphorylation in response to the stimuli. This may be due to differential 
effects of vitamin D on the functional abilities of T lymphocytes, which can inhibit 
immunopathology that leads to exhaustion of T lymphocytes without inducing general 
immunosuppression.  
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3.1 Abstract  
Many viruses alter de novo Fatty Acid Synthesis which can increase the availability of 
energy for replication, and provide specific cellular substrate for particle assembly. 
Marek’s disease virus (MDV), the causative agent of a deadly lymphoma in chickens, 
has been linked to imbalances of lipid metabolism in MDV-infected chickens. Analysis 
of lipid metabolism over a time course of infection with MDV in cultured primary 
chicken embryo fibroblasts demonstrated an upregulation of genes involved in FAS 
pathway, elevated levels of fatty acids, phospholipids and lipid droplet (LD) formation. 
The results demonstrate that virus-induced FAS pathway is crucial for LD formation 
and MDV infectivity as inhibition of FAS pathway significantly reduced the numbers of 
LD, virus titter and virus gene copy numbers. Interestingly, virus-induced FAS pathway 
also increased COX-2/PGE2α pathway as demonstrated by upregulation of arachidonic 
acid, COX-2 gene expression and PGE2α synthesis. Remarkably, PGE2α restored the 
inhibitory effects of FAS pathway inhibitors on MDV titters indicating that the 
activation of COX-2/PGE2α pathway is highly dependent on FAS pathway which 
supports MDV replication. We conclude that MDV uses FAS to activate COX-2/PGE2α 
pathway and PGE2α promotes MDV infectivity through EP2 and EP4 receptors 
engagement. 
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3.2 Introduction 
Despite their great diversity, viruses are highly dependent on host cell factors to 
facilitate maximal viral replication. Elucidating the mechanisms underlying hijacking of 
host cell metabolism by viruses can identify key determinant factors for virus 
replication which consequently contribute to an altered physiological homeostasis and 
disease susceptibility. All herpesviruses including Marek’s Disease Virus (MDV) 
encode metabolic enzymes in their genomes which are involved in their pathogenesis 
(66, 68, 215, 216). MDV is a highly oncogenic herpesvirus and the etiologic agent for 
Marek’s disease (MD). Upon infection of the host, the virus initially replicates in B and 
T cells. Subsequently, the virus establishes latency predominantly in CD4+ T cells, 
allowing the virus to persist in the host for life (217). In addition, latently infected CD4+ 
T cell can undergo neoplastic transformation resulting in deadly lymphomas (217).  
 
A diverse range of human enveloped viruses including human cytomegalovirus 
(HCMV) (218), herpes simplex virus 1 (HSV-1) (219), hepatitis C virus (HCV) (220), 
dengue virus (DENV) (221), Kaposi's sarcoma-associated herpesvirus (KSHV), human 
immunodeficiency virus (HIV) (222), vaccinia virus (VACV) (223) and West Nile virus 
(WNV) (224), have been shown to selectively modulate fatty acid synthesis to support 
virus replication. In this process, acetyl-CoA is converted to malonyl-CoA and 
subsequently to palmitate. The first step towards Fatty Acid Synthesis is the conversion 
of citric acid into acetyl-CoA by direct phosphorylation of ATP-citrate lyase (ACLY). 
The subsequent committed step involves the conversion of acetyl-CoA into malonyl-
CoA by acetyl-coA carboxylase (ACC), a process modulated by HCMV (225) and HCV 
(226). ACC is the rate-limiting step and contributes to cholesterol synthesis. The final 
step involves the committed elongation by utilizing both acetyl-CoA and malonyl-CoA 
coupled to the multifunctional fatty acid synthase (FASN) to make palmitic acid. DENV 
(221), WNV (224), and HCV (227) have been shown to preferentially enhance FASN 
activity and palmitic acid synthesis. 
 
From then on, palmitic acid contributes to several key biological functions such as fatty 
acid oxidation (FAO), β-oxidation in mitochondria, post-translational modification 
(palmitoylation) of proteins or elongation of fatty acid chains to generate a diverse 
repertoire of very long chain fatty acids (VLCFA). This diverse role for the utilization 
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of palmitic acid has been demonstrated in HCV (220), VACV (223), modified vaccinia 
Ankara (MVA) (228), HCMV (229, 230), KSHV (231, 232), respiratory syncytial Virus 
(RSV) (233), and Epstein-Barr Virus (EBV) (234). Both HCV (220) and vaccinia virus 
(223) are highly dependent on mitochondrial β-oxidation to support infection. On the 
other hand, recent data suggest that VLCFA are essential for HCMV replication (235). 
VLCFA contribute to biosynthesis of Arachidonic acid (AA), which can be further 
reduced by cyclooxygenase-1 (COX-1) and inducible COX-2 to make prostaglandin E2α 
(PGE2α), a potent eicosanoid and immune modulator, modulating the functions of 
natural killer (NK) cells (236), macrophages (237), and T cells (238). Induction of 
PGE2α biosynthesis has been observed following infections with HCMV (229, 230), 
KSHV (231, 232), RSV (233), Influenza A virus (IAV) (239) and MVA (228). 
Moreover, a direct association between induction of COX-2 activity and enhancement 
of HCMV (229) and KSHV (232) replication has been reported. For example, PGE2α 
inhibits macrophages recruitment to the lungs, reduces type I IFN production and 
modulated antiviral immunity in IAV infection. Intriguingly, inhibition of COX-
2/PGE2α pathway protected mice against IAV (239) and rescued the inhibitory effects of 
soluble factors released by MDV-transformed T cells on T cell proliferation (240). 
Collectively, these studies suggest that induction of FAS has major implications on 
virus replication and immune evasion and dissemination in the host.  
 
Previously, atherosclerotic plaque formation has been reported in chickens infected with 
pathogenic MDV (241). Vaccination with herpesvirus of turkey (HVT; MDV serotype 
3) prevented the development of atherosclerotic plaques (242). Lipid analysis of the 
arterial smooth muscles (ASM) from MDV infected birds revealed a significant increase 
in non-esterified fatty acids (NEFA), cholesterol, cholesterol esters, squalene, 
phospholipids and triacylglycerol. Furthermore, excess lipids biosynthesis triggered 
cellular deposition in organelles termed lipid droplets (241, 242). Despite these 
intriguing observation, it remained elusive if the fatty acid metabolism is altered in 
MDV infected cells and how MDV causes these alterations in the host.   
 
In the present study, we investigated if Fatty Acid Synthesis and FA derivatives are 
induced in MDV infected cells. We could demonstrate that MDV infection induce de 
novo FAS and upregulation of genes involved in FAS and FAO. Using small 
pharmacological inhibitors and/or addition of exogenous fatty acids, we could show that 
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FAS is essential to support MDV infection in cultured cells. Short chain FAs 
contributed to LCFA synthesis which can be stored in lipid droplets. However, the virus 
replication was not dependent on the ATP production from utilization of short chain 
FAs by FAO. MDV infection induced COX-2 expression and PGE2α synthesis, and this 
process was dependent on activation of FAS pathway by MDV. Taken together, our 
results demonstrate that the major role of FAS to support MDV replication is to activate 
PGE2α/EP2 and PGE2α/EP4 signalling pathways.  
 
 
3.3 Materials and Methods 
3.3.1 Ethics Statement 
Ten day old chicken embryos were culled according to the EU guidelines to generate 
primary chicken embryonic fibroblast cells (CEFs). 
 
3.3.2 CEFs culture and virus preparations 
CEFs were generated from mixed sex SPF Valo eggs (Valo Biomedia GmbH) incubated 
in a Brinsea Ova-Easy 190 incubator at 37oC until 10 days in ovo. CEFs were seeded at 
a rate of 1.5 x 105 cells /ml in 24 well plates with growth medium (E199 supplemented 
with 10% TBP, 5% FCS, 2.8% SQ water, amphotericin B (0.01%), Penicillin (10 U/ml) 
and Streptomycin (10 µg/ml)) and incubated overnight (38.5oC at 5% CO2). Next day, 
80% confluent monolayer was observed and growth medium was removed and replaced 
with maintenance medium (E199 supplemented with 10% TBP, 2.5% FCS, 3.5 % SQ 
water, amphotericin B (0.01%), Penicillin (10 U/ml) and Streptomycin (10 µg/ml). 
RB1B (MDV; serotype 1) and RB1B UL35-GFP virus expressing GFP fused to the UL35 
capsid protein were prepared in CEFs.  
 
3.3.3 Reagents and antibodies 
Chemicals: TOCRIS/SB 204990 (Thermo Fisher Scientific, Paisley, UK), TOFA, C75, 
Clofibrate, Palmitic acid, SC-236 (Sigma-Aldrich, Dorset, UK), PGD2, PGI2, PGE2α 
(Cambridge Bioscience, Cambridge, UK), SC-51322, TG-4-155 and ER-819762 (Bio-
Techne Ltd., Abingdon, UK) were all reconstituted in DMSO. TXA2 (Cambridge 
Bioscience, Cambridge, UK) was reconstitute in ethanol. PGF2α (Cambridge 
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Bioscience, Cambridge, UK), etomoxir and malonyl-CoA (Sigma-Aldrich, Dorset, UK) 
were reconstituted in E199 medium.  
 
3.3.4 Cells and MDV Infection 
Metabolomics: CEFs were either mock infected or with the very virulent RB1B strain 
(100 pfu per 1.5 x 105 cells) in triplicates and harvested at 48 and 72 hrs post infection 
(hpi). The cells were washed, counted and after protein quantification using Bradford 
assay, the samples were sent for Metabolom analysis using GCxGC-MS (Target 
Discovery Institute, University of Oxford). In brief, the cells were homogenized using 
bead beater in methanol/water (1:1), and then t-butyl methyl ether was added for phase 
separation. The organic phase was dried under vacuum, while methanol was added to 
the remaining sample and mixed in bead beater. After incubation at -80oC for 1 hr, the 
phase separation occurred after centrifugation, and liquid layer was collected and dried 
under vacuum. Methoxyamine and MSTFA (1% TMSCI) were added to the dried 
samples and subsequently injected for analysis by GC/GC-MS. The method used in this 
experiment is designed to detect 155 different metabolites including lipids and amino 
acids. The lipid profile of mock and MDV-infected cells were analysed in biological 
triplicates with up to six technical replicates per biological replicate. The data were 
adjusted and normalized based on protein content. Virus infection did not change the 
size of the cells as determined by microscopy.  
 
3.3.5 Viral plaque analysis: MDV infected CEFs were washed 1 times with PBSa, 
subsequently fixed for 5 min at RT (1:1 acetone:methanol; Sigma, UK) and blocked 
with blocking buffer (PBS + 5% FCS) for 1 hr at RT. Blocking buffer was removed and 
next incubated with anti-gB mAb (HB-3; purified monoclonal antibodies) for 1 hr at 
RT. Each well were washed 2x with PBST buffer (PBSa + 0.05% Tween) and then 
incubated with horse radish peroxidase-conjugated rabbit anti-mouse Ig (DAKO, UK) 
in blocking buffer for 1 hr at RT. After development of the plaques using AEC substrate 
(Thermofisher, UK) the cells were washed with super Q water and viral plaques were 
counted using light microscopy.  
 
3.3.6 Determining non-toxic concentration of the inhibitors: To identify non-toxic 
concentrations of the chemicals, mock-infected and MDV-infected CEFs were exposed 
to the chemicals or vehicles and cell morphology and adherence/confluency were 
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monitored under light microscopy at different time points post treatment. Moreover, 
CEFs were trypsinized, stained with 7-actinomycin D (7-AAD; BD Bioscience, Oxford, 
UK) and acquired using a MACS quant flow cytometry and FloJo software for analysis 
of the data. Non-toxic concentrations of the inhibitors and chemicals were selected 
based on flow cytometry data and confluency. 
 
3.3.7 qPCR to amplify MDV genes 
DNA samples were isolated from 5 × 106 cells using the DNeasy-96 kit (Qiagen, 
Manchester, UK), according to the manufacturer’s instructions. A master-mix was 
prepared: primers MEQ-FP and MEQ-RP (0.4 μM), MEQ probes (0.2 μM), ovo forward 
and reverse primers (0.4 μM), and ovo probe (0.2 μM, 5′Yakima Yellow-3′TAMRA, 
Eurogentec) as listed in Table 2 and ABsolute Blue® q-PCR Low Rox master-mix 
(Thermo Fisher Scientific, Paisley, UK). A standard curve generated for both MEQ (10-
fold serial dilutions prepared from plasmid construct with MEQ target) and ovo gene 
(10-fold serial dilutions prepared from plasmid construct with ovo target) were used to 
normalise DNA samples and to quantify MDV genomes per 104 cells. All reactions 
were performed in triplicates to detect both MEQ and the chicken ovotransferrin (ovo) 
gene on an ABI7500® system (Applied Biosystems, Paisley, UK) using standard 
conditions. MDV genomes were normalised and reported as viral genome per 104 cells. 
 
Table 2: List of primers used for MDV Q-PCR 
Gene name Primers 
Tm 
(oC) 
Product size 
(bp) 
MDV-1 MEQ 
MEQ Fwd GGTCTGGTGGTTTCCAGGTGA 
60 oC 73 bp MEQ Rev GCATAGACGATGTGCTGCTGA 
MEQ probe 
AGACCCTGATGATCCGCATTGCGACT 
(5’ FAM, 3’ BHQ1) 
Chicken 
ovotransferrin 
gene (control) 
Ovo Fwd CACTGCCACTGGGCTCTGT 
60 oC 71 bp Ovo Rev GCAATGGCAATAAACCTCCAA 
Ovo probe 
AGTCTGGAGAAGTCTGTGCAGCCTCCA 
(5’ Yakima Yellow, 3’ TAMRA) 
 
3.3.8 Real-Time Polymerase Chain Reaction (RT-PCR) 
RNA extraction and cDNA: Total RNA was extracted from mock and MDV infected 
CEFs using TRIzol (Thermo Fisher Scientific, Paisley, UK) according to the 
manufacturer’s protocol and treated with DNA Free DNase. Subsequently, 1 µg of 
purified RNA was reverse transcribed to cDNA using Superscript® III First Strand 
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Synthesis kit (Thermo Fisher Scientific, Paisley, UK) and oligo-dT primers according to 
the manufacturer’s recommended protocol. The resulting cDNA was diluted 1∶10 in 
DEPC treated water. 
SYBR green RT-PCR: Quantitative real-time PCR using SYBR Green was performed on 
diluted cDNA using the LightCycler® 480 II (Roche Diagnostics GmbH, Mannheim, 
GER) as previously described. Briefly, each reaction involved a pre-incubation at 95 °C 
for 5 min, followed by 40 cycles of 95°C for 20 sec, 55°C–64°C (TA as per primer) for 
15 sec, and elongation at 72°C for 10 sec. Subsequent melt curve analysis was 
performed by heating to 95°C for 10 sec, cooling to 65°C for 1 min, and heating to 
97°C. Primers sequences and accession numbers are outlined in Table 3. Relative 
expression levels of all genes were calculated relative to the housekeeping gene β-actin 
using the LightCycler® 480 Software (Roche Diagnostics GmbH, Mannheim, GER). 
Data represent mean of 6 biological replicates. 
Table 3: List of primers used for Real-Time PCR 
Gene name Accession no Primers 
Tm 
(oC) 
Product 
size (bp) 
Acetyl-CoA carboxylase 
(ACC) 
J03541.1 
Fwd ACGTTCGAAGGGCGTACATT 
60oC 161 bp 
Rev TACGTGGACCATCCCGTAGT 
Fatty acid synthase 
(FASN) 
J03860.1 
Fwd CTTTGGTGGTTCGAGGTGGT 
60oC 170 bp 
Rev CTGTGGGAACCTTGCTTGGA 
Lipoprotein lipase (LPL) NM_205282.1 
Fwd ACTGAAACTTTTTCGCCGCTG 
61oC 128 bp 
Rev ATTCATCTCAGCTTCGGGATCG 
Carnitine palmitoyl 
transferase 1a (CPT1a) 
NM_001012898.1 
Fwd CTAGCCCCTCTAGCTGGCTT 
61oC 113 bp 
Rev ACTTCTCTCAAGGGTTCGGT 
Acyl-coA dehydrogenase, 
Long chain (ACADL) 
NM_001006511.2 
Fwd CTAAGCGGCTGACTGACATCG 
61oC 221 bp 
Rev AATATCCGCTCCAATGCCTCC 
Prostaglandin Receptor 2 
(EP2) 
NM_001083365.1 
Fwd CCTTCACGATCTGCGCCTAC 
60oC 92 bp 
Rev GGGGTTGATGGAGAGGAAGC 
Prostaglandin Receptor 3 
(EP3) 
NM_001040468.1 
Fwd GCTGCTGGTAACGATGCTGA 
60oC 177 bp 
Rev CGGAGCAGCAGATAAACCCA 
Prostaglandin Receptor 4 
(EP4) 
NM_001081503.1 
Fwd ATGTTCCAGGGTACAGGTTTTGT 
60oC 175 bp 
Rev GCCTAGCCTGCACGGTGTT 
Clyclooxygenase 1 
(COX-1) 
XM_425326 
Fwd TCAGGTGGTTCTGGGACATCA 
60oC 123 bp 
Rev TGTAGCCGTACTGGGAGTTGAA 
Clyclooxygenase 2 
(COX-2) 
XM_422297 
Fwd CTGCTCCCTCCCATGTCAGA 
60oC 123 bp 
Rev CACGTGAAGAATTCCGGTGTT 
Cytoplasmic Beta Actin X00182 
Fwd TGCTGTGTTCCCATCTATCG 
60oC 150 bp 
Rev TTGGTGACAATACCGTGTTCA 
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3.3.9 Prostaglandin E2α ELISA 
PGE2α was quantified using a colorimetric assay (R&D Systems, Abingdon, UK) based 
on competition between unlabelled PGE2α in the sample and a fixed amount of 
conjugated PGE2α. The assay was performed according to assay kit manufactures 
recommendation. In brief, CEFs were either mock or infected with RB1B in the 
presence/absence of TOFA (1.54 µM) and C75 (5.9 µM) or SC-236 (0.25 µg/ml) and 
incubated (38.5oC, 5% CO2) for 48 or 72 hpi. The supernatants were collected and 
diluted (1:100) in Calibrator Diluent RD5-56. PGE2α detection antibody was added to 
the wells which were pre-coated with primary anti-PGE2α antibody and incubated for 1 
hr at RT. Next, PGE2α conjugates was added and incubated for an additional 2 hrs at 
RT. The wells were subsequently washed and developed by incubating substrate buffer 
for 30 min at RT. The assay was measured at OD450 nm and concentrations of PGE2α 
were determined against a standard curve. 
 
3.3.10 Determination of Oxygen consumption rate (OCR) and Extracellular 
acidification rate (ECAR) 
CEFs were seeded at a rate of 2.0 x 104 cells per well in an XFp 8-well V-3 PET tissue 
culture mini-plate (Seahorse Bioscience, Agilent, UK) in triplicates and incubated 
overnight at 38.5°C. Next day, cells at 80% confluency were pre-treated with etomoxir 
(4.42 µM) or vehicle control and then either mock or infected with RB1B (100 pfu per 
1.5 x 105 cells) for an additional 24 hrs. Oxygen consumption rates (OCR) was 
measured every 6 min using the Seahorse Bioscience XFp analyzer (Seahorse 
Bioscience, Agilent, UK) from 16-30 hpi at 38.5°C.  
 
3.3.11 Oil Red O staining 
Lipid droplets were stained in CEFs mock or infected with RB1B in 6 well-plates. In 
brief at 72 hpi, cell monolayer was washed with PBS and fixed with 4% formaldehyde 
for 30 min at RT. Plates were subsequently stained with Oil Red O solution for 30 min 
at RT followed by a wash in PBS. Plates were counterstained with hematoxylin for 3 
min at RT followed by a wash with super Q water. Plates were visualized and imaged 
using a light microscope and the pictures were processed using Adobe Photoshop 
software.  
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3.3.12 Fluorescence confocal microscopy 
CEFs were seeded in 24 well plates that contained 12 mm diameter round coverslips at 
a rate of 1.0 x 105 cells per well. At 72h post mock or infection with the pRB1B UL35-
GFP virus in the presence/absence of SB 204990, TOFA, C75 or etomoxir, the samples 
were prepared for imaging. In brief, mock or infected CEFs were fixed with 4% 
formaldehyde for 30 min at RT and washed twice with PBS. Cells were subsequently 
incubated with HCS LipidTox Red Neutral lipid stain (1:1000 in PBS; 568 nm) at RT 
for an additional 45 min. Cells were washed twice with PBS and nuclei were labelled 
with DAPI. Coverslips were mounted in vectashield mounting medium for fluorescence 
imaging. Cells were viewed using a Leica SP2 laser-scanning confocal microscope and 
optical sections recorded using either the 663 or 640 oil-immersion objective with a 
numerical aperture of 1.4 and 1.25, respectively. All data were collected sequentially to 
minimize cross-talk between fluorescent signals. The data are presented as maximum 
projections of z-stacks (23-25 sections; spacing 0.3 mm). Maximum projections of z-
stacks were analysed using IMARIS (Bitplane Scientific Software). Ninety infected 
cells and 40 mock-infected cells were analysed and their LipidTox-labelled Neutral 
lipid containing organelles were detected with the spot function of IMARIS. Images 
were processed using Adobe Photoshop software. 
 
3.3.13 Statistical Analysis 
All data are presented as mean + standard deviation (SD) from at least three 
independent experiments. Quantification was performed using Graph Pad Prism 7 for 
windows. The differences between groups, in each experiment, were analysed by non-
parametric Wilcoxon tests (Mann-Whitney) or by Kruskal-Wallis test (One-way 
ANOVA, non-parametric). Results were considered statistically significant at P < 0.05 
(*).  
 
 
3.4 Results 
3.4.1 MDV infection increases lipogenesis   
To determine if MDV infection affects lipid metabolism, we performed a lipidomic 
analysis on mock and MDV infected primary chicken embryo fibroblasts (CEFs) at 48 
and 72 hrs post infection (hpi). The analysis revealed that 15 lipid metabolites were 
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increased and 9 metabolites were decreased in infected cells at 72 hpi (Figure 11A). To 
provide a better visualization of the metabolic changes, we mapped the altered fatty 
acids (FA) and their derivatives onto the FAS pathways at 48 (Figure 11B i) and 72 hpi 
(Figure 11B ii). At 72 hpi, increased levels of palmitic acid were observed (P = 0.01), 
which are the end product of FAS pathway and are elongated to make long chain fatty 
acids (LCFA) such as stearic acid at 72 hpi (P = 0.03) in the infected cells. Stearic acid 
is further elongated into Oleic acid (P = 0.01), Nervonic acid (P = 0.04), Mead acid (P 
= 0.0028) and Docosahexanoic acid (P = 0.001). In contrast, Arachidic acid and 
Lignoceric acid were significantly reduced in MDV infected cells (P = 0.001). 
Alternatively, palmitic acid can be utilized for phospholipid biosynthesis. Our data 
demonstrate that phosphatidylethanolamine (PE) synthesis is also upregulated in the 
infected cells at both 48 (P = 0.0005) and 72 (P = 0.001) hpi. Similarly, arachidonic 
acid (AA) was also significantly increased at both 48 (P = 0.0031) and 72 hpi (P = 
0.0028). Taken together, our data demonstrate that MDV infection severely impacts 
lipid metabolism.   
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Figure 11: Induction of de novo Fatty acids synthesis in MDV infected CEFs. 
Metabolomics analysis of relative levels of lipid metabolites from mock- (control) and 
MDV-infected (RB1B) CEFs are shown at 48 hpi and 72 hpi. (A) Box and whisker 
plots showing minimum and maximum relative levels of named fatty acids and long 
chain fatty acids (LCFAs) either significantly altered or where no changes were 
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observed as a result of MDV infection. (B) Schematic summary of major metabolites 
outlining preferential utilization of fatty acids for LCFA and phospholipid synthesis by 
comparing (i) 48h and (ii) 72h post MDV infection. Arrows indicate ( ) increase, ( ) 
decrease or ( ) no change in the respective metabolites to demonstrate flux through 
pathways. Non-parametric Wilcoxon tests (Mann-Whitney) was used to assess normal 
distribution and test significance with the results shown as mean ± SD (A). * (P = 0.01) 
and ** (P = 0.001) and *** (P = 0.0005) indicates a statistically significant difference 
compared to control. NS indicates no significant difference. The experiment was 
performed in biological triplicates with six technical replicates per biological replicates 
 
3.4.2 Non-toxic concentration of pharmacological inhibitors were assayed  
To study the metabolic pathways which are essential for MDV infection and replication, 
we first determined the non-toxic concentrations at which cell viability and confluency 
wasn’t affects. CEF cell at 90% confluency were treated with the inhibitors; 
TOCRIS/SB-204990 (0.5, 1.0, 1.5, 2.0, 2.5, 3, 4, 5, 7, 8 and 10 µg/ml), TOFA (0.01, 
0.025, 0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, and 10 µg/ml), C75 (0.5, 1.0, 1.5, 2.0, and 2.5 
µg/ml), Palmitic acid (5, 10, 12.5, 15, 20, 25 and 50 µM), Malonyl-CoA (5, 10, 15, 20, 
25 and 50 µM), Etomoxir (0.01, 0.05, 0.1, 0.5, 1.0, 1.2, 1.5, 1.7, 2.0, 5 and 10 µg/ml), 
Clofibrate (0.0025, 0.005, 0.01, 0.025, 0.05, 0.1, 0.5, 1.0, 2.0, 5.0 and 10 µg/ml), SC-
236 (0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10 µg/ml), ER-819762 (1.0, 2.0, 4.0, 5.0 and 10 
µM), SC-51322 (0.1, 1.0, 2.0, 4.0, 5.0 and 10 µM) and TG 4-155 (1.0, 2.0, 4.0, 5.0 and 
10 µM) at the concentration here listed and incubated (38.5 oC at 5% CO2) for 72 hrs. 
Cells were trypsinized at 72 hrs post treatment and labelled with 7-actinomycin-D (7-
AAD) to determine percentage live cells. Here we report the concentrations at which no 
significant difference in cell death was detected compared to control or non-treated cells 
(Figure 12). Cellular confluency was observed twice a day under a normal light 
microscope for the duration of the treatment to confirm toxic effects as well. The 
concentration highlighted in black were used for the purpose of studying MDV viral 
infection and replication whereby no cell death as well as normal cellular growth or 
proliferation was observed (Figure 12). 
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Figure 12: Non-toxic concentration of small pharmacological inhibitors  
Analysis by MACS quant demonstrating percentages of 7AAD negative CEFs, 
representing live cells, after 72 h treatment with small pharmacological inhibitors 
including (A) Tocris (SB 204990), (B) TOFA, (C) C75, (D) Palmitic Acid, (E) 
Malonyl-CoA, (F) Etomoxir, , (G) Clofibrate, (H) SC-236, (I) ER-819762, (J) SC-
51322 and (K) TG 4-155. Bar graphs with single bars in black represent concentrations 
of the inhibitors which did not induce cell death. All experiments were performed in 
triplicates and data is representative of 2 independent experiments. 
 
3.4.3 MDV replication requires Fatty acid synthesis  
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To validate our lipidomics data and determine how these metabolic pathways are 
altered, we performed gene expression analyses of the cellular enzymes involved in 
FAS pathway using RT-PCR (Figure 13A). Both acetyl-CoA carboxylase (ACC) and 
Fatty acid synthase (FASN) were highly upregulated at 72 hpi (Figure 13B). To 
determine the role of these pathway in MDV replication, we used selective inhibitors of 
ACLY, ACC and FASN, SB 204990, 5-(Tetradecyloxy)-2-furoic acid (TOFA), and C75 
respectively (Figure 13A). Non-toxic concentrations of the inhibitors were determined 
based on viability (Figure 12) and confluency of the treated CEFs. To determine the role 
of these pathways, CEFs were infected with MDV (RB1B - 100 pfu per 1.5 x 105 cells) 
in the presence of these pharmacological inhibitors and in the presence/absence of the 
downstream metabolites (malonyl-CoA and palmitic acid) for 72 hrs. Viral titre were 
quantified at 72 hpi. The ACLY inhibitor SB 204990 (3.85 µM) did not affect MDV 
replication (Figure 13C), suggesting that the conversion of citrate to Acetyl-CoA is not 
important for the virus. In contrast, inhibition of ACC (TOFA; 1.54 µM) and FASN 
(C75; 5.9 µM) significantly impaired MDV replication by 27 (Figure 13D) and 28 folds 
(Figure 13E), respectively. Treatment of MDV-infected CEFs with a combination of 
TOFA (0.77 µM) and C75 (4.5 µM) decreased (p = 0.0043) the transcripts of ACC 
(Figure 13F) and FASN (Figure 13G). To determine if the metabolites can rescue the 
phenotype of the inhibitors, we supplemented the cells with the respective downstream 
metabolites. As expected, treatment with SB 204990 and malonyl-CoA did not affect 
virus replication (Figure 13H). In contrast, addition of malonyl-CoA in the presence of 
TOFA restored MDV titre (Figure 13I). Similarly, palmitic acid restored virus 
replication inhibited by C75 (Figure 13K), while the fatty acid itself did not alter MDV 
titre (Figure 13J). To confirm our data, we assessed MDV replication upon treatment 
with SB 204990, TOFA and C75 by qPCR (Figure 13L). Taken together, the result 
demonstrate that blocking ACC and FASN decreases MDV replication and reveal that 
palmitic acid is a key metabolite required for MDV infection. 
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Figure 13: Fatty acid synthesis is required for MDV infection of CEFs. 
A pathway interference approach to dissect the role of lipids in MDV replication. (A) 
Schematic FAS pathways highlighting the relevant pharmacological inhibitors (red) and 
the respective enzymes (yellow box) as well as metabolites (green box) studied within 
the FAS pathway. (B) Fold change gene expression in CEFs mock-infected or MDV-
infected are shown at 24, 48 and 72 hpi. Analysis of MDV viral  titer (PFU/ml) in 
infected CEFs in the presence of (C) SB 204990 (1.28, 2.56 and 3.85 µM), (D) TOFA 
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(0.03, 0.077, 0.154, 0.31, 0.77 and 1.54 µM) and (E) C75 (0.393, 1.97, 3.93 and 5.9 
µM). Box and whisker plots demonstrating relative fold change in mRNA of (F) ACC 
and (G) FASN in MDV-infected CEFs cells treated with vehicle (Cont.) or TOFA+C75 
(T/C) at 72 hpi. Analysis of MDV viral titre (PFU/ml) in infected CEFs in the presence 
of (H) malonyl-CoA with SB-204990, (I) malonyl-CoA with TOFA or (J) Palmitic acid 
(5, 12.5, 20 and 25 µM) (K) Palmitic acid with C75 (5.9 µM). (L) MDV (RB1B) 
genome copy number per 104 cells (MEQ gene with reference ovotransferrin gene) in 
the presence of SB 204990 (3.85 µM), TOFA (1.54 µM) or C75 (5.9 µM). *** (p = 
0.0002) **** (p < 0.0001) indicates a statistically significant difference compared to 
control. NS indicates no significant difference. $ symbol indicates vehicle treated cells. 
All viral titre experiments were performed in 6 replicates and data is representative of 3 
independent experiments.  
 
 
3.4.4 β-oxidation of fatty acids increases ATP synthesis in the MDV-infected cells  
To determine if fatty acids oxidation increases ATP synthesis, we measured oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) in MDV-infected 
cells over time using a Seahorse Bioscience XFp analyzer (Seahorse Bioscience). 
Thereby, OCR and ECAR correspond to β-oxidation of fatty acids and glycolysis for 
ATP production respectively. Linear regression analysis of the OCR and ECAR 
revealed a significant increase in MDV-infected compared to mock-infected cells 
(Figure 14A and 14B), suggesting that virus infection increases ATP production via 
both β-oxidation of fatty acid and glycolysis. At 90 min post infection, mock-infected 
cells had OCR rate of 75.63 pmol/min, which rose to 108.52 pmol/min by 600 min post 
mock-infection as the nutrient were consumed (Figure 14A). To assess if MDV 
replication relies on import and utilization of palmitic acid within mitochondria to 
generate ATP, CEFs were treated with a vehicle or etomoxir, the pharmacological 
inhibitor of carnitine palmitoyltransferase 1a (CPT1a) which blocks the import of long-
chain fatty acids into the mitochondria. Etomoxir did not modulate β-oxidation of fatty 
acids in the non-infected cells (Figure 14A). In contrast, etomoxir significantly reduced 
the OCR in MDV-infected cells compared to the treated MDV-infected cell (Figure 
14C), indicating that etomoxir can reduce β-oxidation of fatty acid for ATP production 
in the MDV-infected cells. Intriguingly, treatment of MDV-infected cells with etomoxir 
increased the ECAR rate at all time points (Figure 14D), indicating that glycolysis is 
activated independent of oxidative phosphorylation in the MDV-infected cells.  
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Figure 14: MDV infected cells can also utilize non-mitochondrial sources of ATP. 
(A) Oxygen consumption rate (OCR; pmoles/min) and (B) Extracellular acidification 
rate (ECAR; mpH/min) are shown for the mock-infected and MDV-infected CEFs.  
MDV-infected CEFs were treated with etomoxir (4.42 µM) or vehicle during the first 
12 h post mock infection, and (C) OCR (D) ECAR were determined using the Seahorse 
XFp. All experiments were performed in triplicates and data is representative of 3 
independent experiments. 
 
3.4.5 MDV replication is independent of ATP generated by β-oxidation of fatty 
acids  
To investigate if the ATP generated by β-oxidation are required for MDV replication, 
we inhibited CPT1a responsible for fatty acids transport from cytoplasm into 
mitochondria for β-oxidation using non-toxic concentrations of the physiological 
inhibitor malonyl-CoA and pharmacological inhibitor etomoxir. To activate β-
oxidation, non-toxic concentrations of Clofibrate was used in this study (Figure 15A). 
Gene expression analysis revealed an up-regulation of CPT1a, acyl-CoA dehydrogenase 
long chain (ACADL) and lipoprotein lipase (LPL) in the MDV-infected CEFs using 
RT-PCR at 72 hpi (Figure 15B). To examine the role of β-oxidation in MDV-
replication, CEFs were infected with MDV in the presence of exogenous malonyl-CoA, 
etomoxir or Clofibrate, and viral titre was quantified at 72 hpi. Clofibrate, a 
PPARα ligand which activates β-oxidation, significantly reduced MDV replication 
(Figure 15C). In contrast, neither malonyl-CoA (Figure 15D) nor etomoxir (Figure 15E) 
had any inhibitory effects on viral titre, suggesting that the ATP generated by β-
oxidation is not required for MDV replication. Interestingly, even a slight increase in 
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viral yield was observed in the cells treated with etomoxir or malonyl-CoA. Similarly, 
combination of etomoxir with malonyl-CoA or palmitic acid did not reduce MDV 
replication but increased viral titre by 2-fold (Figure 15F). To confirm the effects of the 
inhibitors on virus replication, we quantified MDV genome copies by qPCR (Figure 
15G).  As observed in the virus titrations, only clofibrate inhibited virus replication 
while no effect was observed with etomoxir, confirming that ATP generation by β-
oxidation is not required for MDV replication.   
 
 
 
Figure 15: β-oxidation is not essential to support MDV infection of CEFs. 
Fatty acyl-CoA derivatives transported into the mitochondria undergo Fatty acid 
oxidation (FAO) to generate ATP, NADH and NADPH. (A) Schematic metabolic 
pathway outlines the relevant pharmacological molecules (red; etomoxir and blue; 
clofibrate) and the respective enzyme (yellow box) as well as metabolites (green box) 
studied within the FAO pathway. Pharmacological molecules were titrated for non-toxic 
levels and where no effect on cellular confluency was observed (supplementary Fig1). 
(B) Fold change gene expression comparing mock and MDV-infected CEFs at 24, 48 
and 72 hpi. MDV viral titre in MDV-infected CEFs treated with (C) Clofibrate (0.01, 
0.02, 0.04, 0.1, 0.2 and 0.41 5.9 µM), an agonist of PPAR-α, (D) malonyl-CoA (5, 10, 
15, 25 and 30 µM) and (E) etomoxir (0.29, 1.47, 2.95 and 4.42 µM). (F) MDV-infected 
CEFs were treated with etomoxir (4.42 µM) with either palmitic acid (5, 12.5 and 25 
µM) or malonyl-CoA (5, 15, 25 µM) and viral titre was analysed using a plaque assay. 
(G) MDV genome copy numbers per 104 cells (MEQ gene with reference ovotransferrin 
gene) were determined using qPCR in CEFs treated with etomoxir (4.42 µM) or 
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Clofibrate (5.9 µM). Non-parametric Wilcoxon tests (Mann-Whitney) and One-way 
ANOVA was used to assess normal distribution and test significance with the results 
shown as mean ± SD. $ indicate vehicle treated cells. **** (P < 0.0001) indicates a 
statistically significant difference compared to control. NS indicates no significant 
difference. All experiments were performed in 6 replicated and data presented is 
representative of all 3 independent experiments.  
 
 
3.4.6 MDV-induced lipogenesis results in formation of neutral lipid droplets 
Lipid droplets (LD) are endoplasmic reticulum (ER) derived organelles that consists of 
a neutral lipids core with a phospholipid bilayer. An increase in the numbers of LD is an 
indication of lipogenesis. We examined if the increase in palmitic acid synthesis and 
excess VLCFA during MDV infection results in LD formation. Initially, Oil Red O 
staining was used to detect neutral lipid and hematoxylin for cell nuclei identification in 
mock and MDV infected CEFs at 72 hpi (Figure 16A). An accumulation of LD was 
observed in the MDV-infected (Figure 16Ai) compared to mock-infected cells (Figure 
16Aii). To quantify the number of LD, pRB1B UL35-GFP-infected CEFs were stained 
with a neutral lipid dye Red LIPIDTOX (488nm), analysed by confocal microscopy and 
Z-stack images taken. As expected, the viral capsid protein UL35 fused to GFP was 
detected in the nucleus, while LD only localized within the cytoplasm (Fig 16F). A 
higher numbers of LD per cell were observed in MDV-infected compared to mock-
infected cells (P = 0.0001) (Figure 16B). This was confirmed with an unbiased 
quantification of the LD using the IMARIS software (Figure 16C). Treatment of CEFs 
with SB 204990, or etomoxir had no effect on total LD numbers whereas treatment with 
TOFA and C75 decrease (P = 0.0001) the LD per cell in both mock (Figure 16D) and 
MDV-infected cells (Figure 16E). Altogether, these data show that MDV infection 
induces the accumulation and redistribution of fatty acids resulting in LD formation. 
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Figure 16: Excess FA are stored in lipid droplets during MDV infection  
(A) Visualisation of cytoplasmic lipids in neutral lipid droplet organelles of CEFS (i) 
infected with MDV and (ii) mock-infected. Cell monolayer was fixed and stained with 
an Oil Red O staining kit and counterstained with hematoxylin and visualized using 
light microscopy (magnification 10X). Black arrows indicate lipid droplets. (B) 
Confocal microscopy imaging with maximum projection of Z-stacks for each channel 
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demonstrating nuclear and cytoplasmic distribution of pRB1B UL35-GFP virus (green) 
and lipid droplets (red). Mock and pRB1B UL35-GFP infected cells were fixed at 72 
hpi and stained with DAPI (nuclear stain) and the neutral lipid stain LIPIDTOX-568nm. 
Images 5 and 10 are 3-D representative images analysed using the IMARIS software. Z-
stacks were analysed using the IMARIS spot function analysis tool to quantify the 
relative amount of lipid droplets per cell in infected CEFs and non-infected CEFs (50-
90 cells). (C) The numbers of lipid droplets per cell in MDV-infected and mock-
infected CEFs. The numbers of lipid droplets per cell in (D) mock infected (E) MDV-
infected CEFs treated with SB 204990 (3.85 µM), TOFA (1.54 µM), C75 (5.9 µM), 
etomoxir (4.42 µM) and palmitic acid (25 µM) are shown. (F) Analysis by IMARIS, 
using the co-localization function, to visualize neutral lipid droplet organelles (red) 
formation and relative position to the pRB1B UL35-GFP virus capsid protein (Green). 
**** (P < 0.0001) indicates a statistically significant difference compared to the 
control. All experiments were performed in duplicates and data is representative of 3 
independent experiments.  
 
 
3.4.7 Virus-induced FAS pathway activates COX-2/PGE2α pathway  
As shown above, AA synthesis was elevated in the MDV infected CEFs (P = 0.003) at 
48 and 72 hpi (Figure 11A). AA is a substrate for the production of eicosanoids, a class 
of lipids mediators converted by clycooxygenase-1 (COX-1) and inducible 
clycooxygenase-2 (COX-2). Therefore, we investigated the importance of eicosanoid 
synthesis in MDV infection as shown in the schematic diagram (Figure 17A). No 
significant difference in COX-1 gene expression levels was observed between the mock 
and MDV-infected cells at 72 hpi (Figure 17B). Treatment of MDV-infected CEFs with 
TOFA, C75 (FAS pathway inhibitors), or SC-236 (COX-2 inhibitor) also did not alter 
the expression of COX-1. However, COX-2 expression was significantly increased in 
the MDV-infected cells (Figure 17C). In addition, treatment of the infected cells with 
TOFA and C75 (T/C), or SC-236 decreased (P = 0.0007) COX-2 mRNA expression, 
suggesting that FAS pathway is involved in activation of COX-2. Treatment of the 
MDV-infected cells with non-toxic concentrations of a COX-2 inhibitor (SC-236) 
diminished MDV replication in a dose dependent manner. Specifically, 4-fold reduction 
in MDV titres was observed in CEFs treated with SC-236 (P = 0.0022; Figure 17D). 
Beyond that, we could demonstrate that PGE2α is the only prostaglandin that can rescue 
the inhibitory effects of SC-236 on MDV titre (Figure 17E). In the absence of the COX-
2 inhibitor, exogenous PGE2α did not alter MDV titre (Figure 17F). A concentration as 
low as 0.1 µg/ml of PGE2α sufficed to rescue the inhibitory effects of SC-236 on MDV 
titre (Figure 17G). Strikingly, exogenous PGE2α also restored the inhibitory effects of 
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TOFA and C75 on virus titre (Figure 17H), suggesting that the inhibitory effects of FAS 
pathway inhibitors is dependent on inhibition of PGE2α synthesis. When CEFs were 
treated with low concentrations of TOFA or C75, exogenous PGE2α fully restored MDV 
replication (P = 0.0007). However, PGE2α only partially recovered MDV titre when 
high concentrations of TOFA or C75 were used (Figure 17H). To determine if PGE2α 
was released from MDV infected cells, we measured PGE2α in the supernatants of mock 
and MDV infected cells at 48 and 72hpi by ELISA (Figure 17I). Higher concentrations 
of PGE2α were released by the MDV-infected compared to mock-infected cells at 72hpi 
(P = 0.0001). Interestingly, inhibition of FAS pathway by TOFA and C75 reduced 
PGE2α release from MDV-infected cells (P = 0.0022), but not the mock infected cells at 
72hpi. The results indicate that the treatment with TOFA and C75 only reduces MDV-
induced PGE2α synthesis, while physiological levels of PGE2α are still produced in 
treated cells. In contrast, SC-236 significantly inhibited PGE2α production from both the 
MDV-infected (P = 0.0001) and mock-infected (P = 0.0001) cells at 48 and 72hpi 
(Figure 17I). Taken together, our results suggest that virus-induced FAS pathway is 
critical for the increased PGE2α synthesis in the MDV-infected cells.  
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Figure 17: MDV infection modulate inducible COX-2 gene expression to produce 
PGE2 
(A) Schematic pathway outlines the relevant pharmacological inhibitor (red) and the 
respective enzyme (yellow box) as well as metabolites (green box) studied within the 
eicosanoid biosynthesis pathway. Fold change in expressions of (B) COX-1 and (C) 
COX-2 in mock-infected and MDV-infected CEFs treated with T/C (TOFA; 0.5 µg/ml 
in combination with C75; 1.0 µg/ml), or SC-236 (0.25 µg/ml). MDV titre (PFU/ml) in 
the MDV-infected CEFs in the presence of (D) SC-236 (0.005, 0.025, 0.05, 0.1 and 0.25 
µg/ml), (E) SC-236 (0.25 µg/ml) in combination with PGE2α (5.0 µg/ml), PGI2 (0.5 
µg/ml), PGD2 (0.5 µg/ml), PGF2α (0.5 µg/ml), and TXA2 (0.5 µg/ml). MDV titre in 
CEFs treated with (F) different concentrations of PGE2α (0.25, 0.5, 1.0, 2.5, and 5.0 
µg/ml) (G) PGE2α (5.0 µg/ml) in combination with SC-236 (0.25 µg/ml) and (H) PGE2α 
(5.0 µg/ml) in combination with either TOFA (0.1, 0.25 and 0.5 µg/ml) or C75 (1.0, 1.2 
and 1.5 µg/ml). (I) PGE2 (ρg/ml) concentrations in supernatant of mock-infected and 
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MDV-infected CEFs were measured using an ELISA assay after 48 and 72 hpi in the 
presence of SC-236, T/C or no treatment. $ symbol indicates vehicle treated cells. * (P 
= 0.03), ** (P = 0.0022), *** (P = 0.0007) and **** (P = 0.0001) indicate statistically 
significant differences. NS indicates no statistical difference. Experiments were 
performed in 6 replicates for plaque assays and 3 replicates for Real-Time PCR and 
ELISA assays. The data are representative of 3 independent experiments. 
 
 
3.4.8 Identification of the PGE2α receptor(s)  
Four different types of PGE2α receptors have been identified in humans termed 
EP1, EP2, EP3, and EP4. Chicken EP2, EP3, and EP4 receptors have been cloned and 
characterized (243, 244) while EP1 has not yet been identified. Analysis of gene 
expressions in the MDV-infected and mock-infected CEFs demonstrated that the EP2 
and EP4, but not EP3, were up-regulated upon MDV infection (Figure 18B), suggesting 
that PGE2α may support MDV replication through an EP2 or/and EP4 mediated 
mechanisms. To examine the role of different EP receptor in MDV infection, we used 
receptor antagonists for EP1 (SC-51322), EP2 (TG 4-155) and EP4 (ER-819762) were 
utilized. As expected, the EP1 receptor antagonist (SC-51322; 0.1, 1, 5 and 10 µM) had 
no effect on MDV replication (Figure 18C). In contrast, TG 4-155 (2 and 4 µM) and 
ER-819762 (0.1, 0.5 and 1.0 µM) impaired MDV infection (P = 0.0001), confirming 
that PGE2α support MDV replication through the EP2 and EP4 receptors (Figure 18D 
and 19E). Taken together, our data indicate that virus-induced FAS enhances PGE2α 
synthesis and that this process is dependent on the EP2 and EP4 receptors in the MDV-
infected cells. 
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Figure 18: MDV infection is dependent on PGE2 receptor engagement 
(A) Schematic pathway outlines the relevant pharmacological inhibitor (red) and the 
respective metabolites (green box) studied within the eicosanoid biosynthesis pathway. 
(B) Fold change in gene expression of PGE2α receptors EP2, EP3 and EP4 in MDV-
infected CEFs at 72 hpi. MDV viral titre (PFU/ml) in MDV-infected CEFs in the 
presence of different concentration of PGE2α receptor antagonists (C) SC-51322 (EP1 
antagonist; 0.1, 1, 5 and 10 µM), (D) TG 4-155 (EP2 antagonist, 1, 2 and 4 µM) and (E) 
ER-819762 (EP4 antagonist; 0.1, 0.5 and 1.0 µM). $ symbol indicates vehicle treated 
cells. * (p = 0.03), ** (p = 0.0022), *** (P = 0.0007) and **** (P = 0.0001) indicate 
statistically significant differences. NS indicates no statistical difference. Experiments 
were performed in 6 replicates for plaque assays and 3 replicates for Real-Time PCR 
and ELISA assays. The data are representative of 3 independent experiments. 
 
 
3.5 Discussion 
Viruses have evolved strategies to target and modulate lipid signalling, synthesis and 
metabolism in the host cells and provide an optimal micro-environment for viral entry, 
replication and morphogenesis. Interestingly, even two related viruses such as HSV-1 
and HCMV drive host cells to achieve distinct metabolic programs. While HCMV 
increased de novo lipid synthesis, HSV-1 enhanced the synthesis of pyrimidine 
nucleotides (219). Other viruses can also modulate common lipid metabolism including 
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upregulation of FAS, providing building blocks for different lipids. Replication of 
different viruses may require activation of distinct lipid pathways and source of energy.   
 
MDV is an alphaherpesvirus that infects chickens and causes a deadly 
lymphoproliferative disease. In addition to transformation of CD4+ T cells, MDV causes 
atherosclerosis by disturbing the lipid metabolism in the infected chickens (245), which 
can be inhibited by vaccine-induced immunity (241, 246). Surprisingly, little is known 
about the processes involved in disturbance of lipid metabolism in MDV infection. Our 
lipidomic analysis of MDV-infected CEFs demonstrates that MDV infection enhances 
FAS and promote synthesis of AA, the prostaglandin precursor. Here, we demonstrate 
that MDV hijacks host metabolic pathways to provide essential macromolecular 
synthesis to support infection and replication. De novo FAS generates the metabolic 
intermediate acetyl-CoA, malonyl-CoA and finally palmitate. Targeted inhibition 
studies against the enzymes involved in FAS during infection have yielded an 
alternative understanding of alteration of lipid metabolism in infections with HCMV 
(247), EBV (234), HCV (248, 249). The first step towards FAS is the conversion of 
citric acid into acetyl-CoA by direct phosphorylation of ACLY. Hepatitis B virus 
(HBV) and HCMV infections activate the expression of ACLY (250, 251), however the 
enzymatic activity of ACLY is not critical for virus-induced lipogenesis. Virus-infected 
cells can use glucose carbon for FAS by ACLY from citrate generated in mitochondria 
and acetyl-CoA synthetase short-chain family member 2 (ACSS2) from acetate (252). 
In our study, blocking ACLY activity via small pharmacological inhibitors had no effect 
on MDV replication and genome copies. This finding suggests that acetate can be 
produced in avian cells via other endogenous mechanism under rich medium conditions, 
which would mask the effects on viral replication. The subsequent step involves the 
conversion of acetyl-CoA into malonyl-CoA by acetyl-coA carboxylase (ACC) and 
finally elongation by utilizing both acetyl-CoA and malonyl-CoA coupled to the 
multifunctional fatty acid synthase (FASN) to make palmitic acid. Our results 
demonstrate that blocking ACC and FASN activity significantly reduces MDV 
replication, suggesting that MDV preferentially modulates the FAS pathway to generate 
a variety of lipids which contributes to several key cellular processes. Our data confirm 
that the inhibitory effects of FAS inhibitors on MDV replication could be overcome by 
the addition of palmitic acid, a metabolite downstream of FASN in the FAS pathway. 
This indicates that inhibition of MDV by FAS inhibitors was not simply detrimental to 
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the cell but was essential for the production of infectious virus. Future studies are 
required to examine the mechanism involved in activation of FAS by MDV which can 
lead to induction and accumulation of fatty acids. 
 
Palmitic acid contributes essential carbons in synthesis of VLCFA that can be 
subsequently utilized in synthesis of various lipids required for membrane biosynthesis 
and lipid droplet formation. Our results demonstrate that VLCFA are increased in MDV 
infection. Alternatively, β-oxidation of fatty acids within the mitochondria can generate 
energy and macromolecular precursors to support cellular activity and fuel viral 
replication. It has been shown that the synthesis and mitochondrial import of fatty acids, 
in which β-oxidation generate ATP production, are essential for replication of vaccinia 
virus (223). This can be explained by the fact that vaccinia virus does not require 
glycolysis for replication and thus depends on the energy generation via β-oxidation. 
Our results demonstrate that β-oxidation is activated in the MDV-infected cells and 
palmitic acid is converted into energy in the mitochondria. However, we could 
demonstrate that limiting energy derived from mitochondrial β-oxidation during lytic 
viral infection had no detrimental effect on MDV replication. In fact, inhibition of β-
oxidation rather increased virus titre, suggesting that MDV-infected cells obtain their 
energy from other sources. This could be explained by the facts that some herpesviruses 
encode metabolic enzymes to support essential functions independent of mitochondria 
derived energy carriers (66, 68, 215, 216). Alternatively, MDV could induces glycolysis 
and thus does not require energy generated via β-oxidation as observed for other herpes 
viruses (219, 247). Consequently, activation of lipolysis (mitochondrial β-oxidation) 
decreased virus titre and genome copies, confirming that β-oxidation is not beneficial 
for MDV replication. This indicates that the generated fatty acids are utilized for 
activation of other lipid pathways, which are crucial for viral replication. 
 
It is known that elongation of palmitic acid in lipogenesis contributes to a total cellular 
pool of VLCFA which are essential components for the initiation of key cellular 
processes such as  membrane lipid synthesis, generation of lipid droplets and eicosanoid 
synthesis (253). It has been shown that the assembly of some viruses such as HCMV are 
highly dependent on induction of VLCFA from FAS (235). Similarly, VLFCA 
contribute to IAV envelope formation in a strain dependent manner (254). Lipid 
droplets are classically defined as organelles with stored neutral lipids and some reports 
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suggest that lipid droplets are a site for replication and assembly of some viruses. 
However the functional relationship of lipid droplets to cellular processes are not well 
defined (255). Infection with a range of pathogens have been demonstrated to induce 
lipid droplet formation including bacteria, specifically M. tuberculosis (256) and M 
leprae (257), as well as protozoan infection such as Trypanosoma cruzi (258) in Chagas 
disease. Viral infection including HCV and its relationship to lipid droplet formation 
has been extensively documented (259). It has been demonstrated that the HCV core 
protein interacts with lipid droplet for virion assembly (260). Similarly, infection with 
HCV (260), DENV (261) and rotaviruses (262) promoted the formation of lipid 
droplets. Similarly, our data demonstrate that MDV infection increases lipid droplet 
formation; however, the exact role of lipid droplets in MDV infection is unknown. 
Formation of lipid droplets in MDV infection was dependent on FAS pathway as FAS 
inhibitors reduced the numbers of lipid droplets. Lipid droplets are a significant source 
of triglyceride-derived arachidonic acid (AA) which can be converted to eicosanoids 
such as prostaglandins. Upon stimulation, AA is released from lipid droplets and 
metabolised into PGE2α by the cyclooxygenase enzymes COX-1 and COX-2. In this 
study, we observed that MDV promotes lipid droplet formation, and synthesis of 
phospholipid and AA. The upregulation of COX-2 but not COX-1 transcripts in MDV-
infected cells confirms that COX-2/PGE2 pathway are induced by the virus. Some 
viruses such as EBV (263) promote viral replication and dissemination by supressing 
PGE2α biosynthesis. In contrast, HCMV (229, 264), KSHV (232) and MVA (228) 
activate PGE2α release in response to infection. Here, we demonstrate that MDV 
upregulate COX-2 expression and PGE2α synthesis, which is highly dependent on the 
FAS pathway. To our knowledge, this is the first report demonstrating that a viral 
infection increases COX-2/PGE2α pathway via induction of the FAS pathway, and 
demonstrate that the inhibitory effects of FAS inhibitors on virus replication could be 
recovered by exogenous PGE2α. The proposed model for the role of FAS and COX-
2/PGE2α pathways in MDV infection is summarized in Figure 19. Taken together, our 
results demonstrate that virus-induced FAS pathway enhances PGE2α synthesis which 
support MDV infectivity through EP2 and EP4 receptors.  
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Figure 19: Schematic representation of MDV modulation of lipogenesis and 
Prostanoids  
MDV systematically modulates cellular lipid metabolic pathways to support its 
replication through FAS and COX-2/PGE2 pathways. The three major phases of 
lipogenesis are grouped under FAS, VLCFA and Prostanoids. 1. Infection of CEFs with 
MDV results in an increase of de novo FAS pathway, which is required for MDV 
replication. 2. Palmitic acid biosynthesized in FAS pathway can be utilized in the 
mitochondria by FAO (β-oxidation) to regenerate energy intermediates, however this 
pathway is not required for virus replication. 3. Elongation of palmitic acid results in 
biosynthesis of VLCFA which can be stored in lipid droplets organelles, utilized for 
phospholipid or eicosanoid synthesis 4. Subsequently, PGE2α are synthesized 
enzymatically from arachidonic acid. Signalling of PGE2α is mediated through its EP2 
and EP4 receptors in MDV-infected cells. Specific enzymes studied along the pathway, 
their relative importance for MDV infection are highlighted in yellow. Major 
metabolites which was identified as essential lipids are highlighted in green.  
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Chapter 4: T cell responses to Marek’s Disease virus in 
resistant and susceptible line of chickens 
 
 
 
4.1 Abstract 
This study defines that pp38 is highly immunogenic and elicits a T cell reactivity in 
birds whether they were challenged, vaccine-challenged or vaccine-boosted. The 
immunodominant peptide epitope (pp385-20, pp38161-176 and pp38171-186) eliciting this 
syngeneic immunoreactivity pattern is identified for the first time in both MD-resistant 
(B21) and MD-susceptible (B19) lines of chickens. In order to identify T cell subsets 
which are recognizing these immunodominant peptide epitopes, we depleted CD4+, 
CD8+, TCRVβ1+ or TCRVβ2+ from splenocytes and the results shows that depletion of 
CD4+ or TCRVβ1+ T cell but not CD8+ or TCRVβ2+ T cell cells diminishes antigen 
specific T cell responses as measured by ex vivo cIFN-γ ELISPOT assay suggesting that 
the reacting T cells are CD4+ TCRVβ1+ T cell in both the resistant and susceptible line of 
birds. Furthermore, these results indicate that CD4+ and not CD8+ T cells proliferate and 
induce upregulation of IL-2, IL-4 and IL-10. Peptide (pp385-20, pp38161-176 and pp38171-
186) specific memory T cells can be identified at 4 weeks post either challenged, 
vaccine-challenged or vaccine-boost in both susceptible and resistant lines of birds. 
However, challenge resulted in a diminished of the ability of T cell degranulation as 
measured by expression of CD107a in both antigen-specific and antigen-non-specific 
manner in both susceptible and resistant lines of birds. Infection of both naïve and 
MDV-vaccinated birds impaired T cell degranulation, however Antigen-specific 
induction of Perforin and Granzyme B (GZMB) mRNA transcripts can be detected in 
splenocytes of both susceptible and resistant lines of birds. This is the first report on 
identification and characterisation of MDV specific CD4+ T cell responses in 
susceptible and resistant lines of birds following challenge, vaccine-challenged or 
vaccine-boosted. 
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4.2 Introduction 
T cells play a critical role in defence against intracellular pathogens. The CD8+ (265) 
and CD4+ αβT (266) cell subsets express T cell receptors (TCR) that recognizes 8-21 
mer. Peptides. These peptides are presented in association with major histocompatibility 
complex (MHC) on antigen presenting cells (APC) which result in directed effector T 
cells cell clonal expansion: differentiation/proliferation, cytokine production (IFN-γ, IL-
2, IL-4), and cytotoxic function (CD107a+) (267). Cytotoxic properties of antiviral 
CD8+ and CD4+ T cells play an important role in the control and clearance of 
many viral infections, and the degranulation process is a necessary prerequisite to T cell 
cytotoxicity. Polarized T cells give rise to memory T cells that form the fundamental 
responding population upon subsequent infection; differentiation back to an effector 
phenotype. All these encompass fundamental T cells characteristics (268). 
 
With identification of T cell targets, the antigenic epitope can be mapped with synthetic 
peptides libraries. Numerous T cell epitopes from various human pathogens specifically 
varicella zoster virus (VZV) (269), herpes simplex virus-1 (HSV-1) (270), Human 
cytomegalovirus (HCMV) (271), Crimean-Congo haemorrhagic fever virus (CCHFV) 
(272), human immunodeficiency virus (HIV), Epstein-Barr virus (EBV) (273) and 
Mycobacterium tuberculosis have been identified (274). Mice infected with M. 
tuberculosispredominantly had CD4+ T cell response which were identified as the 
effector T cell subset. T cells are essential for both recovery and prevention of 
reactivation during primary VZV infection (275). Zoster vaccination on its own elicits a 
broad CD4+ T cell response thus priming helper responses to secondary viral 
reactivation (269). Furthermore, T cells and not B cell functional activity as defined by 
cytokine production (IFN-γ and IL-2) and cytotoxic activity (Granzyme B and Perforin) 
are good determinants for quality of T cell responses which correlates with protective 
immunity in ageing human populations against VZV reactivation (276). In the MD 
susceptible line of chicken, infiltrating CD8+ T cell have be detected in MDV induced 
CD4+ lymphoma (37). However infiltrating CD8+ T cell are unable to perform cytolytic 
activity evident by the metastasis of MDV induced CD4+ lymphoma. Our group has 
previously demonstrated in an avian influenza virus model that T cell responses can be 
detected against the hemagglutinin antigen (HA) of avian influenza virus. These 
minimal epitopes can be utilized to further characterise T cell functions; proliferation 
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and cytokines (IFN-γ, perforin, granzyme and IL-10) gene expression (277). T cell 
epitope mapping studies have yet to be performed against other avian pathogens 
including MDV antigens. In fact, our understanding of MDV induced T cell activation 
is largely based on the study performed by Omar et al. (25) who demonstrated CD8+ T 
cell specific responses against MDV antigens pp38, MEQ, ICP4 and gB. Despite the 
potentially vast number of peptides MHC (pMHC) that could be recognized by the T 
cell repertoire of the host, only a small proportion of the overall viral proteome elicits a 
host response. Therefore, T cell clonal heterogeneity generated against MDV may well 
be limited and haplotype specific (25).  
 
Therefore, the objective of this study was aimed to unravel the differential 
immunoreactivity pattern between two genetically defined lines of chickens, MD 
resistant (Line N; B21) and susceptible (Line P; B19) after either mock, challenge, 
vaccine-challenge or vaccine boosted. Antigen specific T cell recall responses against 
pp38 and MEQ was confirmed by analysing the frequency of IFN-γ producing cells in 
an ex vivo chIFN-γ ELISpot. The magnitude and breadth of antigen specific recall 
response was tracked (week 1, 2, 3 and 4 post inoculation) over the course of this study. 
The results indicate that both MEQ and pp38 are immunogenic in both B21 and B19. 
Interestingly, MEQ was found to be immunogenic in the B21 birds and not B19. 
However pp38 was highly immunogenic in both B21 and B19.  Furthermore, the 
differential response between the animal groups indicate that vaccination not sufficient 
to elicit a recall response upon challenge against MEQ in B19. More importantly, recall 
response against pp38 can be boosted in both B21 and B19 birds and this response is 
directed to specific peptide pools here termed immunodominant peptide pool. These 
results confirm that B21 birds are able to elicit a stronger antigen recall compared to 
B19 birds against MEQ or pp38. This suggest that strength of response and differential 
immunoreactivity pattern could well provide an association for resistance or 
susceptibility to MD. 
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4.3 Material and Method 
4.3.1 Experimental Animals:  
Genetically defined mixed sex Line N (resistant; B21 haplotype) and Line P 
(susceptible; B19 haplotype) SPF chickens were reared at The Pirbright Institute or 
purchased from National Avian Research Facility (NARF) at University of Edinburgh. 
Day old chicks were grouped housed throughout the experiment in specific pathogen 
free as not gnotobiotic filtered-air positive pressure rooms on floor pens with wood 
shaving. Group housed birds had ad libitum access to water and commercial feed. All 
animal works were performed according to United Kingdom (UK) home office licence.   
 
4.3.2 Virus preparation 
Virus stocks were prepared as a cell associated 3rd passage virus for both the pathogenic 
(RB1B) and vaccine strain (CVI988-RISPENS) in chicken embryonic fibroblast cells 
(CEFs) and frozen (liquid nitrogen) in freezing medium (CEF growth medium with 5% 
DMSO). Virus were isolated from splenocytes, kindly provided by Dr.Venugopal Nair, 
harvested from either MD-resistant or MD-susceptible lines of chicken at 2 weeks post 
challenge with the vaccine strain or pathogenic strain.  
 
4.3.3 Synthetic peptide Library 
In total 66 peptides spanning the entire MEQ (GeneBank: ADN05237.1) protein and 55 
peptides spanning the entire pp38 (GenBank: ABR13155.1) protein respectively was 
synthesized by Mimotopes (United Kingdom). Peptides were 15 residues long and 
overlapped by 5 residues. Peptide were dissolved in DMSO and peptide pools (1 mM) 
were prepared at 10 peptides per pool for a total of 7 and 6 peptide pools for MEQ and 
pp38 respectively. For subsequent experiments, individual pp38 peptides (pp385-20, 
pp38161-176 and pp38171-186) were synthesized at a purity of 95% and re-suspended to 
2.25 mM using the solvent recommended by the manufacturer.  
 
4.3.4 Experimental Design 
Line N (B21; resistant) and Line P (B19; susceptible) chickens were either mock 
inoculated (non-infected CEF), challenged (RB1B; 1000 pfu/bird) or vaccinated 
(CVI988-RISPENS; 1000 pfu/bird) at 1 day of age (doa.) via intra-abdominal route and 
the vaccinated group were either boosted (CVI988-RISPENS; 1000 pfu/bird) or 
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challenged (RB1B; 1000 pfu/bird) 2 weeks later via intraabdominal route. Post-
inoculations, birds were culled at different days post inoculation and organs were 
harvested (Figure 20). 
 
Figure 20: Avian infection models developed to study T cell mediated immune 
responses  
Schematic representation of animal models developed to study T cell response to MDV 
in Line N (B21; resistant) and Line P (B19; susceptible) chickens. Day old birds from 
both B21 and B19 were inoculated with (A) Non-infected CEF (B) CEF infected with 
RB1B (1000 PFU/bird) (C) CEF-infected with CVI988/RISPENS (1000 PFU/bird) and 
2 weeks later were challenged (RB1B; 1000 PFU/bird) or (D) boosted 
(CVI988/RISPENS; 1000 PFU/bird) and 2 weeks later Boosted (CVI988/RISPENS; 
1000 PFU/bird). 
 
 
4.3.5 Spleen mononuclear cell preparation 
Spleens harvested from resistant (B21) and susceptible (B19) chickens were stored 
aseptically on ice in PBS and isolated as previously described (278). Following 
isolation, cells were re-suspended in complete RPMI cell culture medium; RPMI 1640 
medium containing 10% foetal bovine serum (Sigma-Aldrich, Dorset, UK), penicillin 
(10 U/ml), and streptomycin (10 μg/ml) at a density of 5 × 106 cells/ml and kept on ice 
until required. 
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4.3.6 In vitro expansion of pp38 specific T cells 
Mononuclear cells isolated at 1, 2, 3 and 4 weeks post inoculation were cultured (AIM-
V medium plus 10% FCS) in the presence of recombinant IL-2 (rIL-2; 2 units per 100 
µl), medium alone, vehicle (DMSO) or specific pp38 pool 1 and 4 peptides; each 
individual peptides were at a final concentration of 2 µmol/mL. At day 8, differentiated 
cells were harvested and used in cultured ELISPOT assay. 
 
4.3.7 T cell epitope mapping: ex vivo ELISPOT Assay 
4.3.7.1 T cell depletion 
Approximately ten million cells were washed in buffer solution (PBS + 0.5% FCS) and 
incubated (4oC for 15 min) in the presence of anti-CD4-PE, anti-CD8-PE, anti-TCRvβ1-
PE or anti-TCRvβ2-PE antibody. Cells were washed (1500 rpm for 4 min) and further 
incubated (4oC for 15 min) with 85 µl of buffer solution and 15 µl of anti-PE micro 
beads (MACS Micro Magnetic Beads). Micro Magnetic bead labelled cells were 
applied to MACS column (Miltenyi Biotec, Surrey, UK; cat no. 130042201) and the 
pass through collected. Depletion purity (> 95%) was confirmed by flow cytometry 
using a MACS quant. Cell suspension were washed again, re-suspended in complete 
RPMI 1640 medium at a rate of 3.3 × 106 cells/ml and stored on ice until required 
4.3.7.2 T cell stimulation with putative epitopes in a Chicken IFN-γ ELISPOT assay 
IFN-γ production was detected using a chicken IFN-γ antibody pair kit (life 
technologies, UK). In brief, MAIPS4510 MultiScreenTM-IP 96 well plates (Millipore, 
UK) were incubated overnight at 4°C with 2 µg/ml mouse anti-chIFN-γ (capture 
antibody) in PBS and next day blocked (1 hr; 37°C, 5% CO2) with blocking buffer 
(RPMI 1640 plus 2% FCS). Mononuclear cells were seeded in triplicates at a rate of 3.3 
x 105 cells per well. The cells were cultured with medium alone (control), diluent 
(control), PMA (50 ng/ml) plus Ionomycin (ION; 1 µg/ml) (positive control); (Sigma-
Aldrich, Dorset, UK), pp38 or MEQ peptide pools (1.0 M), pp385-20, pp38161-176 and 
pp38171-186 peptides or irrelevant peptide (influenza HA peptide: H5246–260) and 
incubated (41°C and 5% CO2) overnight. Next day plates were washed twice with SQ 
water and three time with washing buffer (PBS + 0.1% Tween 20). Plates were 
subsequently incubated (1 hr in the dark at RT) with detection antibody (1 µg/ml of 
anti-chicken IFN-γ biotinylated antibody) in assay buffer (PBS + 0.1% Tween 20 + 
1.0% BSA). Following a further incubation (1 hr in the dark at RT) with Streptavidin-
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HRP (1/1250) in assay buffer, plates were washed three times with washing buffer and 
developed in the presence of 3-Amino-9-ethylcarbazole (AEC) substrate solution (BD 
Biosciences, UK) at RT in the dark. Reactions were inactivated after 20 min by washing 
in distilled water, air dried overnight  
The frequency of IFN-γ specific T cell (spots forming units; SFU) were counted using 
an automated ELISPOT reader. The SFU was calculated by subtracting the number of 
spots obtained in the non-stimulated control well from the stimulated samples. A 
positive control was included with each plate to validate the sensitivity of the assay 
 
4.3.8 Flow Cytometry: CFSE proliferation, T cell cytotoxicity (CD107a)  
4.3.8.1 CFSE staining 
In brief, approximately 1.0 x 107 spleen mononuclear cells were labelled with CFSE 
(5 µM; eBioscience, Thermo fisher Scientific, UK). Staining was quenched by washing 
and further incubating (37oC for 15 min) cells in complete RPMI culture medium.  
4.3.8.2 In vitro T cell proliferation assay 
Stained mononuclear cells were stimulated in the presence or absence of specific pp38 
peptide (pp385-20, pp38161-176 and pp38171-186). At 72 hrs post stimulation cells were 
harvested and stained with anti-CD4-PE and anti-CD8-APC (Southern Biotech, UK) 
and dead cells marker (7AAD; Miltenyi Biotech Ltd, UK). Cell proliferation and 
frequency of specific T cell subsets were detected by monitoring changes in 
fluorescence intensity of CFSE-labelled cells at 72 hrs post stimulation. 
4.3.8.3 T cell Cytotoxicity (CD107a) assay  
Unconjugated CD107a (LEP) and isotype control (CC63) antibodies were conjugated 
using the Alexa Fluor 647 labelling kit (Life Technologies, UK) according to 
manufacturer’s recommendation prior to use. Mononuclear cells were seeded in 
triplicates at 5.0 x105 cells. The degranulation marker, CD107a, of mononuclear cells 
were assessed by pulsing cells with pp38 peptide (pp385-20, pp38161-176 and pp38171-186), 
irrelevant peptide, medium alone (control), diluent (control), PMA (50 ng/ml) plus 
Ionomycin (ION; 1 µg/ml) (positive control); (Sigma-Aldrich, Dorset, UK) and co-
cultured (4 hrs; 41°C, 5% CO2) with the following antibodies; LEP (CD107a-Alexa 
Fluor 647) or isotype control (cc63-Alexa Fluor 647). Following a wash in PBS, cells 
were labelled with CD4 or CD8 PE (Southern Biotech, UK) for 15 min at 4°C and dead 
cells were excluded using 7-AAD-PE (Miltenyi Biotech Ltd, UK) staining. For all flow 
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cytometry assays, cells were acquired on a MACS quant and data analysed using the 
Flow Jo software. 
 
4.3.9 Real Time-PCR  
RNA extraction and cDNA synthesis: Total RNA was extracted from splenocytes 
isolated from both resistant (B21) and susceptible (B19) chickens stimulated ex-vivo 
with the putative pp385-20, pp38161-176 and pp38171-186 peptides, irrelevant peptide 
(influenza HA peptide: H5246–260), and PMA; 50 ng/ml plus ION; 1 g/ml (positive 
control); (Sigma-Aldrich, Dorset, UK) using TRIzol (Thermo Fisher Scientific, Paisley, 
UK) according to the manufacturer’s protocol. Subsequently, 1 µg of DNase (Thermo 
Fisher Scientific, Paisley, UK) treated and purified RNA was reverse transcribed using 
a Superscript® III First Strand Synthesis kit (Thermo Fisher Scientific, Paisley, UK) 
and oligo-dT primers according to the manufacturer’s recommended protocol. The 
resulting cDNA was diluted 1∶10 in DEPC treated water for use in Real Time-PCR 
assay. 
SYBR green Real Time-PCR: Quantitative real-time PCR using SYBR Green was 
performed on diluted cDNA using the LightCycler® 480 II (Roche Diagnostics GmbH, 
Mannheim, GER) as previously described. Each reaction involved a pre-incubation at 
95°C for 5 min, followed by 40 cycles of 95°C for 20 sec, 55°C–64°C (TA as per 
primer) for 15 sec, and elongation at 72°C for 10 sec. Subsequent melt curve analysis 
was performed by heating to 95°C for 10 sec, cooling to 65°C for 1 min, and heating to 
97°C. Primers sequences and accession numbers are outlined in Table 4. Relative 
expression levels of all genes were calculated relative to the housekeeping gene β-actin 
using the LightCycler® 480 Software (Roche Diagnostics GmbH, Mannheim, GER). 
Data represent mean of 6 biological replicates. 
 
Table 4 List of primers used for Real-Time PCR 
Gene name Accession no Primers 
Tm 
(oC) 
Product 
size 
Interleukin 2 (IL-2) NM_204596.1 
Fwd ACAGTGGCTATAGGAGACGA 
60oC 166 
Rev TGTCTTGCTGGCTGTTGTGT 
Interleukin 4 (IL-4) NM_001007079.1 
Fwd TGTGCCCACGCTGTGCTTACA 
60oC 193 
Rev CTTGTGGCAGTGCTGGCTCTCC 
Interleukin 10 (IL-10) XM_025143715.1 
Fwd GGGAGCTGAGGGTGAAGTTTGAGGA 
60oC 200 
Rev CTGCTGATGACTGGTGCTGGTCTG 
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Perforin XM_004945690.3 
Fwd ATGGCGCAGGTGACAGTGA 
60oC 271 
Rev TGGCCTGCACCGGTAATTC 
Granzyme A (GZMA) NM_204457.1 
Fwd TGGGTGTTAACAGCTGCTCATTGC 
60oC 454 
Rev CACCTGAATCCCCTCGACATGAGT 
Cytoplasmic Beta 
Actin (ACBT) 
NM_205518.1 
Fwd TGCTGTGTTCCCATCTATCG 
60oC 150 bp 
Rev TTGGTGACAATACCGTGTTCA 
 
 
4.3.10 Epitope conservation analysis 
In order to identify conserved putative T cell epitopes from different serotypes, the 
MDV strains (GaHV-2: RB1B, CVI988-RISPNES, MD5, and GA, GaHV-3: SB-1, 
HPRS24, MeHV-1: HVT) pp38 (GenBank: ABR13155.1; RB1B, YP_001033989; 
MD5, ABF72309.1; CVI988-RISPENS, NP_066892.1; SB-1 and NP_073357.1; 
MeHV-1) were aligned within and with each other. Clustal W was employed for the 
protein sequence alignment in MEGA6.  
 
4.3.11 Statistical Analysis 
ELISPOT SFU data were adjusted to 1.0 x106 cells. Quantification was performed using 
Graph Pad Prism 6 for windows. All data were analysed by Wilcoxon and Mann 
Whitney non-parametric to test significance and presented as mean + SD. Results were 
considered statistically significant at P < 0.05 (*). 
An immunological response/responder was defined as a 2-fold increase in the frequency 
of cytokine-producing cells above control peptide/pools. 
 
 
4.4 Results 
4.4.1 Higher frequencies of MEQ-specific IFN-γ producing T cells in MD-
resistant (B21) compared to susceptible (B19) lines of chickens 
To investigate the role of cell mediated immunity against MDV in both the MD-
resistant (B21) and susceptible (B19) lines of chickens, antigen specific T cell responses 
to a panel of MEQ peptide pools (7 pools) was analysed using ex vivo chicken IFN-γ 
ELISPOT assay from 6 MD-resistant (Figure 21A) and susceptible (Figure 21B) line of 
chickens at weekly intervals. MEQ specific T cell responses were detected in the MD-
resistant line of chickens that were challenged, vaccine-challenged and vaccine-boosted. 
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Interestingly, MEQ-specific T cell responses were not detected in the MD-susceptible 
line of chickens that were primed-boosted. No MEQ-specific T cell response was 
detected in mock infected chickens. Higher frequencies of MEQ-specific IFN-γ 
producing T cell responses were detected in the MD-resistant (Figure 21A) compared to 
the susceptible (Figure 21B) line of chickens. The highest frequency of IFN-γ producing 
T cells to MEQ peptide pools was observed at 2 weeks post infection or vaccination in 
both the MD-resistant and susceptible line of chickens; challenge (mean = 49.5 SFU/106 
cells), vaccine-challenge (mean = 347 SFU/106 cells), or vaccine-boost (mean = 198 
SFU/106 cells). MEQ-specific T cell responses were reduced and no antigen specific T 
cell response to any of the MEQ peptide pools were detected at week 4 post either 
challenge, vaccine-challenge or vaccine-boost in both the MD-resistant or susceptible 
line of chickens. Furthermore, a robust T cell response was observed in the MD-
resistant line of chickens that were either vaccine-challenge or vaccine boosted. 
However, our results demonstrate antigen specific T cell recall responses to MEQ 
peptide pools in the susceptible line of chickens that were either vaccine-challenge or 
vaccine boosted at all weekly intervals. However, in both MD-resistant and susceptible 
line of chickens which were challenged only, no detectable antigen specific recall 
response was observed at either week 1, 2, 3 or 4 to MEQ peptide pools. Interestingly, 
vaccine-boost was unable to elicit any detectable antigen specific T cell responses in the 
MD-susceptible lines of chicken (Figure 21B). 
 
 
 
Figure 21: Differential T cell response to MEQ peptide pools. 
MEQ-specific T cell responses were in an ex vivo chIFN- ELSIPOT assay. The 
frequency of IFN- producing T cells, presented as cumulative spots forming unit (SFU) 
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per 1.0 x106 cells, are graphed as weekly responses in both the MD (A) resistant (B21) 
and (B) susceptible (B19) line of chickens that were mock, challenged, vaccine-
challenged and vaccine-boost. All experiments were performed in triplicates and results 
are representative of 32 chickens each from both the resistant and susceptible lines of 
chicken.  
 
 
4.4.2 MDV pp38 is highly immunogenic in both the MD-resistant (B21) and 
susceptible (B19) lines of chicken 
Antigen specific T cell responses against a panel of pp38 peptide pools (6 pools) were 
analysed from both the MD-resistant (B21) and susceptible (B19) lines of chickens. The 
frequency of IFN-γ (SFU/1.0x106 cells) producing cells was tested in an ex vivo chicken 
IFN-γ ELISPOT assay from both MD-resistant (yellow; Figure 22A) and susceptible 
(blue; Figure 22B) lines of chickens at weekly intervals. Our results demonstrate that 
pp38 peptide pools elicited potent antigen specific T cell recall responses in both the 
MD-resistant and susceptible lines of chickens. Antigen specific T cell eliciting 
responses were observed in chickens that were only challenged, vaccine-challenged and 
vaccine-boosted but not mock inoculated. Furthermore, our results demonstrate that 
pp38 peptide pools elicited a more potent T cell recall response, at least 2 folds greater, 
in the MD-resistant compared to the susceptible line of chickens. The highest frequency 
of IFN-γ producing T cell to pp38 peptide pools was observed at 2 weeks post 
inoculation in both the MD-resistant; challenge (mean = 169 SFU/106 cells), vaccine-
challenge (mean = 556 SFU/106 cells), or vaccine-boost (mean = 482 SFU/106 cells) 
and susceptible line of chickens; challenge (mean = 140.1 SFU/106 cells), vaccine-
challenge (mean = 274.5 SFU/106 cells), or vaccine-boost (mean = 214.2 SFU/106 
cells). No antigen specific T cell recall response to any of the pp38 peptide pools were 
detected at week 4 post either challenge, vaccine-challenge or vaccine-boost in both the 
MD-resistant or susceptible lines of chicken. The highest frequency of IFN-γ producing 
T cell to pp38 peptide pools was observed in both the MD-resistant and susceptible 
lines of chicken that were vaccine-challenged. However, a lower antigen specific 
eliciting T cell response to pp38 was observed in the susceptible line of chicken that 
were vaccine-boosted compared to the MD-resistant line of chicken.  
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Figure 22: Differential T cell response to pp38 peptide pools. 
T cell specific responses were analysed against the MDV pp38 antigen in an ex vivo 
chIFN- ELSIPOT assay. The frequency of IFN- producing T cells, presented as 
cumulative spots forming unit (SFU) per 1.0 x106 cells, are graphed as weekly 
responses in both the MD (A) resistant (B21) and (B) susceptible (B19) line of chickens 
that were mock, challenged, vaccine-challenged and vaccine-boost. All experiments 
were performed in triplicates and results are representative of 32 chickens each from 
both the MD resistant and susceptible lines of chicken.  
 
 
4.4.3 Immunoreactivity pattern to pp38 peptide pools indicates the presence of 
an immunodominant epitope 
The immunoreactivity pattern eliciting antigen specific responses against MEQ and 
pp38 peptide pools are here reported at two week post inoculation in both the MD-
resistant and susceptible lines of chicken. The frequency of IFN-γ producing antigen 
specific T cell is presented as a heat map with red indicating highest SFU and white 
representing lowest SFU (Figure 23). The breadth of response differed among each 
group and lines of chicken. No detectable responses were observed in mock inoculated 
chickens (Figure 23Ai and v). Vaccine-challenge elicited the greatest breadth of 
response against MEQ and pp38 in the MD-resistant lines of chicken only (Figure 
23Aiii and vii). In contrast, challenge (Figure 23Aii and vi) or vaccine-boost (Figure 
23Aiv and viii) were poor at increasing the breadth of response to MEQ in both the 
MD-resistant and susceptible lines of chicken based. Comparing between the resistant 
and susceptible lines of chicken, post challenge, vaccine-challenge and vaccine-boost, a 
haplotype specific response was observed against pp38. The most potent T cell 
responses were detected to pool 4 in the MD-resistant and pools 1 and 4 in the MD-
susceptible lines of chicken. Based on the immunoreactivity pattern, pp38 was defined 
  
115 | P a g e  
 
as immunodominant; high immunoprevelance of multiple peptide pools eliciting 
immunoreactivity in all chickens regardless of the grouping, while MEQ here is defined 
as subdominant; low immunoprevelance whereby most individuals react to dissimilar 
peptide pools. Therefore pp38 peptide pool 1 and 4 potentially contain an 
immunodominant peptide (black arrows) based on the immunoreactivity  
 
 
Figure 23: Differential eliciting response to MEQ and pp38 peptide pools. 
T cell specific responses were analysed against the MDV MEQ and pp38 peptide pools 
in an ex vivo chIFN-γ ELISPOT assay. The frequency of IFN-γ producing T cells are 
presented as a heat map from both the MD (A) resistant (B21) and (B) susceptible (B19) 
lines of chicken at two weeks post mock (i and v), challenge (ii and vi), vaccine and 
challenge (iii and vii), and vaccine and boosted (iv and viii) inoculums. Columns 
represent specific peptide pools generated for both MEQ and pp38. Rows demonstrate 
the mean magnitude of chIFN-γ (spot forming units; SFU/106 cells) production per 
chickens in response to peptide pool stimulation. Black arrows indicate the peptide 
pools identified for further  
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4.4.4 Putative peptide epitope screening of pp38 library confirms the presence of 
an immunodominant peptide in both MD-resistant and susceptible lines of chicken 
To identify the putative epitopes eliciting antigen specific T cell responses, candidate 15 
mer single peptides from pp38 peptide pool 1 and 4 were screened against mononuclear 
cells isolated from both the MD-resistant and susceptible lines of chicken. Our approach 
to peptide pool deconvolution involved stimulation with smaller pools. Fine mapping of 
smaller pools, single peptides for discrete analysis and differentiation, was utilized to 
identify the minimal epitope eliciting IFN-γ production (Figure 24). Representative 
chIFN-γ ELISPOT assay from the MD-resistant (Figure 24A and B) and susceptible 
(Figure 24C and D) lines of chicken are shown. Our results demonstrate identification 
of 3 peptides eliciting antigen specific T cell response. Eliciting responses to the peptide 
epitopes were only detected in chickens that were either received vaccine strain of 
MDV or the oncogenic virus, while no response was detected in mock injected chickens 
from both the MD-resistant and susceptible lines of chicken. Specifically, two 
immunodominant-peptides were identified in the MD-susceptible and one 
immunodominant-peptide in the MD-resistant lines of chicken (Figure 24E). Candidate 
single peptide epitope were clearly differentiated. pp38161-176–specific T cell responses 
(YADLLVEAEQAVVHS) were observed in all the MD-susceptible chickens (n=29), 
while  pp385-20–specific T cell (EHEGLTASWVAPAPQ) was detected in 18 MD-
susceptible out of 25 chickens. T cell response to pp38171-186 (AVVHSVRALMLAERQ) 
was detected in all the MD-resistant chickens examined in this study (n=25). 
Interestingly, none of the immunodominant peptide epitopes, pp385-20, pp38161-176 or 
pp38171-186, induced a cross-reactive eliciting T cell response, demonstrating that T cells 
are activated in a MHC restricted manner.  
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Figure 24: Deconvoluted pp38 peptide pools illustrates identification of three 
immunodominant peptides.  
T cell specific epitope mapping was performed by confirming single peptide able to 
elicit antigen specific responses as analysed in an ex vivo chIFN- ELSIPOT assay. Data 
are presented as spot forming units (SFU/106 cells). Representative ELSIPOT assay as 
performed in the MD (A and B) resistant (B21) and (C and D) susceptible (B19) lines 
of chicken are presented. Each candidate peptide pool was deconvoluted with single 
peptide eliciting response presented from the MD (B) resistant (B21) lines of chicken 
pp38 pool 4 and (C) susceptible (B19) lines of chicken pp38 pool 1 and pool 4. Dotted 
line demonstrates cut-off value based on 2X background to identify specific single 
peptides. (E) All positive responses as single peptide reactivity are demonstrated for 
each chickens assayed with coloured in boxes from the MD-susceptible lines of chicken 
highlighted in Blue and resistant line of bird highlighted in Yellow. White boxes 
indicate negative responses. All experiments were performed in triplicates and results 
are representative of 30 chickens each from both the resistant and susceptible lines of 
chicken.  
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4.4.5 Immunodominant epitopes within pp38 antigen (pp385-20, pp38161-176 and 
pp38171-186) are highly conserved within the GaHV-2 strains 
Here, we used an approach to determine whether the peptide sequences identified were 
conserved across the known MDV serotypes (Figure 25), and whether sequences were 
also present in other avian or non-avian pathogens. Peptide sequences, pp385-20, pp38161-
176 and pp38171-186 were blasted using the NCBI SMARTBLAST tool (2017) and 
confirmed that these sequences are highly conserved within MDV strains. Alignments 
were performed using the NCBI multiple alignment tool with default settings. We 
present our sequence alignment based on GenBank deposited amino acid sequences for 
pp38 of GaHV-2 (RB1B, MD5, MD11, GA, CVI988/RISPENS), GaHV-3 (SB-1 and 
HPRS24) and MeHV-1 (HVT/FC-126) major strains. Blue and yellow highlighted 
regions correspond to the susceptible and resistant single-antigenic peptides identified 
respectively. Alignment of sequences demonstrate that pp385-20 
(EHEGLTASWVAPAPQ) is conserved only within the MDV-1 (MD5; 
YP_001033989.1, GA; AAF66817.1, MD11; AAS01704.1, RB1B; ABR13155.1 and 
CVI988/RISPENS; AAB33524.1) strains. Peptide pp38161-176 
(YADLLVEAEQAVVHS) and pp38171-186 (AVVHSVRALMLAERQ) sequences are 
also highly conserved (15/15 aa) across MDV-1 strains and weakly conserved (6/15 aa) 
with MDV-2 strains. Both pp38161-176 and pp38171-186 identified from the susceptible and 
resistant lines of chicken share a short overlapping segment of 5 amino acids long. 
Sequence variations were noted in SB-1 (AEI00271.1), HPRS-24 (BAB16570.1) and 
HVT/FC-126 (NP_073357.1) with HVT/FC-126 containing a truncated pp38 protein 
(Figure 27). No pp38 peptide sequence (pp385-20, pp38161-176 and pp38171-186) similarities 
were observed with HVT/FC-126. All together our results demonstrate the identification 
of peptide epitope-containing regions shared within the MDV-1 strains. 
  
119 | P a g e  
 
 
Figure 25: Alignment of MDV pp38 proteins with emphasis on peptide sequences. 
Specific peptide segments identified were blasted against all known avian viruses as 
well as MDV to assess whether these peptide sequences were conserved. (A) Alignment 
of pp38 amino acid sequences from all known MDV serotypes (MDV-1; RB1B, 
CVI988/RISPENS, MD-5, HPRS-24, GA, MDV-2; SB-1 and MDV-3; HVT/MeHV-1). 
Blue box represent B19 peptide sequence (pp385-20 and pp38161-176) and Yellow box 
represent B21 peptide sequence (pp38171-186) previously identified.  
 
 
4.4.6 pp38 antigen is recognized by CD4+ TCRvβ1+ T cell subsets  
The recognition of peptide specific T cell responses was analyzed using an ex vivo 
depletion assay. Our approach involved depleting mononuclear cells of specific T cell 
subsets, CD4+, CD8+, TCR2νβ1+ or TCRνβ2 and stimulating them with the identified 
pp385-20, pp38161-176 or pp38171-186 epitopes in an ex vivo chIFN-γ ELISPOT assay from 
both MD-resistant (yellow; Figure 26A) and susceptible (blue; Figure 26B) lines of 
chickens. Our results demonstrate that depletion of CD4+ (Figure 26A and C) or 
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TCRvβ1+ T cells (Figure 26B and D) but not CD8+ or TCRvβ2 T cells diminishes the 
frequency of peptide specific chIFN-γ producing T cells, suggesting that the reacting T 
cells are CD4+ TCRνβ1+ T cell subset in both the MD-resistant and susceptible lines of 
chickens (Figure 26).  
 
 
 
Figure 26: Peptide specific IFN-γ responses to pp385-20, pp38161-176 and pp38171-186 
are restricted to CD4+ TCRνβ1+ T cell subsets. 
Specific T cell subsets were depleted by magnetic beads and stimulated ex vivo in a 
chicken IFN-γ ELISpot assay with the identified pp38 peptides. Depletion assay 
performed for both (A and B) the MD-resistant (B21) and (C and D) susceptible (B19) 
lines of chicken. (A and C) CD4+, CD8+, (B and D) TCRνβ1+ or TCRνβ2+ T cells were 
depleted. Data here presented as spot forming units (SFU/106 cells). All experiments 
were performed in triplicates and results are representative of 5 chickens each from both 
the MD-resistant and susceptible lines of chicken performed on different days.  
 
 
4.4.7 Induction of Th1/Th2 cytokines expression in a peptide-specific manner 
The ability of T cell to express peptide specific (pp385-20, pp38161-176 and pp38171-186) 
cytokines other than IFN-γ was analyzed using real-time PCR. Transcript levels of 
interleukin (IL)-2, IL-4 and IL-10 were analyzed over non-stimulated cells in both the 
MD-resistant (B21) and susceptible (B19) lines of chickens that had been challenged. 
Our results demonstrate peptide specific induction of IL-2, IL-4 and IL-10 which were 
demonstrated in five chickens from MD-resistant or susceptible lines (Figure 27). 
Furthermore, in a peptide specific manner, our results indicate a higher induction of IL-
2 (Figure 27A) and IL-4 (Figure 27B) transcript levels in the MD-resistant (yellow; n = 
5) compared to the susceptible (blue; n = 5) lines of chicken. Both pp385-20 and pp38161-
176 peptides were able to induce T cell specific IL-2 and IL-4 transcripts in the MD-
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susceptible lines of chicken. However, similar levels of peptide-specific IL-10 
transcripts (Figure 27C) were observed between the MD-resistant and susceptible lines 
of chicken. Taken together our results indicate that the pp385-20, pp38161-176 and pp38171-
186 epitopes are able to elicit, other than IFN-γ, T cell specific cytokines such as IL-2, 
IL-4 and IL-10. 
 
 
Figure 27: T cell specific cytokine mRNA expression in response to pp385-20, 
pp38161-176 and pp38171-186 stimulation. 
Real-Time PCR was used to analysed fold change gene expression of mononuclear 
stimulated ex vivo with pp385-20, pp38161-176 and pp38171-186, peptide solvent or positive 
control from the MD-resistant (Yellow) and susceptible (Blue) lines of chicken for (A) 
Interleukin (IL)-2 and (B) IL-4 and (C) IL-10 and normalized to β-actin. Data is 
representative the mean of experiment triplicates performed from 5 individual chickens 
on different days. * and ** Indicates a statistically significant difference compared to 
control (p < 0.05, 0.001). Irre pep. indicates irrelevant peptide (influenza HA peptide: 
H5246–260), and NS indicates no significant difference. 
 
 
4.4.8 Peptide specific induction of CD4+ T cells proliferation 
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The ability of peptide specific (pp385-20, pp38161-176 and pp38171-186) T cells to recognize 
the relevant peptide and proliferate in vitro was analysed using an in vitro CFSE based 
proliferation assay. The percentage of CD4+ or CD8+ T cells recognizing the identified 
peptide epitope and proliferate in vitro and the representative dot plot are outlined to 
demonstrate gating strategy (Figure 28A and C) from both the MD-resistant and 
susceptible lines of chickens. Concanavalin A (Con A) was utilized as positive control, 
medium alone was used as negative control (Cont.) and irrelevant peptide (influenza 
HA peptide: H5246–260) was utilized to demonstrate T cell specific proliferation (Figure 
28). Our results demonstrate that T cells from both the MD-resistant (Figure 28B) and 
susceptible (Figure 28D) lines of chickens proliferate in a peptide specific manner. 
Stimulation with the peptide epitope elicited CD4+ T cells proliferation in a peptide 
specific manner (P = 0.0095), and no CD8+ T cell proliferation was detected. Similarly, 
in the MD-susceptible lines of chicken, a significantly higher frequency of CD4+ (P = 
0.0095) and not CD8+ T proliferated in a peptide specific manner. No T cell 
proliferation was detected in the presence of medium alone. 
 
 
Figure 28: CD4+ T cell subsets from MD resistant and susceptible lines of chickens 
recognize pp38 peptides and proliferate in vitro.  
Splenocytes isolated from MDV-infected chickens were cultured in the presence of 
putative peptides pp385-20, pp38161-176, and pp38171-186, Concanavalin A (Con A), or cell 
culture media (Cont.) and T cell proliferation was analysed using CFSE based 
proliferation assay. Representative dot plot and gating strategy for both (A) the MD-
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resistant (C) and susceptible chicken lines are shown. The frequency of proliferating 
CD4+ or CD8+ cells are demonstrated for both (B) the MD-resistant and (D) susceptible 
lines of chickens. Data is representative of the mean of experiments performed from 5 
individual chickens in triplicates. * and ** Indicates a statistically significant difference 
compared to control (P < 0.05, 0.001). NS indicates no significant difference. 
 
 
4.4.9 MDV infection significantly impairs CD4+ and CD8+ T cell degranulation in 
the MD-resistant (B21) chicken line 
Cytotoxic function are essential for antiviral activity mediated by the degranulation 
pathway identified by CD107a cell surface translocation. Splenocytes isolated from the 
MD-resistant chickens were stimulated with the identified B21 restricted 
immunodominant CD4+ T cell epitope (pp38171-186) or PMA/ION to investigate antigen 
specific and antigen non-specific T cell surface expression of CD107a, respectively 
(Figure 29A). Splenocytes cultured in cell culture medium alone or an irrelevant peptide 
(influenza HA peptide: H5246–260) were used to determine the baseline expression of 
CD107a expression in CD4+ and CD8+ T cells using flow cytometry (Figure 29). As 
pp38171-186 is identified as a B21 restricted CD4
+ T cell epitope, upregulation of 
CD107a+ on CD4+ T cells in the MDV infected chickens are considered as antigen 
specific T cell degranulation. No significant increase in MDV-derived peptide-induced 
cell surface translocation of CD107a was detected in either CD4+ (Figure 29B) or CD8+ 
T cells (Figure 29C) at 1-4 weeks post infection. Our results demonstrate that the 
percentage of CD4+CD1017a+ and CD8+CD107a+ in response to PMA/ION stimulation 
were significantly diminished in the MDV-infected chickens at 1-4 weeks post 
infection. Within 4 weeks post infection, the highest frequency of CD4+CD107a+ T cells 
in response to PMA/ION was observed at 2 weeks post infection (mean = 8.75%) with 
the lowest being detected  at the first week post infection (average of 1.9%). In contrast, 
the highest percentage of CD8+CD107a+ T cells in response to PMA/ION was detected 
at 2 (mean = 6.25%) and at 4 (mean = 8.04 %) weeks post infection with the lowest 
percentage being detected at first week post infection (average of 0.16%). Taken 
together, our results suggest that infection with MDV impairs T cell degranulation.  
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Figure 29: Impaired CD4+CD107a+ and CD8+CD107a+ T cell degranulation in the 
MD-resistant line of birds 
Spleen mononuclear cells were isolated from B21 chickens at 2 weeks post challenge. 
Cells were subsequently incubated for 4 hrs in the presence of the putative 
immunodominant peptide (pp38171-186), PMA (50 ng/ml) plus Ionomycin (ION; 1 
g/ml) and/or cell culture medium only. The frequencies of CD4+CD107a+ and 
CD8+CD107a+ T cell population were analysed using flow cytometry. (A) 
Representative dot plot and gating strategy of CD4+CD107a+ and CD8+CD107a+ are 
demonstrated. The frequencies of (B) CD4+CD107a+ and (C) CD8+CD107a+ are 
presented as a percentage of CD4+ T cells. The data are representative as the mean 
percentage from 5 individual chickens. ** Indicates a statistically significant difference 
compared to control (p < 0.05, 0.001). NS indicates no significant difference. 
 
 
 
4.4.10 MDV infection impairs T cell degranulation in the MD-susceptible (B19) 
line of bird in antigen-specific as well antigen-non-specific manner 
To further address the question of cell surface translocation of CD107a, we analyzed 
CD4+ and CD8+ T cell degranulation in MDV-infected MD-susceptible lines of chicken. 
Splenocytes isolated from MDV-infected and mock-infected chickens were stimulated 
with the identified immunodominant epitopes (pp385-20 and pp38161-176) or PMA/ION to 
investigate the ability of T cell degranulation using CD107a detection as our readout  in 
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antigen-specific and antigen-non-specific manner, respectively. Representative dot plot 
are outlined to demonstrate gating strategy (Figure 30A). Splenocytes cultured in cell 
culture medium alone or an irrelevant peptide (influenza HA peptide: H5246–260 ) were 
used to determine the baseline expression of CD107a expression in CD4+ and CD8+ T 
cells using flow cytometry (Figure 30). As pp3815-20 and pp38161-176 is identified as a 
B19 restricted CD4+ T cell epitope, upregulation of CD107a+ on CD4+ T cells in the 
MDV infected birds were considered as antigen specific T cell degranulation. Our 
results demonstrate no significant increase in peptide-specific induction of cell surface 
translocation of CD107a in either CD4+ (Figure 30B) or CD8+ T cells (Figure 30C) at 1-
4 weeks post infection. Non-antigen-specific activation of T cell cells with PMA/ION 
demonstrate that T cells isolated from MDV-infected chickens have lower expression of 
CD107a compared to that observed in mock-infected chickens. Surprisingly, cell 
surface translocation of CD107a in CD8+ T cell was completely abrogated at week 3 
(mean = 0.78%) and 4 (mean 0.77%) post challenge (Figure 30C) while CD4+ T cell 
still retained partial ability to express CD107a (Figure 30B). Cell surface translocation 
of CD107a in CD8+ T cell was diminished but detectable at week 1 (mean = 2.53%) and 
2 (mean = 6.33%) post infection albeit still significantly lower compared to that 
observed in the mock-infected chickens. Taken together, our results demonstrate that 
the overall reduction in T cell degranulation are severely impaired and this failure is 
more pronounced in the MD-susceptible chickens compared to that observed in the 
MD-resistant lines of chicken. 
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Figure 30: MDV infection impairs T cell degranulation in the MD-susceptible line 
of birds  
Spleen mononuclear cells were isolated from B19 birds post challenge and were 
subsequently incubated for 4 hrs in the presence of the putative immunodominant 
peptide (pp38171-186), PMA (50 ng/ml) plus Ionomycin (ION; 1 g/ml) or cell culture 
medium only. The frequencies of CD4+CD107a+ and CD8+CD107a+ T cell population 
were analysed using flow cytometry. (A) Representative dot plot and gating strategy are 
demonstrated. The frequencies of (B) CD4+CD107a+ and (C) CD8+CD107a+ are 
presented as a percentage of CD4+ T cells. The data are representative as the mean 
percentage from 5 individual chickens. ** Indicates a statistically significant difference 
compared to control (P < 0.05, 0.001). NS indicates no significant difference. 
 
 
4.4.11 Vaccination is ineffective at inhibiting MDV-induced T cell degranulation 
in both MD-resistant and susceptible lines of birds  
We have shown that MDV infection impairs T cell degranulation in naïve chickens 
within both the MD-resistant and susceptible lines of chicken. To examine the effects of 
MDV infection on T cell degranulation in vaccinated lines of chicken, vaccinated MD-
resistant and susceptible l lines of chicken were subsequently challenged two weeks 
after vaccination. Splenocytes were stimulated with B19-restrcited immunodominant 
epitopes and surface CD107a expression was analysed using flow cytometry. To 
examine antigen non-specific T cell degranulation, CD107a expression in response to 
PMA/ION was also analysed at week 2 post challenge in the MD resistant (B21) lines 
of chicken. Representative dot plot are outlined to demonstrate gating strategy (Figure 
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31A) in both the MD-resistant and susceptible lines of chicken. Medium alone and an 
irrelevant peptide was used for controls (Figure 31). The results demonstrate that 
vaccination prior to challenge had no effect in restoring the ability of either CD4+ or 
CD8+ T cell degranulation in both the MD-resistant (Figure 31A and C) and susceptible 
(Figure 31B and D) lines of chicken. Again, in the vaccine-challenge group, no peptide 
specific induction of degranulation was observed.  
 
 
 
Figure 31: MDV infection also impairs T cell degranulation in vaccinated chickens 
Spleen mononuclear cells were isolated from both MD-resistant and susceptible lines of 
chicken 2 weeks after mock-infection, MDV-infection or vaccine-challenge. Cells were 
subsequently incubated in the presence of the putative immunodominant peptides 
(pp385-20, pp38161-176, and pp38171-186) or PMA (50 ng/ml) plus Ionomycin (ION; 1 
g/ml) for 4 hrs and expression of surface CD107a+ was determined using flow 
cytometry. The frequency of (A and B) CD4+CD107a+ and (C and D) CD8+CD107a+ 
are presented as a percentage of CD4+ or CD8+ T cells for both the MD-resistant (A and 
C) and MD susceptible (B and D) lines of chicken. The data are representative as the 
mean percentage from 5 individual chickens. 
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4.4.12 Antigen specific Granzyme B and Perforin expression in MDV infected 
birds  
Cytotoxic abilities of CD8+ and CD4+ T cells utilize the perforin/granzyme 
cytotoxic pathway to kill virally-infected cells and tumours. We had observed that 
antigen-specific and antigen non-specific T cell degranulation is impaired in MDV 
infected chickens. Here, we examined whether T cells from MDV infected birds are 
able to upregulate Granzyme B and Perforin expressions in both antigen specific and 
antigen non-specific manner. Splenocytes isolated from MDV infected chickens were 
stimulated with pp385-20, pp38161-176 or pp38171-186, and the expression of perforin and 
Granzyme B were analysed using real-time PCR. Transcript levels of perforin and 
Granzyme B were also analyzed following stimulation of the cells with PMA/ION in an 
antigen non-specific manner in both the MD-resistant and susceptible lines of chicken 2 
weeks post MDV infection. The results demonstrate a peptide specific induction of 
perforin and Granzyme B in both the MD-resistant and susceptible lines of chicken 
(Figure 32). In contrast, stimulation of the cells with an irrelevant peptide did not induce 
upregulation of perforin (Figure 32B and D) and Granzyme B (Figure 32A and C) 
expressions in both the MD-resistant and susceptible lines of chicken. Furthermore, our 
results demonstrate a higher induction of perforin (Figure 32B and D) and Granzyme B 
(Figure 32A and C) transcript levels in the MD-resistant (yellow; n = 5) compared to the 
MD-susceptible (blue; n = 5) lines of chicken. Taken together our results indicate that 
the pp385-20, pp38161-176 and pp38171-186 epitopes are able to elicit upregulation of 
perforin and Granzyme B transcripts. 
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Figure 32: Upregulation of Perforin and Granzyme B in an antigen specific 
manner  
Real-Time PCR was used to analyzed fold change gene expression of Perforin and 
Granzyme B in mononuclear cells stimulated with pp385-20, pp38161-176 or pp38171-186 
peptides. Fold change expression of (A) perforin and (B) Granzyme B in splenocytes 
isolated from the MD-resistant (Yellow) and susceptible (Blue) lines of chicken are 
shown. Data is representative the mean of experiment triplicates performed from 5 
individual chickens on different days. * and ** Indicates a statistically significant 
difference compared to control (P < 0.05, 0.001). Irre pep. indicates irrelevant peptide 
(influenza HA peptide: H5246–260) and NS indicates no significant difference. 
 
 
4.4.13 Induction of memory pp38 specific T cells in MDV infected chickens  
Short-term T cell lines were expanded in vitro from spleen mononuclear cells isolated 
from the MD-susceptible line recognizing the immunodominant pp385-20, pp38161-176 
and from the MD-resistant line recognizing pp38171-186 peptides (Figure 33A). After 8 
days, the frequencies of peptide specific chIFN-γ producing effector T cell were 
analysed in both the MD-resistant and susceptible lines of chicken (Figure 33B and C). 
Here we outline for the first time that MDV-specific effector T cells are detected using 
ex vivo ELISPOT assay, While chicken antigen-specific memory T cells can be detected 
using cultured ELISpot assay for chicken IFN-γ (Figure 21 and 23). Short term T cell 
lines stimulated with the MDV-derived peptide epitope elicited antigen specific T cell 
recall response in all 6 chickens tested from both the MD-resistant and susceptible lines 
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of chicken. Antigen specific memory T cell responses were only detectable at week 4 
post either challenge, vaccine-challenge or vaccine-boost in both the MD-resistant 
(Figure 33B) and susceptible (Figure 33C) lines of chicken. Furthermore, no detectable 
antigen specific memory T cell responses were observed within 1, 2 or 3 weeks post 
infection in both the MD-resistant (Figure 33B) and susceptible lines of chicken (Figure 
33C), suggesting that memory T cells are generated 4 weeks post vaccination or 
infection. No response was detected in the cells, isolated from vaccinated or infected 
chickens, cultured with an irrelevant peptide. No antigen specific T cell response was 
detected in the mock infected control chickens. Antigen specific T cell responses were 
detected in both the MD-resistant and susceptible lines of chicken that were either 
vaccine-challenged or vaccine boosted. Interestingly, a lower frequency of antigen 
specific memory T cell responses was detected in the MDV-infected MD-susceptible 
lines of chicken (pp385-20; mean = 56.3 SFU/10
6 and pp38161-176; mean = 50.5 SFU/10
6 
cells) compared to that in the MD resistant lines of chicken (pp385-20; mean = 202.9 
SFU/106).  
 
 
 
Figure 33: MDV infection or vaccination induces memory MDV-specific T cell 
responses  
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Short term peptide specific T cell lines were generated in vitro from MDV infected or 
vaccinated MD-resistant (B21) and susceptible (B19) lines of chickens to detect antigen 
specific memory T cell responses. The cells were expanded from the birds isolated from 
mock infected, challenged, vaccine-challenged or vaccine boosted groups, and the 
presence of antigen-specific IFN-γ producing T cells were analysed using a cultured 
ELISPOT assay as (A) outlined in the schematic diagram. The frequency of antigen 
specific IFN-γ producing T cells (spot forming unit; SFU / 106 cells) are presented for 1-
4 weeks post infection/vaccination for both (B) the MD resistant (Yellow) and (C) 
susceptible (Blue) lines of chicken. All experiments were performed in triplicates from 
6 different chickens. **** Indicates a statistically significant difference compared to 
control (P < 0.001). Irre pep. indicates irrelevant peptide (influenza HA peptide: H5246–
260) and NS indicates no significant difference. 
 
 
4.5 Discussion 
Marek’s disease virus (MDV), an alphaherpesvirus, is the etiologic agent for Marek’s 
disease (MD) and causes a lymphoproliferative disease in chickens. Immunity elicited 
by vaccination inhibits formation of deadly lymphoma and thus prolongs host survival 
without inhibiting persistent viral infection, viral replication or transmission. The 
question of how vaccines provide protection against tumour formation while failing to 
prevent infection has not been fully addressed, and there are contrasting reports on the 
role of T cells in the control of tumour growth and infection. One of the first steps of 
analysing the role of T cells in vaccine-induced immunity is to identify and characterize 
MDV-specific T cell responses in infected and vaccinated chickens. The present study 
is the first report which present data on identification and characterisation of MDV-
derived T cell epitopes which are restricted to the MD-susceptible (B19) and resistant 
(B21). In this study, we utilized an epitope mapping approach and synthesized a library 
of overlapping peptides spanning the length of the MDV MEQ and pp38, and examined 
anti-MDV T cell responses using various immunological techniques including ex vivo 
and cultured ELISpot assays for detection of effector and memory T cell responses. For 
this study, we selected two immunogenic MDV antigens that are expressed at different 
phases of virus replication, the early protein pp38 and the major oncogene MEQ 
expressed during lytic replication and transformation. Selection of MEQ and pp38 was 
based on previous work demonstrating that antigen specific responses could be detected 
in vaccinated chickens against pp38 and MEQ (25) in an in vitro chromium release 
assay. However, no T cell epitope was identified and the quality and quantity of T cell 
responses to these MDV antigens were not studied. In this study, we identified 
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immunodominant T cell epitopes within pp38 antigen restricted to B19 (pp385-20 and 
pp38161-176) or B21 (pp38171-186) haplotype in chickens that were either challenged, 
vaccine-challenged or vaccine-boosted. The pp385-20, pp38161-176 and pp38171-186 
peptides were found to be fully conserved in GaHV-2 strains of virus regardless of their 
origin. These immunodominant peptides were not found to be cross-reactive between 
B19 and B21. Moreover, we identified CD4+ TCRvβ1+ T cells as the reacting T cells to 
these immunodominant epitopes, in both the MD-susceptible (B19 haplotype) and 
resistant (B21 haplotype) chickens. Further characterising T lymphocytes confirm that 
the identified immunodominant peptides elicit IL-2, IL-4, IL-10, gene expression in an 
antigen specific manner. For the first time, in this study we report a method for 
identification and characterization of memory T cell responses in chickens, and 
demonstrate that memory T cell responses are detectable only after 4 weeks post 
infection or vaccination against MDV.  
 
More importantly, our results demonstrate that MDV infection impaired T cell 
degranulation in both antigen specific and antigen non-specific manner. The induction 
of multi-functional virus-specific effector T cells, which have cytotoxic ability and 
produce cytokines, are believed to be critical for immune defence against viral 
infections and current opinion is that this should be considered for vaccine 
development. T lymphocyte cytotoxicity can occur through direct secretion of lytic 
granules containing perforin and granzymes into immunological synapses and this 
process is called “degranulation. Virus-specific CD4+ and CD8+ cytotoxicity T cells 
plays an important role in deciding the outcome of viral infections. Our results 
demonstrate a cytotoxic dysfunction resulting in a decrease frequency of both CD4+ and 
CD8+ T lymphocytes that degranulate (CD107a+) either in response to pp38 antigen or 
PMA/ION stimulation. Antigen-non-specific stimulation of T cells from both naïve 
MD-resistant and susceptible chickens demonstrated that there is no significant intrinsic 
ability of T cell degranulation between chicken lines. However, T cell degranulation in 
MD-susceptible line of chicken was significantly lower than MD-resistant chickens 
after MDV infection. This may explain why higher virus titres are detected in MD-
susceptible chickens than that in the resistant chickens. Taken together the evidence 
presented here indicate that a major determinant of pathogenicity in B19 birds could be 
a lack of T cell degranulation within cytotoxic CD4+ and CD8+ T cells. The differential 
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T cell responsiveness to pp38 peptide epitope in B19 and B21 could provide an 
indication for MDV pathogenesis.  
 
Beyond just cytokine secretion and proliferation, a new expanding role of cytotoxic 
activity (CD107a+, perforin+ and granzyme A+) have been identified for antigen 
experienced effector CD4+ T cell (266). The ability to kill virus infected cells is a key 
feature to prevent dissemination and provide sterile immunity. However chronic 
infection is usually associated with a failure to either recognize, control or kill infected 
cells. Cytotoxic CD4+ T cells responding to WNV infection are essential for resolving 
infection and increased survival rate in mice (279). The antiviral response is mediated 
by secretion of granzyme B and IFN-γ production. Furthermore, CD4+ T cells secreting 
perforin protect against lethal influenza infection in an antibody independent manner 
(280). In macaques, antiretroviral therapy have been shown to elicit cytotoxic CD8+ T 
cells (281) which when depleted resulted in decrease prognostic, and increased viral 
load. Our results demonstrate that splenocytes isolated from MD-susceptible and 
resistant lines of chicken can recognize MDV antigen, and unlike T cell degranulation, 
are able to express both perforin and granzyme B.  Based on our results, we concluded 
that dysfunction of T cell degranulation is not associated with their failure to express 
perforin and granzyme B. Our group has previously shown in a peptide specific manner 
induction of perforin and granzyme B transcripts in CD8+ T cells post vaccination with 
TROVACTM-AIV H5 vaccine in B19 haplotype birds (277). In MDV infection of B19 
haplotype, infiltrating CD8+ T cells have been identified in tumor environment (37). 
However the progression and eventual deadly lymphoma in B19 haplotype birds 
suggest a failure of cytotoxic activity. Here the results demonstrate that MDV impairs 
both CD4+ and CD8+ T cell cytotoxic function as indicated by a reduction in the 
frequency of CD107a+ T cells post PMA/ION stimulation. Peptide specific 
degranulation was further impaired in CD4+ and CD8+ T lymphocytes in birds either 
challenged, vaccine-challenged or vaccine-boosted. Taken together the evidence 
presented here indicate that vaccination is not sufficient to restore either CD4+ or CD8+ 
T cell cytotoxic activity in the face of challenge.  
 
Following a rapid proliferative antiviral response, the majority of effector CD4+ T cells 
contract due to exhaustion (282, 283), leaving a much smaller population of antigen 
specific memory CD4+ T cells that persists. Memory T lymphocytes have unique 
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functional attributes which allow for a rapid and effective anti-viral response which is 
an important part of a long-lived protective immune response following both 
vaccination and infection (284). The mechanism of virus mediated clearance hasn’t 
been filly elucidate but rapid expansion of effector CD4+ T cell mediated antiviral 
activity against corona virus induced encephalomyelitis is critical for mice survival 
(285). In addition, lung resident memory CD4+ T cell against the Influenza HA in a 
mice infection model has been shown to elicit protective and antiviral responses 
independent of CD8+ T cell. Therefore, directed protective immunity through 
elimination of bystander contributing factors can be generated depending on the balance 
between TH1/TH2 responses even in the absence of B cells (286). However in EBV 
infection, dendritic cells pulsed with viral antigen were shown to elicit a CD8+ T 
lymphocytes responsiveness (271). Antigen specific long lived memory CD8+ T cells 
have been identified against CCHFV (272). Regardless of the antigen, the mechanism 
of presentation will dictate activation of specific immune cell subsets. In HSV-2 
infection, re-activation of antigen specific memory CD4+ T cells mediate NK cell 
activation for enhance antiviral function (287). Our results demonstrate that in vivo 
generated memory T cells can be cultured in vitro and differentiated into effector T cell 
in both MD-susceptible (B19) and resistant lines of chickens (B21) in a peptide specific 
manner based on recall response in an IFN-γ ELISPOT assay. Moreover, we could 
identify a higher frequency of peptide specific effector T cell derived from memory T 
cells in vaccinated but not MDV infected MD-susceptible chickens. Higher frequencies 
of MDV-specific memory T cells were generated in MD-resistant chickens that were 
infected with MDV or vaccinated against MDV. A better understanding of memory T 
cells functions will allow us to evaluate their potential contribution to immunity when 
they are induced by either infection or vaccination and also following re-infection or 
viral re-activation. 
 
To develop into effector populations that combat viral infections, naive CD4+ T cells 
need to recognize peptide antigens presented by MHC class II molecules on activated 
APCs. In humans, Dengue virus infection leads to expansion of antigen specific effector 
CD4+ T cells which is associate with protective immunity (288). It has been previously 
shown that effector CD4+ T cells play a critical role in the clearance of HSV-1 infection 
of sensory ganglia and spinal cords (289). Furthermore this helper response can play a 
major role in long lived immunity against subsequent viral reactivation. Similarly, 
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varicella zoster (269) and West Nile virus infection (279) elicits a broad yet effective 
primary CD4+ T cell response sufficient to elicit antiviral protection. Activation of 
effector CD4+ T cells results in IL-2, IL-4 and IFN-γ production which support 
lymphocyte activation. The frequency of antigen experience effector CD4+ T cells is 
maximum at 2 weeks post infection and secret IL-2 and IFN-γ in an antigen dependent 
manner. During Respiratory syncytial virus infection, tissue resident effector CD4+ T 
cell in the lung play a critical role in protection against infection (290). Furthermore, 
enrichment of primed effector CD4+ T cells during HSV-1 infection leads to improved 
prognostic in mice as well as effective viral clearance from sensory ganglia and spinal 
cords supported by IL-2 production (289). Expression of IFN-γ is not always required 
for CD4+ T cell IL-4 and IL-10 cytokine production (280). Our group has shown that 
peptide specific induction of cellular proliferation, and IFN-γ production can be detect 
in chickens vaccinated against influenza (277). This is due to the promiscuity of antigen 
presentation and/or T cell recognition of varying length peptides. In accordance, the ex 
vivo depletion studies confirmed that pp385-20, pp38161-176 and pp38171-186 peptide 
specific responses observed following MDV infection were a results of eliciting 
responses from CD4+ and TCRvβ1+ but not CD8+ and TCRvβ2+ cells. Furthermore, 
expansions of peptide specific CD4+ and not CD8+ T cells during natural infections 
following ex vivo flow-cytometric analysis reveals a highly polarized phenotype. In 
vitro peptide pulse splenocytes isolated from both MD susceptible and resistant 
chickens are able to express IL-2, IL-4 and IL-10 transcripts. The induction of CD4+ T 
cell subset activation demonstrate that peptide presentation is highly haplotype 
restricted and does not exhibit promiscuity as we would expect p-MHC-II/B-F 
presentation to CD4+ T cells.  
 
Taken together, we have identified, for the first time, a CD4+ T cell restricted 
immunodominant epitope against pp38 in both MD-susceptible and resistant chickens. 
In addition to cytokine production, our data show that both CD4+ and CD8+ T cells lack 
cytotoxic function post infection. Memory T cell response can be generated against 
MDV however the abundance and maintenance of the cellular compartment is 
unknown. The model presented here should be of value in determining the correlates of 
protection against MDV infection as well as a platform for screening further MDV 
proteins which could be used in combination for subunit vaccines.   
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Chapter 5: General discussion 
 
5.1 Overall objective and perspective 
The last 30 years in MDV research has been marked by implementation of a vaccine 
(CVI988/RISPENS), the first of its kind against an oncogenic virus; which provided 
protection against severe neurological symptoms and subsequent transformation and 
proliferation of CD4+ T cell lymphoma in susceptible chickens (4). Migratory and 
backyard birds act as a reservoir for MDV in the wild and may contribute to virus 
spread into poultry production facilities. Surveillance data have demonstrated an 
increase in virulence of field MDV strains marked by severe acute onset of MD (20). 
Vaccinated day-old chicks still become infected, at the expense of already pre-
established biosecurity measure, and shed virus from the feather follicles as part of dust 
and dander into the environment (3). As a result, renewed emphasis is being placed for 
research into new therapeutic interventions so as to prevent further losses associated 
with culling of infected birds. MD is a very attractive proposition as a model to study 
the mechanism of herpesvirus induced atherosclerosis (246), lymphomagenesis (37) and 
mode of virus infection and replication (11) in its target host. Therefore, translating 
already established tools (206, 278) for studying immune responses (16, 35, 277) in the 
avian host and elaborating on host-pathogen interaction will help us elucidate new 
research opportunities (217).  
 
A medley of growth factors and cytokines such as myelomonocytic growth factor 
(MGF) (291) and IFN-γ (292) have been considered as immuno-modulators and vaccine 
adjuvants against MDV. The treatment of MDV-susceptible chickens with MGF, a 
growth and activation factor for monocytes/ macrophages, reduced viral load, increased 
survival rate and reduced tumour incidence after challenge (291). It is postulated that 
MGF increases the number of macrophages and their response to stimuli as shown by 
an increase in NO production by activated macrophages. However the role of 
macrophages and other innate immune system cells during MD is still unclear. As a cell 
associated alphaherpesvirus, induction of cell mediated immunity is regarded as the 
primary defence against virus infected cells and clearance (217). Our group have 
recently shown that administering HVT vaccine with a plasmid expressing recombinant 
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chicken IFN-γ enhanced the protective efficacy of the vaccine against MDV and 
reduced viral load and tumour incidence (292). IL-18 has been shown to stimulate IFN-
γ production from CD4+ T cells and can also indirectly stimulate CD8+ T cell 
proliferation (293). In addition, IFN-γ can enhance the development of Th1 type 
responses which is known to be important in the control of viral infections as well as 
activating innate immune system cells such as macrophages and NK cells.  
 
In the present work, an in vitro and an in vivo approach was utilized to investigate two 
main objectives. The primary objective was to establish an in vitro understanding of 
essential macronutrients for virus infection and replication. This could then be utilized 
to interrogate whether they are antiviral and immune modulating factors. The secondary 
objective was to understand in an in vivo model whether either pathogenic (RB1B) or 
vaccinal (CVI988/RISPENS) strains of MDV can elicit a cell mediated immune 
response. Furthermore, the specific cell mediated immune responses could be 
characterized in the MD-resistant (B21) or MD-susceptible (B19) lines of chickens.  
 
In the first objective of this study, we initially confirmed that MDV infected CEFs have 
an accumulation of lipid droplets. Therefore, MS-GC was utilized to interrogate 
induction of lipogenesis during MDV infection. The results demonstrated firstly that the 
small pharmacological inhibitors are effective antiviral molecules and can also be 
utilized to validate the MS-GC data. Essential pathways and nutrients dispensable to the 
host cell but not MDV were mapped thoroughly. β-oxidation is dispensable as other 
intracellular sources of energy support MDV infection and replication. Secondly, a link 
was established between induction of lipogenesis and eicosanoid synthesis, specifically 
PGE2, here demonstrated as essential for viral replication. Our groups have previously 
reported that MDV transformed cell lines produce soluble factors such as PGE2 which 
inhibited T cell proliferation and migration (240). Therefore we concluded that PGE2 is 
an essential factor for viral replication and immune evasion tactic. Furthermore, this can 
then be translated to an in vivo model as a multi subunit antivirals to assess the quality 
of cell mediated immune response in conjuncture with supressing viral replication and 
dissemination. 
 
In the second objective, T cell specific responses were evaluated in both the MD-
resistant (B21) and MD-susceptible (B19) lines of chickens. Although significant effort 
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have been invested to characterise MDV gene function, limited information is available 
on MDV antigens or cell mediated immunity. Previous work have demonstrated that 
MDV MEQ and pp38 are able to elicit a cytolytic T cell response and potentially are 
highly antigenic (25, 26). Even though MD is controlled effectively by vaccination, the 
antigens associated with protective immunity are poorly defined. Some degree of 
protection is afforded to all chickens regardless of their MHC haplotype (294). 
However, using MHC specific defined line of chickens is an attractive proposition to 
elucidate clonal similarities or difference in T cell responses. Therefore, both MDV 
MEQ and pp38 were selected to characterise the quality and quantity of antigen specific 
T cell responses in both the MD-resistant (B21) and MD-susceptible (B19) lines of 
chickens. Both the vaccine (CVI988/RISPENS) and pathogenic strain (RB1B) of MDV 
elicited CD4+ T cell responses directed against the pp38 peptides; pp385-20 and pp38161-
176 in the MD-susceptible line of chicken and pp38171-186 in the MD-resistant line of 
chicken. The fact that these peptides are conserved among vaccinal strains (SB-1, 
HPRS24 and CVI988/RISPENS) of MDV confirms that protective and long lasting 
immunity could be afforded through pp38 and not MEQ. An alternative, but not 
mutually exclusive scenario is that the immunoreactivity pattern observed may be a 
line-specific response. It is important to note that the chickens currently utilized in 
poultry production facilities, but not backyard operations, are derived from the MD-
resistant line. As such, the findings reported here are highly significant in the broader 
scope for next generation subunit vaccines. 
 
5.2 Concluding Remarks 
Our understanding of innate and adaptive immunity to MDV infection is continuously 
improving. This growing knowledge can be further enhanced by our understanding of 
immunity to human alphaherpesviruses and host-pathogen interaction. However, there 
are many differences between the human and avian immune system as well as different 
characteristics between MDV and human alphaherpesviruses (VZV, HSV-1 and 2). 
MDV is a highly cell associated virus which imposes certain limitations. In terms of 
vaccine research and development, the developments of potent cell-free vaccines that 
can inhibit infection as well as the disease are paramount to research in this area.  Going 
forward, the research presented here have outlined alternative avenues for antiviral 
research and established a baseline for vaccine design.  
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